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PREFACE 
Pharmacokinetics of amphetamines deals with the description and the analysis 
of time-dependent changes of the concentration of a drug in blood and body 
fluids after the administration of the drug to man or animal. Absorption from 
the side of application, distribution over various tissues of the body, elimi­
nation by metabolism in the liver and excretion by the kidneys are the most 
important processes, governing the kinetic behaviour or other chemical sub­
stances. It is because of the extreme low blood concentration of the amphet­
amines and their pronounced central stimulant effects in man, which do not 
allow intake of large doses, in this study the kinetic analysis on basis of the 
blood concentration has been limited to a number of typical examples. 
Predominantly renal excretion data have been used for a detailed analysis of 
the kinetic behaviour and the metabolism of amphetamine like drugs. 
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For most amphetamines, elimination occurs for more than 50% by means of 
metabolism via different routes. Therefore a link between drug metabolism in 
vivo and the mechanism of metabolism on microsomal enzymes, especially 
cytochrome P-450, was established. 
The Grand Tour through the different classes of amphetamines, like phenter-
mines, ephedrines, aminopropiophenones, saturated amphetamines, N-alkyl, 
and N-cycloalkyl substituted derivatives, non benzenoid amphetamine ana-
logues, inhibitory compounds, made it possible not only to provide an analysis 
of the fate of amphetamines in our body, but also an attempt to elucidate how 
and by what means the enzyme cytochrome P-450 metabolizes the drugs or 
xenobiotics we are exposed to. 
We hope that the reader will share the opinion that "the amphetamines" are 
excellent model compounds in the elucidation of the interaction drug-cyto-
chrome P-450 and the specific metabolic pathways which may be performed. 
The thesis is divided into 5 sections: 
Section I describes the pharmacokinetics of renal excretion and metabolism, 
section II the analytical procedure which is used throughout the study, section 
III the metabolism of the amphetamines in man, section IV concerns with the 
enzyme cytochrome P-450 and section V deals with the social impact of this 
amphetamine research with regard to the doping control. 
Part of the studies of this thesis have been published in several papers*. 
* The papers on which a part of this thesis is based are indicated with an arterisk in 
the list of personal publications presented with the curriculum vitae. 
SECTION I 
KINETICS OF METABOLISM AND EXCRETION OF 
AMPHETAMINES IN MAN 
CHAPTER 1 
KINETICS OF ABSORPTION AND ELIMINATION OF AMPHETAMINES 
Introduction 
Drugs introduced into the body of man or animals by means of direct in­
jection in the blood (intravenous route), oral administration or otherwise, are 
distributed over the entire body through the blood circulation. The blood pas­
ses through organs responsible for elimination of foreign compounds as the 
liver and the kidney. Consequently simultaneously with distribution elimination 
takes place. Obviously if a drug is not injected directly into the blood stream, 
transport of the drug from the gastro-intestinal tract to the general circulation 
occurs. This process is referred as drug absorption. Pharmacokinetics deals 
with the kinetics of drug absorption, distribution and elimination of drugs and 
other substances introduced into the body. 
Drug elimination 
The elimination of drugs from the body is in general governed by a first 
order process (Wagner 1971, Dost 1953 and 1968, Teorell 1937, v. Rossum 
1972). This means that the higher the drug concentration in the body fluid, 
the more of the drug is eliminated per unit of time. The elimination rate can be 
described by the following differential equation, provided that absorption and 
distribution processes are fast as compared to elimination (see fig 1). 
d O _ _ k ,C or dC ke|C m 
dt - e l tiT--^-
where dQ/dt is the elimination rate (e.g mg/h or ug/min), kej the total body 
clearance or elimination clearance constant (l/h or ml/min), С the drug con­
centration in the blood plasma (mg/l or ug/ml) and V f the apparent volume 
of distribution (I or ml). Vf is an apparent or hypothetical volume because 
the concentration of the drug is not necessarily the same in the various parts 
or tissues of the body. The concentration of a drug in the plasma as a function 
of time under the conditions described may be given by the following equation: 
C = C 0 ë t / T e l = С 0 е - Г е ' / 1 = С02-*/ M 
where C0 is the initial plasma concentration, τ,., the elimination time constant, 
t1/2 the halflife time and re) the elimination rate constant. The following rela­
tionships hold between rate constant, time constants and the elimination clear­
ance: 
T e i = ^ i — ; re l = _ L _ and t ^ = 0 . 6 9 т е | 
k e i
 Tel ' l d J 
So the time constant of elimination τ,., is equal to the quotient of the volume 
of distribution Vf, and the clearance constant. A small t1/2 may imply a small 
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f igure 1 : Plasma decay curve according to first order kinetics of a hypothetical drug. 
The same curve is plotted linearly and semi logarithmically against time. 
Vf or a large kel. The Initial concentration C,, bears a relation to the dose D 
and the volume of distribution provided that distribution is much more rapid 
than elimination so that actually distribution is achieved before elimination 
starts. Then: 
D.F 
о V( 
or V r - P-F (4) 
where D is the dose and F the fraction of the dose that ultimately becomes 
absorbed. From equation 2 it fol lows that the logarithm of the drug concen­
tration in the plasma decreases linearly with time: 
log С = log C 0 — 0.301 (t/ti/J (5) 
A semi logarithmic plot of the data of blood concentration reveals straight 
lines as required for single compartment f irst order kinetics. The volume of 
distribution may be obtained from the quotient of intercept of the semi loga­
rithmic concentration time curve and the dose administered, (if F has been 
determined). 
V, = C 0 / DF (6) 
Once Vf and r e j , r,.f or V/2 have been determined, the elimination clearance 
constant can be determined: 
Vf/τ
β
| = Vf .г., = 1.44 Vf / t i (7) 
It should be realized that the total body clearance will be found too large if 
drug absorption is incomplete (F < 1). A large elimination clearance constant, 
a large V/2, does not imply automatically a slow elimination rate process. A 
drug, e.g. amphetamine, that is rapidly cleared may still reveal a large V/2 
when the volume of distribution is very large. Under the assumption of single 
compartment first order kinetics, the clearance constant is calculated from 
the biological half life time and the volume of distribution. For amphetamines 
the total body clearance is in the order of 30 l/h or 500 ml/min. 
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Drug absorption and elimination 
After oral administration, a second exponential term has to be added to 
equation 2, representing the first order absorption process if absorption is 
not very fast as compared to elimination. The plasma concentration may then 
be given by the fol lowing equation: 
- t / T
a
 . 
(8) e v
l
a 
where re l is the time constant for elimination, та the time constant for ab­
sorption, and F is the fraction of the drug that reaches the general circulation. 
The curve of the logarithm of the plasma concentration shows a maximum 
and thereafter decreases linearly with time. From the straight line segment 
τ,.ι or the half life time of elimination may be obtained. Obviously, the maximum 
concentration cannot be used as an accurate estimate for the calculation of 
Vf unless T(.|>)r.,. The time constant for absorption may be obtained with a 
substraction method, provided that enough points in the ascending part of 
the curve are given. The biological availability, F, ultimately may be calculated 
from the area under the plasma curve (AUC). It is evident that the total 
quantity of drug eliminated, Qe i is equal to the amount D.F. that has been 
entered the body. The quantity eliminated is related to the "area under the 
curve" as may be shown by integration: 
0) 
D.F or 
This implies that F can be calculated from the so-called A.U.C provided that 
kei has been determined. Thereafter V f can be calculated from the intercept 
with the ordinate of the straight descending part of the semi logarithmic plasma 
curve. In formula: 
V D.F / Tel 
Again it is evident that V t will be found too large if absorption is incomplete 
( F < 1). 
1R 
CHAPTER 2 
BLOODLEVELS OF AMPHETAMINES 
Introduction 
Since it is very difficult to study the plasma concentrations of amphetamines 
and amphetamine like compounds in human subjects, kinetic studies are scar­
ce. The low concentrations (ng-pg/ml) of amphetamines in blood require a 
very sensitive analytical method. In section II the possibilities to measure 
blood concentrations by means of gas chromatography with different detectors 
are outlined. The best method is detection of a derivatized compound by 
means of GLC and the electron capture detector. In this way the plasma levels 
of amphetamine and N-methylamphetamine have been measured by Rowland 
(1969), Nooan (1969), Bruce (1969), Anggard (1970), caffeine by Grab (1968) 
and phenmetrazine by Anggard (1969) and Quinn (1967). In general a method 
for the estimation of one single compound is developed. The amphetamines 
also can be detected in blood by means of GLC and flame ionisation detector 
or with the nitrogen detector (Campbell 1969). A high dose of amphetamine 
(40-50 mg) permits detection until 12 hr after ingestion. After chronic ad­
ministration of the drug the blood levels are so "h igh" that this method is sen­
sitive enough to fol low the concentrations over a large period of time (see 
fig. 2). In this study the analysis of the blood concentration was made by GLC 
with flame ionisation detector, while the combination gas chromatography-
mass spectrometry always was used for identification of the peaks. 
1 The blood concentration of amphetamines and kinetic parameters derived 
from concentration-time curves 
The blood concentration reaches the peak concentration within one hour after 
oral administration. The peak in the curve is sharp, indicating that the ab­
sorption is fast (fig 2). The amount of absorption can be derived from the 
amount of compound excreted unaltered. For amphetamines, after oral ad­
ministration of the compound in a gelatine capsule, the absorption was found 
to be practically complete. The blood concentration of N-alkyl substituted 
amphetamines is parallel to the renal excretion rate (fig 2). The relationship 
is governed by the fol lowing equation: 
dOv / dt = kr. С 
The renal clearance constant k r therefore could be calculated when both the 
blood concentration and renal excretion rate have been determined. It ap­
peared that there is a considerable variation between the k r values derived 
from different subjects, under different conditions as pH and urine flow. In 
general the k r values range table 1 between 150 and 300 ml/min for most 
amphetamines, (see table 1) From table 1 it can be derived that the maximum 
in the blood concentration exhibits a relationship with the dose ingested: 1 
mg of amphetamine HCl salt corresponds with a blood concentration of 3-4 
ng/ml. The same relationship is found for the renal excretion rate: 1 mg HCl 
salt ingested results in a maximal excretion rate of 1 ug/min. An example of 
the last finding is given in section V, ¡n which this phenomenon is used in 
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cumulative renal 
ехсгеЬюп (015 base) 
45 
f igure 2: Blood concentration, saliva concentration, renal excretion rate, urine pH, urine 
production and cumulative renal excretion of (—) amphetamine. Note that the renal 
excretion rate is parallel to blood and salvia concentration. 
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doping control. Both data fulfill the requirements of the equation mentioned 
above: 
1 μ9/ηΊίη = 300 ml/min χ 3.5 ng/ml 
Similar results have been obtained by Anggard (1970), Campbell (1969), 
Rowland (1969), Bruce (1969) and Beckett (1969). The corresponding volume of 
distribution of amphatamine ranges between 200-300 I. The N-alkyl substitued 
amphetamines, N-ethyl-, N-isopropyl- and N-dimethylamphetamine reveal a 
much higher blood concentration and a smaller volume of distribution. (50-
100 I). The relationship is roughly that 1 mg HCl salt results in a maximum 
blood concentration of 6-7 ng/ml. 
Partition experiments of the N-alkyl substituted amphetamines over plasma 
and red blood cells shows that the partition is 1:1. There is no irreversible 
binding to plasma proteins. 
The blood concentration is lowered by the continuous extraction of the amphe­
tamines by the saliva and sweat gland, the kidney and by "extract ion" by the 
liver (metabolism). Therefore excretion of amphetamines in saliva and sweat 
will be discussed in the next paragraphs. The renal excretion is discussed in 
chapter 3 and section III. 
Table 1 
Clearance constants of urine and saliva, fictive volume of distribution, blood 
concentration and half life times of N-alkyl substituted amphetamines in blood, 
saliva and urine. 
subject 
ЕЕ 
FR. 
C.V. 
C.V. 
c.v. 
H.к. 
F.H. 
W S . 
ev. 
н.к. 
P.N. 
H P . 
cv. 
A.B. 
c.v. 
e.G. 
H.K. 
A.B. 
F.H. 
F.R. 
compound 
(—) amphetamine 
( + ) N-methylamphetamine 
(-) 
( + ) N-ethylamphetamine 
(-) 
( + ) N-isopropylamphetamine 
(-) 
( + ) N-dimethylamphetamine 
(-) 
phentermine 
dose 
mg 
62 
61 
25 
50 
63 
54 
50 
50 
50 
50 
50 
59 
61 
50 
50 
30 
35 
50 
38 
37 
blood 
4 
6 
8 5 
9 
9 
4 5 
1,5 
2 
3 
6 
4 
2 
4 5 
4 5 
4 
9 
6 
4 5 
12.5 
13 
t i t a (hr) 
saliva urine 
3 
4 
3 5 
3 5 
4 
3 
2 
2 
— 
— 
5 
2.5 
5 
— 
— 
— 
— 
— 
6 
4 
7 
7 
7 
6 
7 
6 
2 5 
2 5 
5 
7 
5 
2 5 
7 5 
3 
4 5 
7 
5 
5 
10 
9 
* r *sal 
ml/min 
452 
143 
293 
278 
245 
178 
333 
257 
147 
181 
290 
305 
314 
100 
180 
30 
130 
100 
241 
160 
9 
4 
6 
9 
10 
13 
16 
8 
— 
— 
5 
10 
10 
— 
— 
— 
— 
— 
4 
4 
Vf 
1 
208 
137 
190 
182 
164 
143 
37 
55 
120 
55 
90 
158 
245 
78 
116 
82 
65 
40 
166 
111 
max blood 
concentration 
ng/ml. 
215 
300 
75 
190 
230 
280 
470 
320 
195 
420 
450 
175 
135 
320 
250 
250 
280 
580 
170 
250 
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2. Excretion of amphetamines in the saliva 
The amphetamines are taken orally as HCl salt in a capsule. When saliva 
samples, taken after various time intervals after ingestion of the drug, were 
extracted and analysed, it could be demonstrated that the amphetamine was 
present. 
The concentration of the amphetamine in the saliva parallels the blood con­
centration. The ratio between the concentration in salvia and blood is about 
10. (Tsujimoto 1971). 
dQ s a | / dt = ks Сд wherein k, is the saliva clearance constant. 
After excretion in the saliva, it is swallowed again, thus creating a cycle. 
Thereby, Beckett (1967) showed a strong buccal absorption of the ampheta­
mines. This particular excretion does not contribute to the total elimination, it 
is more an elimination delaying process, but of limited importance. With these 
two extraction procedures (urine and saliva) the excretion in tears, sweat etc 
may be investigated likewise. 
3 Excretion of amphetamines in human sweat 
Electrolytes present in the blood, as sodium, chloride, bromide, iron, are to 
the same extend excreted by the sweat gland (Licht 1957, Plaggemeyer 1914). 
Also various organic compounds as urea and mucus are present in human 
sweat (Seutter 1970). Several exogenous compounds as sulphonamide, hexa-
mine, bromide are excreted by the sweat gland (Thaysen 1953). 
Sweat originates from the bloodplasma while its composition is mainly de­
termined by reabsorption and exchange mechanisms (Siegers 1966). The 
pH of sweat may differ considerably in different individuals (Licht 1957, Plag­
gemeyer 1914). The production of sweat and urine are to some extent related 
processes. It is therefore of importance to do a comparative study on the 
excretion of amphetamines in sweat and urine. 
Since athletes, cyclists etc. produce a large amount of sweat, doping control 
could also be done by analysis of sweat, provided that the doping agents are 
excreted in sweat. Therefore (-) N-dimethylamphetamine HCl, in contrast t o ( + ) 
N-dimethylamphetamine, a relative non-toxic, non-stimulating amphetamine, 
was given to healthy subjects as an oral dose of 20-25 mg. Sweating was 
stimulated at regular intervals following ingestion of the drug by letting the 
subjects make exercises on a bicycle ergometer (table 2). During 10 min of 
sweating, sweat was rapidly collected from the forehead and the back of the 
subject. In each sweat trial 3-10 ml sweat were collected. Simultaneously the 
urine was collected for a period of 60 hr. (-) N-dimethylamphetamine, as well 
as its metabolite (-) N-methamphetamine, is excreted in sweat of human sub­
jects (fig 3). Following ingestion of 20-25 mg of this amphetamine analogue, 
the maximum concentration in sweat is in the order of 2-4 цд/ті . The concen­
tration of these drugs in sweat increases during the first few hours after in­
gestion, while from 6 hr on there ¡s a gradual decrease of the concentration. 
The concentration of the parent drug and its metabolite in sweat parallels the 
rate of excretion in the urine. The concentration of N-dimethylamphetamine in 
the sweat of subject C.G., 7 hr after ingestion, was 2.7 ng/ml (table 2), 
while in the urine the average concentration during the period 5 hr after in-
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urine ml/min 
figure 3: Sweat concentration, renal excretion rate, urine pH, sweat pH, urine production 
and cumulative renal excretion of (—) N-dimethylamphetamine and its metabolite (—) 
N-methylamphetamine. The sweat concentration of both compounds are parallel with 
the renal excretion rate. The excretion rate of the amphetamines in the sweat is in-
dependent of the pH of the sweat. 
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jection was 2.88 цд/т і . At that time the pH of the sweat was 7.35, while the 
pH of the urine then was 5.30. So although the pH of the two fluids differ 
by 2 pH units, the concentration of the amphetamine is in the same order of 
magnitude. Both subjects received ammoniumchloride in order to keep the 
pH of the urine around 5. Nevertheless, in the one subject the sweat pH re­
mained high (fig 3). Tentatively it may be concluded that the pH of the sweat 
can less easily be changed by intake of acidifying substances than the urine 
pH. Probably the sweat pH is for each person a typical function of the blood 
pH. Excretion of amphetamine-like compounds in human sweat is largely in­
dependent on sweat pH. 
Extensive studies have been made with regard to the excretion of ampheta­
mine and amphetamine-like compounds in the urine of a large number of hu­
man subjects (Anggard 1970). However, only recently has been shown that 
the excretion in the urine and saliva parallels the blood concentration decay 
curves (Rowland 1969). In this study it has been shown that the excretion 
curves of amphetamine in sweat fol low the same pattern as that in the urine. 
Analysis of human sweat or of sweat in the shirt of an athlete immediately 
after the athletic performance may be used as a means of doping control. 
Table 2 
subject 
T.V. 
dose 
20 mg 
85 kg 
C G . 
dose 
25 mg 
80 kg 
time ') 
(hr) 
1.30 
5.30 
8.30 
25.25 
32.00 
54.00 
3.10 
7.00 
24.00 
28.00 
ml 
10 
8 
8 
7 
7 
7 
3 
3 
4 
5 
sweat 2 ) 
pH 
4.85 
4.70 
4.65 
4.70 
4.60 
4.50 
6 9 0 
7.35 
7.50 
7.80 
|ig/ml sweat 
(—) N-meth- (-
amphetamine 
0.118 
0.75 
0.50 
0.21 
0.19 
0.04 
0 2 5 
0 3 3 
0.17 
0.07 
—) N-dimethyl-
amphetamine 
1.38 
4.27 
2.63 
0.33 
0.29 
— 
2.50 
2.70 
0.49 
0.16 
w e i g h t 3 ) 
loss 
(kg) 
0.600 
0.274 
0.210 
0.235 
0.230 
0.230 
0 2 0 0 
0 2 0 0 
0.180 
0 240 
w a t t 4 ) 
150 
150 
150 
150 
150 
150 
150 
150 
150 
150 
rotations 
80 
80 
80 
80 
80 
80 
80 
80 
80 
80 
5 time o f
6 ) 
excretion 
20 min 
20 
20 
20 
20 
20 
25 min 
25 
25 
25 
') Time after ingestion of the drug. 2) The sweat pH is measured in the collected sweat. 
3) Weight loss of the subject during the excesie. 4) Load of the bicycle ergometer. 
5) Velocity of bicycle ergometer. 6) Time course of sweat production. 
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CHAPTER 3 
KINETICS OF EXCRETION OF DRUGS INTO THE URINE 
Introduction 
The analysis of plasma concentration curves provides an information about 
the kinetic processes that occur in the body following administration of a drug, 
if indeed the plasma levels can be measured accurately. For many of the 
Central Nervous Stimulant drugs, with a large volume of distribution, the 
plasma concentration is very low, even at the peak level ( < 50-100 ng). The 
analysis of the plasma concentration may not be accurate enough. The drugs 
may however be excreted in the urine for a considerable percentage. 
1 The renal excretion rate 
The rate of the renal excretion is directly proportional to the plasma con­
centration, under constant conditions (fig 4). 
dQr / dt = kr. CA 
where dQ r /dt is the renal excretion rate f^g/min) and k r the renal clearance 
constant (ml/min). From this equation it is evident that the renal excretion 
rate curve ought to have the same shape as the plasma concentration curve. 
The halflife time can be calculated from the rate of the renal excretion curves 
as a function of time. If, in addition, a few plasma concentration determinations 
are made, the value of the renal clearance constant can be calculated. Experi­
mentally, in man, the renal excretion rate is not determined over infinite small 
time intervals, but over discrete periods of time. Hence, the average renal 
excretion rate is determined. It is evident that, unless very small time intervals 
are used for the collection of urine samples, the time constant for absorption 
can hardly be determined from the excretion rate curves. The average renal 
excretion rate is obtained by integration of equation: 
AQr 
Δί 
. D F k r . 
V f At 
Tei 
Tel ~~ T a el 
•
4tAei\-tA el 
- т
а
( 1 _ е :Мле-
1
А (1) 
in where It is the time period over which the urine is collected. Unless 
these periods are constant and small, it is better to present the renal ex­
cretion rate in block diagrams. Indefinite small time intervals do pass the his­
togram in a smooth curve. See fig 4. 
Qr = k rCdt = 
2 Cumulative renal excretion 
The amount of unchanged drug excreted in the urine increases with the time, 
as may be seen from the following equation: 
D F Tel 
'f Tel 
r 
"a L 
T e i 1 1 (2) 
25 
Cone, (m £/1} 
100
Ί 
001 
evcretion rate (ug/min) 
100
Ί 
cumulative excretion (π-j basel 
10-, 
AS 
time ( h ) 
figure 4: Blood concentration, saliva concentration, renal excretion rate and cumulative 
renal excretion of ( + ) N-isopropylamphetamine. 
after oral administration of the drug. It is evident from equation 2 that after 
sufficient time, the amount of drug excreted unchanged in the urine is a 
fraction of the total amount of the drug being absorbed, (t ))rc\) 
t=oo 
= DF.JlrL 
l
el 
The total amount excreted as fraction of D.F equals the ratio of the renal and 
total body clearance. To determine the biological availability two drugs were 
ingested in the same dose and elimination was followed under exactly the 
same circumstances. Thus k r and Qv\ are drug and subject parameters while 
F is only dependent on the preparation. This means that Q r (t = эо) is a direct 
measure for the biological availability, F, if the same drug is given in different 
formulations to the same subject. Phentermine is excreted for 100 % un­
changed, so the biological availability of phentermine preparations that is 
known to be excreted completely in the unchanged form (section III, chapter 
4) may easily be determined from renal excretion data. When a drug is lar­
gely excreted unchanged, one may not conclude that such a drug is metaboli-
cally stable. Such a drug might be metabolized substancially if it were not so 
rapidly excreted. It only means that k r is large with respect to other clearance 
constants contributing to the overall clearance constant. 
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3 The total body clearance 
The total body clearance is the sum of the renal clearance and all metabolic 
constants indicating various routes of bio degradation. 
kci = kr + km 
The blood concentration of amphetamines cannot be estimated easily, due to 
the small dose that can be ingested and the large volume of distribution. 
This implies that plasma concentrations can not or only be determined over a 
limited concentration range. It is therefore difficult to evaluate whether the 
renal excretion rate is directly proportional to the plasma concentration. We 
have however been able to demonstrate such a relationship for N-dimethyl-, 
N-isopropyl-, N-ethyl-, and N-methylamphetamine while Rowland (1969) show-
ed a similar relationship for amphetamine. Consequently, it is reasonable to 
calculate pharmacokinetic parameters from renal excretion curves. With the 
renal excretion rate of the amphetamine dérivâtes it is also possible to eval-
uate the relative importance of renal and metabolic routes of elimination. With 
such an approach it was possible to discover differences in metabolism be-
tween stereo isomers, the influences of substituents in the alkyl side chain, 
such as a hydroxyl group in ephedrines, a carbonyl group in aminopropio-
phenones, ring saturation with cyclohexyl-isopropylamines and stimulation of 
the rupture of the a- C-Η bond in the a- C-oxidation. All these possibilities 
are fully discussed in section III. 
4 The renal clearance constant 
The renal clearance constant, governing the rate of renal excretion, is given 
by the fol lowing equation: 
d Q r /dt = kr. С 
The renal clearance constant is composed of the fol lowing constants: 
К = k| + kl5 — ktr 
where k| characterizes glomerular f i ltraton, k ts tubular secretion and k l r 
tubular reabsorption. Tubular reabsorption depends on diffusion of drug from 
the urine of the tubuli back to the blood. Basic drugs like amphetamine may, 
depending on the pH, occur in the ionized form which is hydrophilic and in 
the neutral form which is lipophilic. Back diffusion occurs merely for the neu­
tral form. This implies that renal clearance may be strongly pH dependent. 
We were able to measure blood concentrations and excretion rates of N-
methylamphetamine and the metabolite amphetamine and calculate the renal 
clearance constant after chronic administration of the drug (Faber 1972). In 
figure 5 the relationship between urine pH and k r is shown (Anggard 1970). 
In the renal excretion curves of drug naïve subjects in our study, this process 
also is demonstrated clearly. The kr values found for amphetamine under 
acid urine conditions may achieve 400 ml/min or more. When differences 
between metabolic routes are to be investigated, such studies ought to be 
done under conditions of constant urine pH and constant urine flow. With 
drug addicts, Anggard (1970) was able to show the dependence of the renal 
clearance constant of the urine production too. If the tubular secretion and 
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renal clearance constant (ml/min) 
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ο methyl-amphetamine 
• amphetamine 
figure 5: The renal clearance con­
stant kr is dependent on the urine 
PH. 
pH urine 
tubular reabsorption would be absent, the renal clearance would be equal 
to the glomerular fi ltration rate which accounts to 125 ml/min. This indicates 
that there must be an active tubular transport for the amphetamines. The 
excretion curves of amphetamine to doses of 500 mg are straight lines (loga­
rithmically plotted). This behaviour elicits that the maximum of the tubular 
active excretion is not reached at the concentrations studied. 
5 The urine pH 
As mentioned with the renal clearance constant, the tubular reabsorption 
process is dependent upon the pH of the urine, because the neutral form of 
the amphetamine is reabsorbed (fig 6). Compared with the "in v i t ro" partition 
of the compound over two organic solvent layers, the neutral form of the am­
phetamine is the main constituent that is dissolved in the organic phase while 
the protonated form, or ionised form, is remaining in the water layer. 
The pH of the urine varies under physiological conditions between 4.70 and 
7.50 while the pKa of the amphetamine derivatives vary between 9.90 and 
10.50. At pH 7.40 of the blood only 0,3% of the amount amphetamine is in the 
neutral form while at pH 5 of the urine this factor is about 0,003%. The process 
of reabsorption may be compared with the partition over two layers in vitro, 
where in at infinite fast equilibrium k t u i / k r e a i , is equal to the apparent par­
tition coefficient. 
At this moment we may state something about the efficiency of the re-
absorption: When the reabsorption is a very fast process, faster than the urine 
f low through the tubuli wherein the reabsorption takes place, then at every 
pH of the urine, the partition is 100%. This means that with an urine pH of 
5, a particular amphetamine derivative may be excreted for 100% unchanged 
in the urine, but only for 1 % at pH 7. For N-methylamphetamine, amphetamine 
28 
Cumulative renal e x c r e t i o n ime bas figure 6: Renal excretion 
rate, urine pH, urine pro­
duction and cumulative 
renal excretion of ( + ) 
amphetamine under two 
urine pH conditions: acidic 
and uncontroled. Under 
acidic urine conditions the 
compounds is mainly ex­
creted unchanged in the 
urino (70%). 
excret ion rate ίμζ/min. log scale) 
10 η AMPHETAMINE H 2 5 0 4 5rng 
uncontroled 
subject TV 
and tranylcypromine, this ratio between the percentages excreted at pH 5 
and 7 only is a factor 10 instead of the theoretical factor of 100. It must be 
concluded that the partition rate, or the rate of the reabsorption is influenced 
by the urine flow. This conclusion is supported by the findings that with con­
stant urine pH, an increase in the urine production results in an increase of 
the renal excretion rate. With alkaline urine the excretion rate of the ampheta­
mines is very low. The compound fencamfamine is not excreted at all when 
the urine is made strongly alkaline. The excretion rate of fencamfamine under 
acidic and alkaline urine conditions will be described in the next paragraph. 
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6 Suppression of renal excretion of fencamfamine in man 
Introduction 
It is well known that the renal excretion of acidic and basic drugs depends on 
the urinary pH. If in man, acid urine is produced (pH 5-6), at least 5 0 % of the 
dextro amphetamine is excreted (Beckett, 1964, 1965). Under alkaline con­
ditions (pH 7-8) the renal excretion of dextro amphetamine is reduced to 
about 10 percent (Beckett 1965, 1968). 
From a comparative study of the basic strength and the lipophilic nature of 
amphetamine-like agents it was found that certain psychomotor stimulants 
were considerably less basic than amphetamine (pK a = 9.97) but at the same 
time more lipophilic (Section II). This suggested that under alkaline conditions 
the suppression of renal excretion for drugs like fencamfamine (pK :, = 8.7) 
might be much greater than that of amphetamine. The urinary excretion of 
these drugs might fall below detectable levels using methods currently avail­
able. 
As a consequence the doping control might be circumvented by the intake 
of alkalising agents if such drugs were being used. 
Results and discussion 
Fencamfamine was rapidly absorbed as evidenced by the relatively high renal 
excretion rate (1-2 ид/тіп) during the first hours after ingestion. The rate of 
renal excretion declined over several days. Since, under conditions of constant 
urinary pH and constant tubular secretion rate, the renal excretion rate is 
directly proportional to the plasma water drug concentration it may be con­
cluded that fencamfamine is slowly eliminated from the human body. The bio­
logical half life time was about 12 hr. 
Table 3 
The influence of alkali intake on the renal excretion of fencamfamine and 
pipradrol in man. 
drug 
Fencamfamine 
Fencamfamine 
Fencamfamine 
Fencamfamine 
Fencamfamine 
Pipradrol 
Pipradrol 
Pipradrol 
dose (mg) 
20 
20 
20 
20 
20 
10 
10 
20 
subject 
F N. (a) 
H.H. 
T.V. 
T V . (b) 
C.V. 
H.K. 
C.V. 
T.P. 
(g) 
N a H C 0 3 
10 
20 
10 
10 
6 
2 
6 
— 
(g) 
NH 4 CI 
— 
1 6 
1 6 
3 2 
4 8 
— 
— 
8 0 
t l , 2 ( h ) 
— 
— 
10 
12 
27 
22 
12 
(%) 
excreted 
— 
— 
— 
8 
5 
30 
20 
86 
suppression 
during 
18 hr 
24 hr 
24 hr 
23 hr 
8 h r 
not 
not 
not 
All subjects took 0.8 g NH4CI per day prior to the ingestion of bicarbonate. 
One day following bicarbonate intake NH4CI was given; the total amount is indicated in 
the table. 
(a) This subject also ingested acetazolamide (250 mg) and experienced a very strong 
diuresis. 
(b) This subject excreted 26% of the ingested alkali. 
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FENCAMFAMINE HCl 2 0 m g 
ur ine (ml/min) 
7.0 
6 . 0 -
5.0 
4.0 
3.0 
2.0 
1.0 
Ш///т////„»,тйШ 4. Ж Ρ—' 
bicarbonate excretion (mg/ml) 
Γ 70 
60 
-50 
40 
30 
20 
10 
pH 
5.Ü 
cumulative renal excretion (mg base) 
renal excretion rate ( / /g /min : log scale) 
1.0 
0.1-
0.01 
Ü1 fencamf amine 
η J 
Г^ 
10 о Na-bicarbonate 
— -
12 24 
—
r~ 
36 
800mg Ammonium Chloride ( 5 x ) 
43 6 0 72 &4 96 h 
figure 7: Renal excretion rate, urine pH, urine production and cumulative renal excretion 
of fencamfamine following after intake of 20 mg fencamfamine HCl under normal urine 
pH conditions and under influence of alkalisation with sodiumbicarbonate (10 g). The 
excretion of alkali is also shown The production of alkaline urine was terminated by the 
intake of 4 g ammoniumchloride. Note that the excretion of fencamfamine is completely 
suppressed during one day by the intake of bicarbonate. 
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Ingestion of 10 g sodium bicarbonate caused the production of basic urine 
and the secretion of alkali as evidenced by titration of the urine (see fig 7) 
Consequently the rate of excretion of fencamfamine was drastically reduced 
to such an extent that fencamfamine could not be detected in the urine 
The amount of bicarbonate ingested determined the duration of the production 
of alkaline urine and the amount of alkali excreted (see table 3) If less than 
5 g sodium bicarbonate was ingested, alkaline urine was produced only over 
a few hr, while 10 g caused alkaline urine over several hr (20-28 hr) Si-
multaneously there was an osmotic diuresis induced by bicarbonate that 
could be significantly increased by simultaneous ingestion of acetazolamide 
(250 mg), see table 3 
Another stimulant, pipradol, was less rapidly eliminated from the human body 
as evidenced by its longer halflife time about 25 hr After ingestion of pipra-
drol HCl, the excretion rate following intake of sodiumbicarbonade was also 
reduced but to a lesser extent Pipradol could also be detected in the urine 
under alkaline conditions Its stimulating effect was however greatly enhanced 
It may be concluded that the control on doping may lead to false negative 
results when fencamfamine has been used in combination with alkalizing 
agents 
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CHAPTER 4 
KINETICS OF DRUG METABOLISM 
Introduction 
After ingestion of an amphetamine derivative, for instance N-isopropylamphe-
tamine, N-dealkylation under formation of the metabolite amphetamine occurs. 
This metabolite in turn is metabolized further to benzoic acid. The metabolic 
routes involved are presented in figure 8. 
Dose N-ieopropyl 
amphetamine 
X 
de*l 
km 
, deam 
km 
benzoic 
J 
acid 
ζ 
, des 
amphetamine 
V 
/ óeam 
/ * m m 
m 
*mm 
Calculation of the relative importance of various routes of bio degradation of 
amphetamines from renal excretion data. 
The rate of elimination of the compound N-isopropylamphetamine and there-
fore the chango of blood concentration (x) per unit of time may be described 
by the following equation: 
dQipa = V f d j L = _ k e , x = _ ( k r + k 
dt f d t e l \ r + 
deal deam 
m + k m + kr 
The renal excretion rate of unchanged product is: 
dQi 
dt 
P§. = k r .x 
The rate of formation and elimination and therefore the change in the con-
centration of the N-dealkylated metabolite (y) per unit of time is. 
^deal 
i!ân_ . V fm . *¿_ = k * a ' x _ fk' 
dt T - - ^* 'deal d t
deal .deam 
mr •+ K m m + k m m * y 
Because the metabolite is further eliminated by excretion and metabolism the 
amount amphetamine (y) excreted as metabolite may be given by 
. - d e a l _, . 
d Q m r _
 k
d e a l
 v 
dt " m r ' y 
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The rate of deamination of N-isopropylamphetamine is: 
а эгп 
d Ç m ,
т
 d z k d e a m x u. k d e a m v k d e a m z 
= f Τ ' 7 Π - = m , x + K m m , y ~ "mei ' 
d t deam a t 
and the amount excreted for instance as benzoic-acid, methylbenzylketone (z) 
is: 
m m e l 
When the excretion process is completed (t>)rt,,) and the amount N-isopro-
pylamphetamine and metabolite amphetamine excreted totally (cumulative) has 
been measured, the percentage excreted can be calculated· 
d Q e | = k e , x d t _ ^- <?el = k el / 
f t=oo 
' x.dt 
Л-0 
The total amount of the drug that can be eliminated is the fraction of the dose 
(D) that is absorbed, thus Qe| = D F with 0 < F < 1. 
^ = 0 0 
x dt = DF_ 
k e J 
' t - o 
The amount of drug excreted unaltered in the urine is given b y 
d Q r = k r χ dt and therefore Q f = D F Jíü 
kel 
Thus, under the assumption (when not measured) that the dose administered 
is absorbed completely (F = 1) then the amount excreted totally (mg) can be 
expressed in % of the dose given. 
The amount totally N-dealkylated is. 
d Q d e a , = k d e a , x c j t 
.-deal _ c i/te31 Q „ , = D F K m 
m
 к 
K e l 
In the same way: the amount N-isopropylamphetamine deaminated is: 
„deam _ _ k d e a m Qm = D F _2m 
k e l 
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The amount N-dealkylation and deamination of N-isopropylamphetamine can­
not be measured directly The amphetamine formed also is metabolized and 
excreted Hence, the values of N-dealkylation, deamination and renal excretion 
of the parent compound amphetamine must be substituted in this case After 
infinite time (t = ~ ) the total amounts deammated are given by the following 
equations 
. _ d e a l deal 
d 4 n « i = k m * i - y d l 
t=oo 
deal deal к 0 ® a l . d e a l / D F Ç 3 
O m e l = <?m = D F ^ = k m e l / У d t = Т^ёШ-^ — 
K e l / K m e l e ' 
The total amount of metabolite due to N-dealkylation, excreted in the urine is 
_, —deal , deal . t d Q = k m , .y.dt Y m r m r J 
_, , , deal . deal 
d e a . _ D F k ^ 3 
m r
 ~ . d e a l . 
m 
v m e l el 
In practice, under acidic urine conditions (pH5) amphetamine is excreted for 
about 70% unchanged This means, that from every small amount ampheta­
mine, circulating in the body, (parent compound or metabolite) 70% is ex­
creted unchanged Let it be assumed that with N-isopropylamphetamine, 30% 
amphetamine («Mol) is excreted as metabolite 
This means that with the factor kr (deal) / km (deal)e! = 07 the value of 
km (deal) / ke| is 10/7 30% = 43% 
Thus the N-dealkylation of N-isopropylamphetamine under formation of 
amphetamine then occurs for 43% while only 33% is excreted as amphetamine 
Furthermore the total amount eliminated is the sum of all partial elimination 
routes 
Qei = Qm (deam) + Qm (deal) + Qm (other routes) + Qr = 100% 
It is observed that with phentermine about 100% is excreted unchanged and 
from the literature it is derived that parahydroxylation in man accounts only 
1-5%, thus this figure may be neglected Therefore under these further re­
strictions it holds that Elimination = deamination + dealkylation + excretion 
= 100% The percentage excretion and the percentage N-dealkylation can be 
measured so that by substraction, the percentage of deamination can be cal­
culated Examples are given in section III 
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CHAPTER 5 
ROUTES OF ADMINISTRATION OF AMPHETAMINES 
Introduction 
The normal route of administration of amphetamines is via oral ingestion of 
a tablet, or capsule, containing the drug Drug addicts preferentially use the 
intravenous route which leads to extremely high "peak" concentrations 
Beckett (1967) studied absorption after application in the oral cavity (not 
ingestion) We have studied percutaneous absorption and absorption following 
rectal administration 
1 Percutaneous absorption of amphetamines in man 
Amphetamines and related substances are excreted with the sweat in human 
subjects (chapter 3) An application of this excretion may be that doping con­
trol may be performed not only on urine but also on sweat The amphetamine 
concentration in the sweat parallels the blood concentration and the renal 
excretion rate The rate of excretion of amphetamines in sweat was found to 
be independent of the sweat pH and in this way this excretion process differs 
from that performed by the kidney Since amphetamines in sweat on the 
skin may be present to a certain percentage as free base, it is possible that 
part of the excreted amphetamine is reabsorbed through the skin again The 
same problem holds for the organic chemist synthesizing amphetamine deriva­
tives, from whom the skin may be in contact with free amphetamine base The 
rate constants governing excretion and absorption determine the degree of 
excretion of the amphetamines by the sweat The aim of the study was 
to investigate the effectiveness of the excretion process of amphetami­
nes by the sweat Therefore the percutaneous absorption of a few amphe­
tamines by the skin under "normal" circumstances has been investigated 
This aim and thus the results are different from those mentioned by Beckett, 
(1972) who studied the possibility of penetration of ephednnes through the 
skin and protected the ephedrme against evaporation by a skin patch The 
rate of absorption is reflected in the blood concentration profile, which in 
turn is related with the renal excretion rate Therefore the overall rate of 
penetration and the amount absorbed therefore could be followed from uri­
nary excretion data 
Results 
15-50 mg of the free base of ( + ) amphetamine, ( + ) N-methylamphetamme or 
phentermine was applied on the skin of the arms of a healthy male adult 
volunteer The arms were previously cleaned thoroughly with methanol-chloro-
form in order to remove fatty layers The amphetamines were allowed to pene­
trate for 8 hour The two surfaces of the skin at which the amphetamines 
were applied were 2 χ 150 cm2 Also several modes of application were used 
as mentioned in table 4 After GLC analysis of the urine it could be con-
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figure 9 Renal excretion rate, urine pH, urine production and cumulative renal excretion 
of ( + ) amphetamine and ( + ) N-methylamphetamine after application at the skin Note 
the extremely low amount of the amphetamines that is absorbed 
eluded that the compounds applied had penetrated the skin and were excreted 
in the urine (table 4) The excretion rate was extremely low in comparison with 
the excretion rate of the compounds after oral administration (Stuttgen 1972) 
In fig 9 the renal excretion rate of both amphetamine and N-methylamphe-
tamine are given From the cumulative renal excretion it can be derived that 
only about 0 5 % of the amphetamine is excreted in the urine In figure 9, 
20 hours after application of amphetamine, N-methylamphetamine was applied 
percutaneously, and from figure 9 it can be observed that amphetamine now 
is excreted as metabolite of N-methylamphetamine There is a remarkable 
difference in the ratio parent compound/metabolite, depending on the route 
of administration (oral, intravenous, percutaneous) in the excretion rate and 
cumulative renal excretion From the equation for the blood concentration of 
a drug after oral administration it can be derived that when the absorption 
process is very slow the top of the curve is f lattened The continuous ab­
sorption process enables a continuous metabolism and formation of the 
metabolite The increase of the concentration of both parent compound and 
metabolite may be considered as a slow infusion or chronic administration 
The same situation is observed at the end of the elimination process of 
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N-alkyl substituted amphetamines where in the renal excretion rate of both 
parent compound and metabolite are of the same magnitude V d Kleyn 
(1971) showed this phenomenon after accumulation of diazepam and its me­
tabolite desmethyldiazepam Dollery (1971) observed an increase of the per­
centage metabolite after oral (slow) administration of propanolol and isoprote­
renol compared with intravenous (fast) administration Also the N-methylam-
phetamine may be formed slowly as metabolite as is observed with the 
compounds N-dimethyl-, N-methylethyl-, N-methylisopropyl-, and N-methyl-
benzylamphetamine (see section III, chapter 3) Beckett (1972) recently re­
ported that ephednnes in doses up to 20 «Mol (4 mg) were resorbed by the 
skin very well The route of application was different from the route fol lowed 
in this study (skin path-free skin) It was also observed that the peak in the 
renal excretion is shifted to longer times as compared with oral administration 
These different results reveal that the skin in the natural surroundings, after 
excretion of amphetamines by the sweat, is an ideal barrier to protect against 
uncontrolled penetration Amphetamine in contact with the skin is from this 
view not very dangerous 
2 Absorption following by rectal administration of amphetamines 
In the foregoing paragraph it was shown that the route of administration has 
a great influence at the blood concentration profi le and related renal excretion 
and metabolism Hence, it was interesting to investigate the difference in 
absorption and metabolic behaviour of closely related compounds administered 
orally and by means of a suppository For this purpose phentermme was given 
orally and the amphetamine rectally, at the same time Phentermme was con­
sidered as standard for the absorption, because the compound is excreted 
for 100% unchanged (section III, chapter 4) From the percentage of com­
pound excreted and the corresponding half life time given in table 5 and fig­
ure 9, it can be derived that there exists hardly any difference between the 
two routes of administration From both endpomts of the gastro-mtestinal 
tract the compounds are resorbed fast and very well 
Table 4 
Absorption of CNS stimulants by the human skin 
% Abs 
0 57 
0 67 
0 88 
0 1 6 
0 30 
0 22 
2 0 
1 0 
tl/2 
10 
21 
16 
max exc 
ц д / т і п 
0 1 2 
0 25 
0 1 0 
0 040 
0 080 
0 060 
0 80 
0 1 0 
hr 
30 
30 
48 
36 
30 
31 
30 
32 
compound 
( + ) amphetamine 
( + ) amphetamine 
( + ) amphetamine 
( + ) amphetamine 
( + ) amphetamine 
phentermme 
( + ) N methylamphetamine 
( + ) N-methylamphetamine 
dose mg 
15 
30 
30 
35 
36 
24 
12 
48 
solvent 
base 
ethanol 
midalgan ® 
ethanol 
ether 
base 
base 
base 
% E 
0 4 
0 47 
0 62 
0 11 
0 21 
0 22 
0 80 
0 25 
% E(M) percentage of the dose applied excreted in the urine (M = metabolite) 
% Abs percentage of the dose absorbed by the skin 
ti/2 halflife time of renal excretion 
Max exc maximum renal excretion rate in цд/тіп 
hr Duration of the experiment (hr) 
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urine production ml/mm 
25 
cumulat ive rena i 
excret ion ( m g base) 
12 
01 
0 0 1 
[Л^ phent 
amph 
» 17 90 m¿ phentermine HCl L-
(1Л Λ m¿ base ) o ra l 
• 2 0 m ¿ ( + ) amphetamine su lphate 
(11 6 m¿ b a s e ) rec ta l 
S u b j e c t J В 
T í . 7 hi 
ги 
36 Ав 60 
t i m e ( h ) 
figure 10 Renal excretion 
rate, urine pH, urine pro­
duction and cumulative 
renal excretion of ( + ) 
amphetamine and phenter-
mme after oral and rectal 
administration respective'y 
Phentermine, orally given 
is considered as standard 
for absorption and elimina­
tion 
Table 5 
Halflife time and percentage of the dose excreted of amphetamine, phenter­
mine and norephedrine under acid urine conditions (pH 5) 
compound subject 
phentermine J В 
( + ) amphetamine 
phentermine H F 
( + ) amphetamine 
phentermine Τ Ρ 
( + ) amphetamine 
norpseudoephedrine 
route of 
>e mg 
179 
20 
155 
20 
11 2 
11 4 
10 
administration 
oral 
supp 
oral 
supp 
oral 
supp 
supp 
t'u 
12 
7 
10 
7 
10 
7 
6 
%E 
86 
56 
92 
65 
92 
75 
80 
ti/2 halfhfe time (hr) % E percentage of the dose excreted 
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SECTION II 
ANALYTICAL PROCEDURE AND METHODOLOGY 
CHAPTER 1 
GAS CHROMATOGRAPHY OF AMPHETAMINES 
Introduction 
Ths concentration of amphetamines in biological fluids can be measured in 
various ways The eldest and non selective one is the spectrophotometric 
method described by Axelrod (1954) using methylorange as complexing agent 
To date, the gas chromatographic analysis is used for the estimation of am­
phetamines The method has many advantages above the elder spectropho­
tometric one The compounds can be separated and estimated together 
without interfering with each other The possibility of chosing a column with 
particular separation characteristics in order to separate various types of 
amphetamine like compounds provides the large flexibility of the method The 
detection system makes it possible to measure concentrations in the μg-pg/ 
ml range 
The column 
For the study of the metabolism of a large variety of amphetamine derivatives 
the parent compound and the metabolites formed ought to be well separated 
A silicon type column as 3% Se 30 (Baumler 1969, Brandenberger 1967, Mule 
1971, McMartin 1966) or 3% OV 17 (Jun 1968, Noonan 1969, Bruce 1969, 
Noirfalise 1968, Beckett 1964, Solon 1970, Irvine 1969) is able to separate the 
amphetamine and its N-alkyl substituted derivatives at very low temperatures 
(100-110CC) The column can be used in screening techniques in toxicology, 
but due to the apolar character of the phase, in principle almost any com­
pound can be eluted and may interfere with the compounds that must be 
measured Alkaline stationary phases are more selective for separating and 
eluting amines, compounds with acidic character are not eluted at all The 
stationary phases used may be KOH coated with an apolar phase, such as 
Apiezon, Se 30, OV17 but even a polar one as Carbowax 20 M With Carbo-
wax 20 M-KOH mixtures, the amphetamines are well separated and eluted in 
the following manner N-dimethylamphetamine, N-methylamphetamine and am­
phetamine (Beckett 1967, Donike 1970, van Zwol 1966, Parker 1962, Beckett 
1965) A column packed with 3% Carbowax-2% KOH is the best column for 
the analysis of amines with a relatively high molecular weight as the antihist­
amine and tricyclic antidepressants In this study the liquid phase Apiezon-KOH 
was chosen (Solon 1970, Beckett 1967, Moffat 1972) The phase is very suit­
able for the analysis of amines with a relatively low molecular weight Clas­
ses of phenylethylamines, such as amphetamines, ephednnes, phentermines 
and aminopropiophenones are well separated The KOH is applied in order to 
reduce tailing of the peaks An other effect of the KOH is reduction of the 
retention time The smaller the ratio Apiezon/KOH, the smaller the retention 
time and separation factor between the amphetamines (fig 1) With the mix­
ture 20% Apiezon-5% KOH, the phenylethyamme derivatives are well sepa­
rated and the retention time is not too long for the analysis of large series 
of samples The amount of Apiezon diminishes the elution of free fatty com-
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figure 1 : Gas chromatogram of a mixture of N-alkyl substituted phenylethylamines and 
amphetamines at a column, packed with 20% Apiezon 5% KOH Gaschrom Q 60-80 
mesh. 1 = phenylethylamine and amphetamine, 2 N-methyl-, 3 N-ethyl-, 4 N-isopropyl-, 
and 5 N-n propyl derivatives of phenylethylamine and amphetamine. In a series of 
N-alkyl substituted derivatives the retention time increases linearly with the molecular 
weight. The separation between the derivatives increases with an increasing ratio 
between the load of apiezon and KOH 
pounds after extraction of blood, saliva, sweat and urine samples. In some 
cases the KOH of the column however may act as a reactant. Phacetoperan, 
methylphenidate are hydrolyzed and with secondary aminopropiophenones 
dehydrogenation occurs. For the analysis of these compounds the stationary 
phase OV 17 was used. In table 2 the retention times relative to amphetamine 
of classes of phenylethylamines are given. 
44 
The detection system 
There are many detection systems available for the analysis of central nervous 
stimulants The detectors are flame ionisation detector ( F I D ) , nitrogen 
flame ionisation detector (NFID), electron capture detecor (E С D ) and the 
mass spectrometer The limit of detection of a compound varies among these 
detectors The lowest amount of amphetamine injected into the gas Chromato­
graph and detectable is 1 ng with the F I D and 100 pg with the NFID, de­
pending on the nitrogen content The nitrogen detector has a serious advan­
tage over the F I D for measuring nitrogen containing compounds The signals 
of these compounds are advanced over those derived from compounds with­
out nitrogen In this way the analysis of barbiturates is improved by diminish­
ing interference of unknown blood constituents (Breimer 1972, Domke 1970, 
Faber 1971) 
When a compound has a strong electron affinity or is denvatized to such a 
compound, the limit of 1 pg can be reached with the electron capture detector 
The electron affinity, however, is strongly determined by the compounds, sub-
stituents and position of the substituent (Krejci 1970, Matin 1972, Moffat 
1972, Walle 1970) Amphetamines may be converted into heptafluorobutyryl 
derivatives (Matin 1972, Moffat 1972 and Walle 1972) or to tnchloroacetyl 
derivatives (Anggard 1970) For the measurement of the concentration of one 
single compound this method is very sensitive and useful, but for metabolic 
studies the metabolites must be denvatized and separated too The latter 
requirement has been overcome by Matin (1972) by using an OV 225 column 
in stead of OV 1, but in general it is the limiting factor in the study of phar­
macokinetics of amphetamines 
In this study, the demand of the large separation factor of the column and 
the choice of the Apiezon-KOH column implies that the denvatized ampheta­
mines are not eluted from the column and for this reason EC detection was 
used only incidentally Hence, the FID is used for measuring the amphetamine 
concentration in the urine and during the first hours after ingestion in the 
blood The lack of the use of the very sensitive EC detection directed the 
study from pure pharmacokinetics to the metabolic behaviour of the ampheta­
mines in man 
The internal standard 
For the estimation of the concentration of amphetamine derivatives in blood 
or urine, the internal standard method is used It is well known, that the re­
tention time of the standard must be close to that of the compounds to be 
measured, the standard must be chemical stable and have the same degree 
of volatility as the sample components (Grant 1961, Burchfield 1962) Quanti­
tative results could be calculated from the amount of standard added to urine 
or blood and the ratio of peak areas regardless to losses during sample 
preparation Also the standard may be added after extraction and prior to in­
jection In both cases a correction is needed according to 
As W, 
F = 
Αι Ws 
where F is the correction factor, W, and Wi the masses of standard and 
compound weighed into the calibration mixture and A, and A] the correspond-
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ing peak areas The peak areas are measured as follows peak height times 
peak width at half height The comparison of peak areas of internal standard 
and amphetamines introduces an inaccuracy as does the extraction procedure, 
the separation and the response of the FID These irregularities are reflected 
in the correction factor The choice of the standard depends on the detector 
available The ideal standard, deuterated analogues of the compounds that 
must be measured, can be used with the combination gas chromatography-
mass spectrometry (Knapp 1972) With the FID, the standard must be different 
from the components of the mixture For the analysis of the amphetamines, 
N-methylbenzylamine is used as standard For compounds with a very long re-
tention time, 4-chlorophentermine, N-isopropylphentermine or orphenadnne 
are used The correction factors are given in table 1 
Table 1 
Correction factors of the ratio peaksurface internal standard to peaksurface 
of amphetamines and ratio of corresponding amounts of standard and amphe-
tamines ( ± 5% S E ) 
compound 
amphetamine 
N methylamphetamine 
N ethylamphetamine 
N-isopropylamphetamine 
N-dimethylamphetamine 
N-methylethylamphetamine 
N-methylisopropylamphetamine 
N-cec isobutylamphetamine 
phentermme 
N-methylphentermine 
N-isopropylphentermine 
4-chlorophentermine 
propylhexedrine 
norpropylhexednne 
cyclopentamme 
norcyclopentamine 
amantadine 
fenfluramine 
methoxyphenamme 
N methylaminopropiophenone 
N-dimethylaminopropiophenone 
N-ethylaminopropiophenone 
N-diethylaminopropiophenone 
ephednne 
N-methylephednne 
threo phenmetrazine 
erythro phenmetrazine 
zylofuramme 
correction factor 
0 95 
0 80 
0 75 
0 72 
0 85 
0 85 
0 85 
0 57 
0 80 
0 68 
0 75 
0 80 
0 80 
0 90 
0 90 
0 85 
0 95 
0 72 
2 96 
0 92 
1 04 
0 84 
2 26 
080 
0 80 
0 80 
0 68 
internal standard 
N-methylbenzylamine 
fenfluramine 
4-chlorophentermine 
N-methylbenzylamine 
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Sensitivity and accuracy of the F ID 
In general the sensitivity of the analysis is determined by the step in which the 
highest percentage of components is lost With amphetamines the extraction 
procedure determines the total sensitivity The H&P 402 gas Chromatograph 
with flame ionisation detector, provided with a column of 1 80 m, packed with 
20% Apiezon 5% KOH Diatoport-S 60-80 m, gives a small but distinct signal 
when one ng of reference solution of N-methylbenzylamine, amphetamine, 
N-methylamphetamine and N-dimethylamphetamine is injected If 1 ng of the 
compounds is extracted from 10 or 20 ml urine no signal appears at the 
appropriate retention time In order to be able to inject 1 ng into the gas 
Chromatograph, a much higher amount ought to be present in the sample 
When a series of urine samples, containing 1 цд of the internal standard, and 
respectively 1000 ng, 500 ng, 100 ng, 50 ng, 25 ng and 10 ng of amphetamine 
and N-methylamphetamine is extracted with ether, concentrated to 50-100 μΙ 
and injected (5-6 μΙ) into the gas Chromatograph, the limit of accuracy is 
found to be 50 ng The solutions containing 25 and 10 ng give peaks but the 
concentrations can only be calculated with great errors Thus 50-100 ng can 
be extracted from 10 ml urine without great faults 
Limit of detection 
When excretion studies are made, it is useful to use a lowest limit of ex­
cretion rate This means that values of the excretion rate of a certain com­
pound, found beyond a certain time after ingestion of the compound are of 
no significance for the total process of elimination When after ingestion of 
the compound a maximum excretion rate is found, then the lowest limit in 
the excretion rate can be 1 % or 0 1 % of that maximum value With an accu­
racy of the method of analysis of ± 5% and a fairly great variation in the 
cumulative renal excretion of the subject, the limit of 1 % of the maximum 
excretion rate is useful In general, the excretion rate is expressed by the 
following formulas 
dQ/dt = kr C A C A = CA° '/ti,, 
and it can be calculated that after 3,5 times the halflife time, the excretion 
rate is 10% of the maximal excretion rate and after 7 times only 1 % of its 
maximum value 
When 10 mg of dextro amphetamine is ingested and excreted under acidic 
urine conditions, the maximal renal excretion rate found is 10 μg/mιn During 
60 hours the excretion rate declined to 100 ng/min This value is 1 % of 
the maximum and is reached in 7 times the halflife time of 7 hr In this case 
the detection limit of the method of analysis coincide with the end of the 
excretion process When for instance 1 mg of amphetamine is ingested or 
when a very small amount of amphetamine is absorbed by the skin (see sec­
tion I) the maximum excretion rate is 1 μg/mιn The detection limit still 
remains 100 ng and this situation is reached at 3 5 times the halflife time of 
7 hr In this situation the detection limit is not the end of the excretion process 
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Gas chromatographic conditions 
A Hewlett and Packard 402 gas Chromatograph was used, equipped with F.I.D. 
The column, 1.80 m 3 mm diameter was packed with 20% Apiezon-5% KOH 
on Diatoport-S or Gaschrom-Q, 60-80 mesh. The carrier gas was nitrogen at 
20 ml/mm. The flow rate of hydrogen was 30 ml and of air 150 ml/mm. A 
column packed with 3% OV17 or 3% Carbowax 20 M -2% KOH was used 
in all those cases where the apiezon column could not be used 
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CHAPTER 2 
MASS SPECTROMETRY OF AMPHETAMINES 
Introduction 
From the literature it can be observed that there is hardly any publication in 
which mass spectra of amphetamines and non stimulating anti obesity drugs 
are described. The reason for this lack of information might be that the 
mass spectra are not very remarkable. The cleavage pattern of amphetamines 
in the mass spectrometer is very regular and is determined predominantly by 
the nitrogen atom which serves as the main centre of charge localisation. The 
phenyl ring is less important as a centre of charge localisation. The ratio 
between the two centres is about 1 0 : 1 
с Ç 
©-C&i-R — © - ¿ . C=N*-R 
The nitrogen atom is the centre of charge localisation, a homolytic cleavage 
and the result is an amine kation and a benzyl radical 
с с 
<6V?C-N-R • <0)-C * Ç-N-R 
m/e91 
The phenyl ring is the centre of charge localisation, a homolytic cleavage re-
sults in a tropil ium ion (m/e 91) and an amine radical. 
In general the rate of the formation of ions is dependent upon the energy of 
the electron bombardment (eV) and the intensity of the ions reaches its 
maximum at 40-50 eV. 
When the center of charge localisation is mainly at the phenyl ring the for-
mation rate of the ions may be much slower than when the center is at the ni-
trogen atom (see e.g. cannabinoids Vree 1972, Van Ginneken 1972, Breimer 
1972). 
The cleavage optimum of amphetamine is already reached at 10 eV. The mass 
spectrometnc analysis of metabolites and drugs is important because the 
concentrations of the compounds in blood or urine are very low, and only 
small amounts of sample are needed for recording a mass spectrum. The best 
technique for identification of the metabolites is the combination of gas chro-
matography and mass spectrometry, which avoid the procedure of collecting 
the small amounts of the compounds. In general, the combination GC-MS im-
plies a low resolution mass spectrum. Hence, identification of the compound 
must be done by comparison with mass spectra of known compounds. In this 
way for instance various new cannabinoids and metabolites could be identi-
fied (Vree 1972, Breimer 1972, van Ginneken 1972). In the study of the meta-
bolism of amphetamines, the GC-MS combination L.K.B. 9000 was used for 
identification of compounds and metabolites by comparison with reference 
spectra (fig 2). With deuterated amphetamines the mass spectrometer was 
used as a selective detector. After extraction and separation of a mixture of 
amphetamine derivatives and its deuterated analogues, the mass spectrometer 
was used as a selective detector for the determination of the deuterium con-
tent. The procedure will be described below for the various types of am-
phetamine like compounds. 
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figure 2· Mass spectrum of N-methylamphetamine and N-dimethylamphetamine extracted 
from human sweat after oral administration of N-dimethylamphetamine and mass spectra 
of the reference compounds 
Mass spectrometric conditions 
An L.K.B. 9000 gas chromatograph-mass spectrometer was used. The machine 
was equipped with two additional inlet systems: direct inlet and heated inlet. 
Glass columns, 1.80 m, 3 mm diameter, were used, packed with 20% Apiezon-
5% KOH on Diatoport S or Gaschrom Q, 60-80 mesh, or 3% OV 17 on 
Gaschrom Q 100-120 mesh. The carrier gas was helium at a flow rate of 
10-20 ml/mm. Temperatures: oven 100-200°, separator 230°, ion source 290°. 
Ionisation potential 20-70 eV, accelerating voltage 3,5 kV, trap current 60 μΑ. 
UV recorder paper Kodak, type 1895, spec. 111. 
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Mass spectra of classes of amphetamines 
amphetamines 
The cleavage pattern mentioned in the introduction accounts for the base peak 
m/e 44 in amphetamine and mass fragment m/e 91 (10%) With N-alkyl sub­
stituted amphetamines mass fragment m/e 91 is always present in relative 
low abundance (10-15%) while the base peak is obtained by adding the mass 
of the substituent to m/e 44 (C(CH 3) = N-alkyl) The relative abundance of the 
parent peak for aliphatic amines is very low ( < 1%) (fig 3, fig 4) 
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figure 3 Mass spectra of N-alkyl substituted amphetamines 
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phentermines 
In the same way as with the amphetamines the cleavage pattern in phenter-
mme results in the base peak m/e 58 and mass fragment m/e 91 
ephednnes 
The substitution of a hydroxyl group at the β carbon atom changes m/e 91 
into m/e 105 and m/e 106 The ratio between the relative abundance of mass 
fragments is rather characteristic m/e 105 m/e 106 = 3 1 
ammopropiophenones 
Substitution of a carbonyl group at the β carbon atom changes m/e 91 into 
m/e 105 With ammopropiophenones the ratio between the relative abun­
dances of the fragments m/e 105 and m/e 106 is about 10 1 With the aid 
of these ratio's ammopropiophenones can be distinguished from ephednnes 
by means of mass spectrometry only 
ring substituted amphetamines 
Ring substitution in many cases has no effect on the intensity of the mass-
fragments in the mass spectrum of amphetamines The nitrogen atom as centre 
of charge localisation is much more important than the phenyl ring Monochloro 
substituted amphetamines (2-, 3-, and 4-chloramphetamine) show all the char­
acteristic spectrum of amphetamine (base peak m/e 44) and fragment m/e 125 
due to the halogenated tropilium ion Fenfluramine gives as main fragments 
the base peak m/e 72 and the tnfluoromethyltropilium ion m/e 159 at a relative 
high abundance (60%) Loss of a CR group results in mass fragment m/e 109 
(30%) Methoxyphenamine is relative stable, the parent peak m/e 179 has a 
high relative abundance (10%) 
saturated amphetamines 
The saturated amphetamines, cyclohexylisopropylamines, follow the cleavage 
pattern of the aliphatic amines Mass fragment m/e 91 does not occur The 
fragments m/e 81 and m/e 83 of the cyclohexyl group are now present 
alicyclic amines 
When the nitrogen atom is part of a ring system then mass spectra with a 
strong parent peak are obtained For instance phenmetrazme show a parent 
peak m/e 177 The mass spectrum of threo and erythro phenmetrazme are 
slightly different In both isomers the base peak is m/e 77, but the intensity 
of mass fragment m/e 56 in the erythro isomer is 95% and in the threo 
isomer 40% At the apiezon-KOH column in the gas Chromatograph both com­
pounds could be separated The retention time of threo phenmetrazme is 
shorter than the retention time of the erythro isomer The reason for this par­
ticular gas chromatographic behaviour may be that the threo isomer is more 
spherical than the erythro isomer, the latter compound is more stretched 
Phendimetrazine show a more pronounced difference in the mass spectrum 
between the threo and erythro isomer Also in the gas Chromatograph the 
retention time of the threo isomer is shorter than that of the erythro isomer 
In the threo isomer the abundances of the mass fragments m/e 56 and m/e 
42 are 100% and 95% resp, while these in the erythro isomers are opposite, 
75% and 100% Amantadine gives a parent peak m/e 151 at 20% intensity 
and a base peak m/e 95 1-Phenyl-2-pyrrolidino-pentane, which contains a 
nitrogen atom in the ring system, shows a very weak parent peak The main 
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f igure 4 Mass spectra of N-dialkyl substituted amphetamines. 
cleavage is due to the phenyl ring which is the main centre of charge locali­
sation. So a tropilium ion is formed, m/e 91, and a propyl fragment m/e 175. 
Nicotine can easily be recognized by the parent peak m/e 163 and fragment 
m/e 162. After the cleavage of the methyl group the pyrrol ring is successive­
ly broken to mass fragment m/e 133. Mass fragment m/e 84, the base peak, 
represents the pyrrole group. The nicotine can easily be recognized from the 
ephednnes by comparing the base peaks of the ephednnes, m/e 44 and 
m/e 58 with m/e 84 of nicotine. The retention times of both ephednnes and 
nicotine are nearly the same. 
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Identification of drugs 
Comparison of the mass spectra of drug and reference compound is used in 
doping control, in providing evidence that amphetamines were excreted in 
human sweat, saliva (section I) and that amphetamines were absorbed by the 
skin (section I) (Anthony 1970, Beckett 1967, Sadee 1970, Knoche 1969, Mor­
gan 1972, Marsel 1972, Narasimhachan 1970) For the measurement of the 
deuterium effects in the metabolism of N-alkyl substituted amphetamines the 
concentration of the drugs were estimated by conventional gas chromato­
graphy, while the deuterium content of the mixtures were determined by 
means of mass spectrometry In order to be able to determine the ratio of 
deuterated-non deuterated amphetamine in a mixture of these compounds, we 
used the mass spectrum of this mixture, taking the ratio of the base peaks as 
a measure for the ratio of concentrations in the mixture A calibration curve 
was made using mixtures of D- and Η-amphetamines of known composition 
The mass fragments examined were amphetamine-deuteroamphetamine, line 
intensities m/e 44-45, N-methylamphetamine, N-tndeuteromethylamphetamine, 
line intensities m/e 58-61, N-isopropylamphetamine, N-deuteroisopropylam-
phetamme, line intensities m/e 86-87, N-isopropylamphetamine, N-deuteroiso-
propyldeuteroamphetamme, line intensities m/e 86-88, N-dimethylamphetamine, 
N-ditndeuteromethylamphetamine, by means of mass fragmentometry ratio of 
peak areas of the fragments m/e 72 and m/e 78 
For the calibration curves, line intensities at various concentrations in the 
gas chromatographic peak were measured The average ratio of the line in­
tensities was used This method is allowed when the retention times of the 
H- and D-amphetamine are equal When there is a difference in retention time, 
as is the case with N-dimethylamphetamine, the method of mass fragmen­
tometry must be followed For the other compounds both methods are followed 
but give the same calibration curve The accuracy of the estimation of the 
percentage deuterium in the samples is ± 2% 
An example of a calibration curve is given in fig 5 (section III, chapter 6) 
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figure 5 Calibration curve of the percentage N-deuteroisopylamphetamine and the ratio 
of line intensities of the base peaks m/e 86 and m/e 87 
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т а м - fragmenkogramo of ovveat" sample VZ 5 
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m/e 72 
m/e 5Ö 
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methyl benzylamine 
figure 6 Mass fragmentograms of fragments m/e 58, m/e 72 and m/e 91 recorded of an 
extract of a sample of sweat after oral administration of N-dimethylamphetamine 
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Table 2 
Mass spectra and relative retention times of CNS stimulants 
100% 
m/e 
44 
58 
72 
86 
86 
91 
72 
86 
91 
91 
70 
110 
112 
124 
126 
138 
140 
44 
58 
72 
72 
86 
58 
91 
160 
44 
98 
250 
58 
72 
100 
58 
44 
44 
44 
44 
58 
72 
86 
86-44 
100 
58 
72 
100 
44 
120 
72 
86 
42 
7 0 % 
m/e 
65 
56 
58 
120 
120 
134 
91 
87 
100 
148 
91 
44 
91 
44 
91 
44 
— 
65 
119-91 
100 
91 
207 
42-91 
91 
58 
42 
126 
126 
89 
78 
78 
91 
44 
77 
44 
30 
73-77 
72 
105 
118 
70 
44 
84 
5 0 % 
m/e 
91 
91 
91 
162-91 
162-91 
179-162 
176 
91-98-161 
67-44 
91 
81-44 
91 
44-96 
91-97-56 
154 
168-170 
— 
139 
163 
91 
148-181 
134 
148 
91-117 
125-178 
169 
169 
159 
105 
105 
105 
105 
105 
121 
105 
105 
105 
rel ret time 
compound 
Apiezon-KOH 
amphetamine 
N-methylamphetamine 
N-ethylamphetamme 
N-isopropylamphetamine 
N-propylamphetamme 
N-benzylamphetamine 
N-dimethylamphetamine 
N-methylethylamphetamine 
N-methyhsopropylamphetamine 
N-methylbenzylamphetamine 
N-cyclobutylamphetamine 
N-cyclopentylamphetamine schiff base 
N-cyclopentylamphetamine 
N-cyclohexylamphetamine schiff base 
N-cyclohexylamphetamine 
N-cycloheptylamphetamme schiff base 
N-cycloheptylamphetamine 
cyclohexyhsopropylamine 
N-methyl-
N-ethyl-
phydroxy-N-ethyl-
N-isopropyl-
cyclohexyhsobutylamine 
biamphetamine 
biamphetamine schiff base 
sec butylamphetamme 
N-sec butylamphetamme schiff base 
captagon 
phentermine 
N-methylphentermine 
N-isopropylphentermine 
4-chlorophentermine 
2-chloroamphetamine 
3-chloroamphetamme 
3,4-dichloroamphetamine 
nor-ephednne 
ephedrme 
N-ethylnorephedrme 
N-n propylnorephednne 
N-isopropylnorephednne 
N-n butylnorephednne 
ephedrmeacetate 
N-dimethylnorephednne 
N-diethylnorephednne 
aminopropiophenone 
N-methyl-
N-ethyl-
N-n-propyl-(direct inlet) 
N-n-propyl-
1 00 
1 38 
1 90 
1 97 
2 20 
— 
1 97 
3 25 
4 05 
— 
2 20 
5 92 
7 20 
9 90 
11 80 
21 0 
23 6 
1 00 
1 38 
1 90 
5 20 
1 97 
1 23 
— 
— 
3 30 
3 25 
— 
1 23 
215 
2 50 
315 
1 27 
1 27 
2 94 
2 62 
3 43 
4 05 
9 70 
5 0 
11 0 
3 52 
4 51 
7 33 
— 
— 
3 31 
— 
5 60 
100% 
m/e 
86 
42 
100 
42 
72 
100 
133 
58 
44 
44 
120 
84 
182 
58 
58 
30 
148 
136 
126 
126 
56 
56 
56 
84 
70 
98 
84 
95 
196 
58 
84 
84 
72 
82 
86 
152 
108-109 
108 
71 
71 
57 
42 
163 
191 
44 
7 0 % 
m/e 
44 
84 
44 
98 
105 
105 
132 
41 
152 
180 
243 
283-120 
211 
204 
73 
118-117 
128 
150 
91 
91-119 
73 
239 
133 
89 
215 
105 
151 
110 
91 
92 
130 
159 
96 
146 
181 
137 
137 
42 
56 
42 
57 
135 
57 
168 
5 0 % 
m/e 
105 
105 
105 
77-57 
125 
126 
165 
199-225 
167 
156 
165-166 
91 
91 
91 
175 
162 
196 
145 
162-161 
177 
186 
182 
108 
67 
177-179 
233 
215 
109 
141 
198 
82-120 
179 
80 
177 
177 
191 
191 
194 
206 
137 
compound 
N-isopropyl-(direct inlet) 
N-isopropyl-
N-n-butyl-(direct inlet) 
N-n-butyl 
N-dimethyl-
N-diethyl-
tranylcypromine 
cyclopentamine 
D O M STP 
DOET 
ferrocenyhsopropylamine 
N-isopropyl schiff base 
mescaline 
orphenadrine 
orphenadrine 
3-phenylpropy lamine 
zylofuramme 
thymol 
pyrovalerone 
phenylpyrrohdinopentane (Katovit) 
aminorex 
clominorex 
fluminorex 
nicotine 
pemoline 
fencamfamine 
pipradrol 
amantadme 
Coffeine 
methoxyphenamine 
methylphenidate 
threo phacetoperane 
fenfluramine 
atropine 
scopolamine 
cocaine 
phenacetine 
p-ethoxyanihne 
threo phenmetrazine 
erythro phenmetrazine 
threo phendimetrazine 
erythro phendimetrazme 
p-hydroxy phenmetrazme threo 
p-hydroxy phenmetrazme threo 
metoxamine 
Apiezon-KOH 
rei ret time 
3 82 
— 
9 10 
3 04 
6 28 
1 53 
0 81 
5 55 
100 
8 45 
11 6 
— 
— 
20 0 
1 55 
8 73 
2 71 
— 
14 60 
— 
— 
— 
2 83 
— 
12 60 
100 
2 39 
— 
3 57 
12 20 
100 
1 25 
1 48 
2 35 
1 66 
9 90 
1 97 
5 68 
7 08 
651 
7 93 
— 
— 
— 
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Mass fregmentography 
With the combination of gas chromatography- mass spectrometry it is possible 
to obtain a gas chromatogram, from which the ion current is derived from the 
ions of one single mass fragment. For instance: when only fragment m/e 
44 can reach the collector, and is recorded then each compound which frag-
ments into m/e 44 will show a peak at the chromatogram. In principle each 
mass number between 2 and 800 can be chosen. The method can be extended 
by two additional masses, deviating not more than 10% of the first mass 
chosen. Hammer and Holmstedt (1968) in this way identified metabolites of 
chlorpromazine. The technique is emploid for measuring very low amounts of 
amphetamines in blood (Cattabeni 1972), in the sweat, fig 6, saliva and in 
trace analysis in the urine after penetration through the skin (fig 7, section I). 
The method enables the measurement of deuterium effects (section III). Deute-
rated amphetamines or in general deuterated homologues of the compounds 
that must be measured can be used as internal standard in the mass frag-
mentography (Knapp 1972, Cho 1973, Lundstròm 1970). 
figure 7. Mass spectrum, total ion current, mass fragmentograms of fragment m/e 44 
and m/e 91 of amphetamine, extracted from an urine sample after application of 
amphetamine at the skin. 
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CHAPTER 3 
PHYSICO-CHEMICAL CONSTANTS AND SYNTHESIS 
OF AMPHETAMINE LIKE COMPOUNDS 
Physico-chemical constants 
When studying the behaviour of amphetamines in man, large differences in 
renal excretion rate, metabolic conversion and partition over the body are 
found for the different amphetamines An explanation for these observed 
differences may be a difference in properties of the drug itself, such as pKa 
value, partition coefficients or in the interaction between drug and metabolizing 
enzyme In the latter case, the stencal environment of the drug or the inter-
action between drug and enzyme by polar interactions may be of importance 
Hansch (1968) tried to give an explanation of the oxidative deamination of a 
series of phenylalkylamines The rate of oxidation is not depending on the 
pKa value of the amines, but partition coefficients and steric factors influence 
much stronger the rate of oxidation These two factors are also important for 
the deamination and N-dealkylation of amphetamines If the partition coefficient 
is determined it must be kept in mind that the solvents chosen are arbitrary 
In the study of partition coefficients it may be useful to select solvents that 
can be reasonably well compared with biological membranes It must be sure, 
however, that in the body all the membranes, the amphetamine is dealing with, 
are not constant and of the same origin Macro autoradiographic studies 
showed (Vree 1971) that there are great concentration differences in disposition 
of amphetamines in the body The choice of the buccal mucosa (Beckett 1968) 
is even as arbitrary as the choice of the chloroform- or heptane-water system 
Beckett (1969) found in a latter stage a good correlation between buccal 
absorption and partition coefficient in a heptane-water system The partition 
coefficients of amphetamines reveal the tendency to increase lipid-solubility 
with increasing substitution (table 3) The lipid-solubility may influence metabo-
lism and excretion in the body The partition coefficients and pKa values give 
an idea how amphetamines may be distributed between blood and tissues, 
thus the apparent volume of distribution No information is obtained about a 
probable electric field or induction from the site of the enzyme, which alters 
the dissociation constant (Gregor 1964) or a different pH in the medium at 
the direct site of the metabolizing enzyme from the blood pH and intercellular 
fluid The true partition coefficient (TPC) (Reese 1964, Doluisio 1964, Raaf-
laub 1970) is a measure for the quantity at which the amphetamine can be 
dissolved in and penetrate through the membrane Before this situation is 
reached, the amphetamine, which is solvated by water molecules, have to break 
the hydrogen bonds This rupture may decrease the rate of partitioning In the 
water medium of the blood at pH 7 4, about 0,30% of the amphetamine is in 
the neutral form This form cannot exist in a water medium, it will be surrounded 
by a water shell, it is solvated This watershell has a rigid structure com-
pared with the water molecules in the bulk solvent The hydrogen bonding 
will be stronger with a greater negative charge at the N-atom With the sub-
stitution of a methyl or ethyl group or both at the N-atom there will be an 
increase in negative charge and subsequently an increase in hydrogen bond-
ing The alkyl groups which are substituted also has the effect that the inter-
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action among water molecules in the vicinity of these alkyl groups is streng-
thened, and thus forming a small water layer around the amphetamine mole-
cule. This water layer and the hydrogen bond must be broken if the ampheta-
mine molecule enters a lipid layer or a membrane (Grunwald 1967). 
Synthesis of N-alkyl substituted amphetamines 
The N-alkyl substituted amphetamines were synthesized according to the same 
principle of condensation of ( + ) or (—) amphetamine with the appropriate 
ketone, in methanol as solvent and magnesium sulphate as water trapping 
agent. 
The formation of the schiff base was followed by means of gas chromato-
graphy and combined GC-mass spectrometry (column 20% Apiezon 5% KOH). 
At the moment that all the amphetamine has disappeared or an equilibrium 
has been reached, the schiff base was reduced with NaBH4 or NaBD4. 
The schiff base and N-alkyl substituted amphetamine are separated at the 
20% Apiezon 5% KOH column, thus the reduction could be followed also by 
means of GC-MS. The reaction mixture was hydrolized with 2N HCl, made 
alkaline with KOH and extracted with ether The ether layer was dried over 
magnesium sulphate and HCl gas was passed through the solution. The HCl 
salt of the amphetamine derivative crystallized. If necessary, the salts were 
recrystallized from ethanol-ether until the amphetamine content was less than 
1%. 
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Table 3 
pKa values and partition coefficients of some derivatives of amphetamine 
compound pKa o/ „PiJral A P C chlor APC h e p t ТРС с Ы о г TPCh e p t 
phenylethylamine 
N-isopropyl-
amphetamine 
N-methyl-
N-ethyl-
N-isopropyl-
N-n propyl-
N-benzyl-
N-dimethyl-
N-methylethyl-
N-methyhsopropyl-
N-methylbenzyl-
phentermine 
N-methyl-
N-isopropyl-
4-chloro-
norephednne 
ephedrme 
norpseudoephednne 
pseudoephednne 
N-methylephednne 
phenmetrazine threo 
phenmetrazine erythro 
phendimetrazine threo 
fenfluramine 
methoxyphenamme 
propylhexedrine 
4-CI-amphetamine 
3-CI-amphetamine 
2-CI-amphetamine 
3-4-di-CI-amphetamine 
fencamfamine 
amantadine 
9 88 
102 
9 90 
1011 
10 23 
10 14 
9 98 
7 50 
9 8 0 
9 80 
9 45 
6 55 
10 11 
10 25 
10 20 
9 60 
9 55 
9 60 
9 40 
9 86 
9 30 
8 45 
8 45 
7 55 
9 1 0 
104 
10 74 
9 80 
9 80 
9 80 
9 20 
8 70 
10 70 
0 33 
0 1 5 
0 31 
0 19 
0 1 5 
0 18 
0 26 
44 1 
0 39 
0 39 
0 88 
87 2 
0 1 9 
0 1 3 
0 1 5 
0 62 
0 70 
0 62 
1 00 
0 33 
1 25 
8 20 
8 20 
44 0 
1 96 
0 1 0 
0 043 
0 39 
0 39 
0 39 
1 56 
4 76 
0 050 
0 075 
2 70 
0 48 
1 11 
2 67 
8 09 
21 2 
1000 
11 5 
190 
100 
1000 
1 00 
1 22 
10 1 
4 00 
0 001 
0 0 1 5 
0 001 
0 070 
1 00 
5 6 
4 00 
1000 
32 3 
1 00 
1 11 
0 8 1 8 
200 
0 40 
0 0 1 
0 052 
0 005 
0 0 1 5 
0 058 
0 2 1 2 
0 820 
49 
0 430 
0 666 
1 78 
65 6 
0 123 
0 156 
0 820 
0 111 
0 0001 
0 0001 
0 0001 
0 0001 
0 0 1 0 
0 1 1 
0 14 
3 70 
1 35 
0 0 1 0 
0 075 
0 036 
0 061 
0 25 
5 25 
0 0 1 0 
20 8 
1706 
146 
565 
1790 
4460 
8080 
2250 
2890 
4760 
11300 
1400 
514 
866 
5190 
797 
0 035 
2 42 
0 10 
20 0 
80 6 
190 
49 
2415 
1640 
1000 
2360 
206 
4200 
800 
0 277 
32 9 
1 88 
5 14 
38 6 
117 
312 
110 
108 
166 
200 
74 8 
63 2 
111 
520 
175 
0 001 
0 001 
0 001 
0 029 
0910 
1 35 
1 71 
8 92 
678 
10 
173 
9 1 0 
154 
160 
110 
20 
TPC true partition coefficient 
APC apparent partition coefficient 
hept system heptane-water (Teorell buffer, pH 7,4) 
chlor system chloroform-water (Teorell buffer, pH 7,4) 
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CHAPTER 4 
METHODS OF DRUG ADMINISTRATION AND SAMPLING 
OF BLOOD AND URINE 
Subiects 
Most drugs were given in relative low doses to young healthy human sub­
jects. Drugs that might be toxic or from which little pharmacological data 
were available were only given to rats, e.g. ferrocenylisopropylamine. 
Administration or the drugs 
For the study of the metabolism of amphetamines, the compounds were taken 
orally as HCl salts in gelatine capsules (Nr 3). The capsules were filled by 
hand. 
Blood samples 
In a limited number of experiments blood samples were drawn from the cubi­
tal vein of the right or left arm by vena punction (5 ml sample). The ampheta­
mines were determined in total blood. 
Urine samples 
The urine was voided in a calibrated cylinder (500 ml) and the amount was 
measured in ml (accuracy 2 ml) The time between two urine samples was 
measured in mm. (accuracy 1-2 mm). The average urine production is calcu­
lated by dividing the volume (ml) by the time required for its production (min). 
The average production is presented as a histogram. Indefinite small time 
intervals changes the histogram into the urine production rate at any time. 
The pH of the urine was measured with a Copenhagen Radiometer. Also the 
pH of an urine sample, produced during a certain time, is an average pH 
over that time interval. The urine pH is also presented as a histogram. The 
pH of the urine could be controled by intake of potential acids or basic 
salts. The pH is kept acidic (5-5,5) by the daily intake of 6,4 g of ammonium-
chloride (4 times 4 pills of DiuramonR). The pH is kept alkaline by the daily 
intake of 4 times a day of 2 g of sodiumbicarbonate. The pH in this study was 
kept acidic 
The extraction procedure 
10 ml of the urine is pipetted into a separation funnel (50 ml) and 10 μg of the 
internal standard, N-methylbenzylamine, in 1ml water is added. 30 ml freshly 
destilled diethylether and pellets of KOH are added to alkalimze the medium to 
pH 13 The mixture is shaken and extracted with the ether. The ether layer 
is removed and concentrated in a tapered tube under a mild stream of dry 
air to about 100 μΙ. About 5 μΙ of the concentrated ether layer is injected 
into the gas Chromatograph. 
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CHAPTER 1 
METABOLISM OF AMPHETAMINE 
Introduction 
Drugs with a high hydrophilicity and low lipophilicity are excreted by the 
kidney to a substantial degree unless they are very susceptible to drug-
metabolizing enzymes The ephednnes, which are more hydrophilic than the 
amphetamines, are eliminated from the human body largely by renal excretion 
processes The amphetamines are rather lipophilic so that substantial tubular 
reabsorption occurs and consequently renal clearance is less pronounced 
Drugs which are strongly lipid soluble would not leave the body if drug 
metabolizing enzymes did not exist Drug metabolism serves the elimination 
of the foreign compounds from the body of man and most animal species 
By drug-metabolizing enzymes, drugs or other compounds foreign to the 
body are transformed into one or more metabolites These metabolites may 
be more hydrophilic and less lipophilic than the parent drug, so that the renal 
clearance of the metabolites may be faster than that of the parent drug The 
reverse, however, also may be true The various metabolic routes of biotrans­
formation in different species may contribute in different percentages to the 
total metabolic elimination The biological significance of drug metabolites is 
determined by their pharmacodynamic and toxic properties as well as their 
kinetics of formation and elimination The kinetics of formation and elimination 
of the most important metabolites will be studied in this section 
In general, biotransformation of amphetamines and other phenylalkylamines 
may occur according to the following routes 
1 Oxidation of the phenyl ring 
2 Oxidation of the alkyl side chain, which may be divided in oxidation of the 
α and β carbon atom and of the nitrogen atom 
figure 1 Metabolic pathways of amphetamine 1 parahydro-
xylation, 2 β hydroxylation, 3 a-C-oxidation and 4-N-oxidation 
The various metabolites formed may undergo further biotransformation and be 
excreted via the kidney The kinetics of drug metabolism may therefore be 
studied from overall excretion studies of parent drug and metabolites 
1 Parahydroxylation 
Hydroxylation of the phenyl group in the para-position is a very common 
pathway in the metabolism of drugs Parahydroxy metabolites in general 
undergo conjugation to glucuromdes and sulphates These metabolites may 
therefore be found in blood and urine in the free and conjugated form The 
extent of parahydroxylation can be derived from the plasma concentration 
curve of metabolite and conjugates but also from the cumulative renal ex­
cretion curve (see section I, chapter 3) 
•<§>•' 
Ul· C-C-N-C-R 
β а а 
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Dogs metabolize amphetamine for about 3 0 % to parahydroxyamphetamine 
(Axelrod 1953) and excrete about 3 0 % of the dose (urine pH uncontroled) 
unchanged into the urine The parahydroxyamphetamine has been found to be 
conjugated with glucuromde for 6 5 % while 3 5 % existed in the free form 
Rats metabolize amphetamine in a similar was (Dring 1966, 1970) In general it 
can be stated that in rat and dog about 3 0 % of the dose amphetamine ingested 
is parahydroxylated (Ellison 1966, Debackere 1965, Lewander 1968, Rosso 1968) 
In man, rabbit, guinea pig and monkey, on the contrary the parahydroxyla-
tion of amphetamine is a minor pathway Only 1-5% of the dose of ampheta­
mine is parahydroxylated In man therefore parahydroxylation is a metabol.c 
route of minor importance However "saturated" amphetamines (cyclohexyl 
derivatives) undergo extensive ring hydroxylation (chapter 8) Recently Uden-
fnend (1971) and Brodie (1971) published mechanisms of the parahydroxylation 
via intermediate epoxides The attack of activated oxygen is carried out at 
aromatic positions 
In this epoxide formation, the hydroxylation resembles the mechanism of the 
a-C-oxidation McMahon (1969) has shown that an active oxygen atom, derived 
from the air ( 1 8 02) is inserted into the C-Η bond and resulted in a C-OH binding 
The Brodie mechanism requires also an activated oxygen atom from the air and 
resulted in an attack at the π-electron system With respect to parahydroxyla­
tion of amphetamines evidence that epoxides are intermediates is still lacking 
Whether this mechanism holds for cyclohexyl rings as found with the 
"saturated" amphetamines is even more questionable 
2 Hydroxylation of the fi-carbon atom 
Endogenous dopamine is oxidized via a specific ß-hydroxylase to noradrena-
line in the sympatic nervous system and in the brain, but not in the liver (Lewan-
der 1968, 1971, Molinoff 1969, Fisher 1965) Exogenous octopamme is taken up 
by nerves and also oxidized to a |3-hydroxycompound Amphetamine, which also 
is taken up in the same nerves, may also be subject to ß-hydroxylation Indeed, 
Goldstein (1964, 1965) showed that in rats a ß-hydroxylation occurs In 
radiograms, obtained after extraction of a heart homogenate two radioactive 
zones were found which coincide with the Rf values of 3H-amphetamine and 
3H-p-hydroxynorephednne Only dextro amphetamine is oxidized in this way 
but not its levo isomer Disulfiram, a notorious (3-hydroxylase inhibitor, blocks 
the formation of ß-hydroxyamphetamine (Goldstein 1964, 1965) ß-Hydroxylation 
is not important as a metabolic route of amphetamine degradation but it may 
be important for certain pharmacodynamic effects Following administration 
of amphetamine, norephedrine has been found only in heart and brain 
However following ingestion of prenylamine, an amphetamine derivative, Palm 
and Grobecker (1968) claimed the formation of such a metabolite It has also 
been proposed that ß-hydroxylation of amphetamine is of greater importance 
in addicts using high doses of amphetamine for a long period of time (Costa 
1970, Anggard 1970) 
3 Deamination of amphetamines 
Deamination is an important way in the metabolism of amphetamines in man 
and all species of animals The reaction pattern is given in fig 2 
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Phenylaceton and methylphenylalcohol are intermediates in the deamination 
of amphetamine The percentage of amphetamine wh:ch is deammated and the 
reaction rate only can be measured exactly when the intermediates can be 
measured. When 1 4C-amphetamine was ingested by an animal, it was im­
possible to detect these two intermediates in the urine or blood. (Axelrod 1955, 
Asatoor 1965, Alleva 1963, Ellison 1966, Dring 1970). The two intermediates for­
med are not soluble in the water medium at the enzyme site in the liver, so it is 
very unlikely that these intermediates leave the enzyme site and circulate free 
with the blood and can be excreted subsequently in the urine. Due to the 
high lipid-solubility it is much more likely that these intermediates are trans­
formed further to benzoic acid. The concentration profile of benzoic acid in the 
blood or the cumulative renal excretion of benzoic acid may be taken as a 
measure for the degree of deamination of amphetamine. Unfortunately, benzoic 
acid is used as a food additive and is the end product of many metabolic con­
versions occurring in the body, so measuring benzoic acid or its conjugate in 
the urine is of little significance. Benzoic acid is easily conjugated to hippunc 
acid. The latter substance undergoes strong renal excretion. Deuterium or 
radioactive labelled amphetamine should be used for the direct estimation of 
the deamination. 
Recently attempts were made to trap the intermediates in the deamination 
reaction of amphetamine. Dring (1966) showed that the ketone and alcohol were 
bound to the glucuromde and excreted as such, no free alcohol was detected 
in the urine of man, dog and rat Hucker (1970) showed that the phenylacetone 
oxime was an intermediate in the deamination of amphetamine The compound 
was recovered from a mixture of rabbit liver homogenate and amphetamine 
and identified by GC-MS. The proposed reaction intermediates in the microso­
mal oxidation of the amphetamine are given by Parli and McMahon (1971) 
с 
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C-C=N-OH 
figure 3 Proposed reaction interme­
diates in the microsomal oxidation of 
d-amphetamine (after Parli, 1971) 
The amount of deamination varies with the species from 5-60%. In rats only 
5 % of hippunc acid is found in the urine (Alleva 1963, Ellison 1966, Dring 1970) 
but dogs deaminate 2 0 % of the amphetamine and squirrel monkey 15% (Ellison 
1966). Man deaminates amphetamine after ingestion for 20-30% (Dring 1966, 
1970). Similar f igures are obtained for rabbit and guinea pig. The amounts of 
benzoic acid and hippunc acid found in the urine are fluctuating from subject 
in one clearance constant influences the quantity of drug that is deammated 
to subject. Since the total elimination clearance is the sum of the renal 
clearance and the clearance constants for various metabolic routes, variation 
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Because of the reasons stated before, in the present study deamination was 
fol lowed by indirect means Subject to subject variation has to be excluded 
especially if one uses indirect methods For this purpose the same subject 
received two different substances simultaneously, for instance amphetamine 
and phentermine These two substances are then studied at every moment 
under exactly the same conditions The only important routes of elimination 
of amphetamine are renal excretion of unchanged drug and deamination, while 
the only important route of elimination of phentermine is renal excretion 
Consequently the deficit in renal excretion of unchanged drug is a measure for 
deamination As pointed out in section I, renal clearance of a basic drug is pH 
dependent The urinary pH therefore was kept constant at pH 5- 5,5 In this 
case, the amphetamine is excreted unaltered for 70% by all subjects When 
phentermine is administered, and the urine of the subject is kept acidic, nearly 
100% of the phentermine is excreted unaltered This means that the para-
hydroxylation of phentermine may be neglected, and that for both compounds, 
amphetamine and phentermine, renal excretion and deamination are the predo-
minant pathways of elimination (Dring 1966, 1970) When both compounds are 
admin stered to one person, the difference in excreted amounts of unaltered 
compound still remains 30% 
From these experiments it may be stated that the deamination of dextro amphe-
tamine occurs for 30% when the renal excretion rate is maximal The halflife 
time of phentermine is 8-9 hours and that of amphetamine 5-6 hours When 
mephentermine and N-methylamphetamine are administered together to the 
same individual person, mephentermine is excreted unaltered for 85% and the 
metabolite phentermine for 15%, while the N-methylamphetamine is excreted 
for 65% and the metabolite amphetamine for 7% With these two com-
pounds, the percentage of deamination of N-methylamphetamine can be cal-
culated to be 25% When amphetamine as a metabolite of N-methylampheta-
mine is excreted in the urine for 7% it means that more amphetamine is 
formed Because this metabolite itself is excreted only for 70%, actually 10% 
of N-methylamphetamine ought to be N-dealkylated to amphetamine The 
degree of deamination of some phenylethylamme derivatives is given in table 
1 under the assumptions that parahydroxylation and ß-hydroxylation may be 
neglected and absorption is complete 
Table 1 
Percentage of deamination of some phenylethylammes 
kr/ke, k_,/k0| km/kr 
0 05 
0 70 
0 80 
1 0 
0 65 
0 85 
0 95 
0 30 
0 20 
0 
0 35 
015 
19 
0 43 
0 25 
0 
0 54 
017 
Note It is not certain that phenylethy'amme is comp'etely absorbed because the in-
testinal flora may metabolize it substantially 
,, . deamim 
/0 
phenylethylamme 
( + ) amphetamine 
(—) amphetamine 
phentermine 
( + ) N-methylamphetamine 
N-methylphentermino 
2 
6 
7 
9 
7 
9 
95 
30 
20 
0 
25 
0 
70 
The differences observed in excretion rate, halflife time and total amount 
excreted unaltered between phentermines and amphetamines give an indication 
that the abstraction of the hydrogen atom, attached at the α-C atom next to 
the nitrogen atom, is the rate-determining step As possible intermediates 
in the oxidative N-dealkylation or deamination N-oxides and hydroxylamines 
are mentioned in the literature (McMahon 1971, Hucker 1970) When in the 
deamination of the compounds phenylethylamine, amphetamine and phenter-
mme the attack of the oxygen atom at the α hydrogen atom is not the rate-
limiting step, the rate of deamination should be the same Due to the amount 
of excretion of unchanged phentermine the formation of an N-oxide or 
hydroxylamine of phentermine is not probable However, such a reaction may 
exist but should then be very slow If the abstraction of the α hydrogen atom 
plays an important role in the deamination, then the origin of the C-Η binding 
should be of importance In the latter case the two α hydrogen atoms in 
phenylethylamine, compared with the one in amphetamine, should not be only 
a statistical factor in the deamination When the quantity of Η atoms present 
is of importance, the deamination of phenylethylamine should be twice the 
deamination of amphetamine, 6 0 % When phenylethylamine is administered to 
a person and excreted with maximal excretion rate only 5 % of unaltered 
phenylethylamine is found in the urine This means that the origin of the C-H 
binding is of importance and that the Η atom might be involved into the 
reaction Whether the α-H atom is involved in the rate-limiting step of the 
deamination, can be elucidated by replacing the Η atom by a deuterium 
atom In this case, the deamination should be slower than with the hydrogen 
atom There should be a measurable deuterium effect 
In chapter 6 experiments to this aim will be described From the results it can 
be seen that there is indeed a deuterium effect, though, due to the high 
excretion rate, it is a small one The stability of phentermine with respect to 
«-C-oxidation is due the lack of an α-H atom and not to the so-called "packing" 
of the N-atom as has been proposed (Ariens 1972, 1964) 
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CHAPTER 2 
N-DEALKYLATION OF N-ALKYL SUBSTITUTED AMPHETAMINES 
Introduction 
Removal of an alkyl substituent by liver enzymes is a similar process as 
oxidative deamination, because also here a-C-oxidation may be an intermediate 
step As deamination always leads to bio inactivation, N-dealkylation may result 
in bio active metabolites Gaudette (1958), Brodie (1957), McMahon (1961, 1966) 
tried to solve the problem of oxidative N-dealkylation Finally three hypotheses 
remained valuable for this mechanism It should be realized that evidence for 
one mechanism in a particular group of compounds not necessarily implies 
that the same mechanism holds for another group of compounds The fol lowing 
three mechanisms of N-dealkylation are worth-while to be considered 
1 A nitrogen-oxide as an intermediate in the N-dealkylation reaction 
2 A radical mechanism in the a-C-oxidation 
3 A direct hydroxylation of the group that is finally eliminated 
Mechanism 1 
A great difficulty in providing evidence for this mechanism consists in 
isolating the intermediate, the nitrogen oxide, from the microsomal fraction 
Evidence for the occurrence of an nitrogen oxide is found for a certain group 
of tricyclic, amines The molecule should have et least two phenyl groups, a 
bulky head and a chain of 3-5 atoms, with at the end the amine group 
Representatives of this group of compounds are orphenadrme, Imipramine, 
amitnptyline, chlorpromazine etc With all these compounds, a nitrogen oxide 
was excreted into the urine (Hammar 1968) 
When the nitrogen oxide of the compound is synthezised, and added in vitro to 
a microsomal fraction, then the reaction to the N-dealkylated products occurs 
very slowly (McMahon 1966) We have to keep in mind that a certain nitrogen 
oxide added to microsomes may not reach the enzyme site of action due to a 
change in lipid-solubility It is postulated that, in vivo, there should be an enzyme 
which attacks the nitrogen atom If this attack is the rate-limiting step in the 
reaction, the next step, the formation of the alcohol and the elimination of 
the aldehyde, must be rapid and nearly independent of the medium In this 
case it is impossible to trap the nitrogen oxide from the reaction mixture 
If the formation of the nitrogen oxide is not rate limiting, but the conversion 
of the nitrogen oxide to the alcohol is, then there must be a great concen-
tration of the nitrogen oxide in the microsomal fraction, and the intermediate 
must be a relatively stable compound It should be possible to trap the com-
pound and prove its structure Up to now, it was possible to trap the nitrogen 
oxides of orphenadrme etc but not of the small amines like secondary amphe-
tamines Addition of an N-oxide to a microsomal fraction and measuring the 
rate of the conversion do not give an answer to the problem if one is not 
sure that the N-oxide can reach the enzyme site of action For the same 
reason, the addition of a 14C labeled compound and its N-oxide to a fraction 
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of microsomes in order to get a radioactive labeled N-oxide, is not a definite 
way to prove this intermediate. 
The first stage must be to examine the difference in lipi-solubility and then 
take care that the added N-oxide can reach the reaction centre of the enzyme. 
Baker (1962), Ziegler (1964) and Petit (1964) found N-oxides of tertiary amines. 
N-Dimethylanilmeoxide is converted into N-methylaniline and formaldehyde 
by liver microsomes The N-oxide of propoxyphene, on the contrary, is not 
demethylated (McMahon 1964) Maybe the N-oxide formation and direct 
hydroxylation are competitive ways in the metabolism of tertiary amines If 
cholate is added to a fraction of microsomes, N-dealkylation and oxidative 
systems are destroyed, but N-demethylation still occurs (Ziegler 1964) 
Probably here N-oxide formation occurs. 
2 Radical mechanism in the a-C-oxidation 
In general, in organic chemistry, an "in v i t ro" situation, there is no direct attack 
at a saturated carbon atom by an oxygen atom. The attack must be carried 
out by an activated oxygen atom, an oxygen radical (Breslow 1960, Gilette 1963) 
or N-oxide radical (Stier 1971). An N-dealkylation has been found a more rapid 
process than an N-demethylation (Leadbeather 1964). This finding might be un­
derstandable when a radical mechanism is assumed, because then one of the 
intermediates is an allyl radical with a resonance structure (fig 4). 
H о· н н 
R-N-C-R «· R-N-C-R ^ = R - N = C - R 
H NADPH - f igure 4 
This mechanism eliminates stereochemical effects in the metabolism of amphe­
tamines The N-dealkylation of amphetamines however is stereoselective. 
This mechanism therefore can be ruled out for the amphetamine analogues. 
3. The direct hydroxylation of the group that is eliminated 
This mechanism is analogous to oxidative deamination. Also hydrogen atoms 
at α C-atoms are required as is the case with deamination. N-dealkylation by 
u-C-oxidation appears to be a predominant mechanism for the N-substituted 
amphetamines and related drugs as may be seen from the fol lowing paragraphs. 
urine ml min cumulative renal 
excretion (m^twise) 
24 36 43 6 0 h 
figure 5· Renal excretion rate, urine pH, urine production and cumulative renal excretion 
of ( + ) N-methylamphetamine The renal excretion rate of the metabolite ( + ) ampheta-
mine is flat topped, indicating that the N-dealkylation of the parent compound is slow. 
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N-Methylamphetamine 
The total amount of N-methylamphetamine and metabolite amphetamine ex­
creted in the urine varies slightly from person to person Beckett (1965) exa­
mined large groups of subjects for the excretion rate of N-methylamphetamine 
and found with acidic urine conditions 55-70% of the dose excreted unchanged 
and 6-7% of the metabolite amphetamine In table 2 it is shown that the total 
amount of N-methylamphetamine recovered from acidic urine may vary from 
73-85% (fig 5) 
It might be stated that under acidic urine conditions about 10% N-dealkylation 
takes place if we take into account that the metabolite is excreted for 7 0 % 
and deaminated for 3 0 % In N-methylamphetamine there is a competition 
between the different pathways for elimination, excretion, deamination and 
N-dealkylation 
If deamination and N-dealkylation are part of the same reaction mechanism, 
then from the statistical point of view, N-dealkylation of the methylgroup 
must occur three times faster than deamination provided that the reactivity 
of the H atoms at the a-C-position is identical From the results it is observed 
that the tertiary and pr т а г у H atoms are not equivalent in this reaction 
process In addition there is stereoselectivity for dextro N-methylamphetamine 
Table 2 
Halflife time of N-methylamphetamine and its metabolite amphetamine and the 
percentages of both compounds excreted in the urine 
subject 
C V 
C V 
H К 
HK 
PN 
C V 
H К 
t'/2 
7 
6 
5 
6 
6 
6 
6 
'ЧаА 
12 
13 
7 
9 
11 
10 
7 
% E 
65 
63 
79 
87 
62 
95 
73 
% C A 
9 
10 
β 
3 
9 
5 
4 
kr/kc| 
0 65 
0 03 
0 79 
0 87 
0 62 
0 95 
0 73 
kdeal/ kel 
0 13 
0 14 
011 
0 04 
0 13 
0 07 
0 05 
k dcam' k cl 
0 22 
0 23 
0 10 
0 09 
0 25 
0 
0 22 
t i l 2 ha'flife time of N-methylamphetamine (hr), t i | 2 A half life time of the metabolite amphe­
tamine, % E percentage of the dose excreted of N methy amphetamine, % Ед percentage 
oxcre'ed of the metabolite amphetamine 
N-Ethy ¡amphetamine 
N-Ethylamphetamine is metabolized in a similar way as N-methylamphetamine 
The amount of the metabolite amphetamine excreted in the urine is higher than 
the amount of amphetamine excreted after ingestion of N-methylamphetamine 
(fig 6) For the dextro isomers N-dealkylation takes place for about 30% 
Hence there is an indication that the N-dealkylation is dependent upon the 
group that is split off The only difference between the methyl- and ethyl group 
that can be of importance for an explanation of the difference in metabolic 
conversion is the difference between the primary and secondary H atom at 
the α-carbon atom of the substituent Results mentioned by Beckett (1970) 
pointed into the same direction The ratio parent compound metabolite varies 
with the pH of the urine, but this ratio is also different for both isomers 
(table 3) 
75 
urine ml/mm — - cumulative renai 
excrehon (mg base ) 
excrehon rate (jAg/min-, log scale) -
100 
SOmsi«) ETHYLAMPHETAMINE HCl 
ι—ι amphetamine 
L j l-n 
u ^ 
ethyldniphetrtmine 
blood \элІі а 
Subject F H 
figure 6: Renal excretion rale, urine pH, urine production and cumulative renal excretion 
rate of ( + ) N-ethylamphetamine and its metabolite ( + ) amphetamine. The metabolite is 
formed fast, the renal excretion rate shows a maximum. The concentration of N-ethyl­
amphetamine in the saliva is independent of the saliva pH. 
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Table 3 
Ratio between N-ethylamphetamine and amphetamine under different pH 
values of the urine 
compound 
d,l N-ethylamphetamine 
d N-ethylamphetamine 
1 N-ethylamphetamine 
ratio 
1 8 
2 5 
1 3 
2 1 
10 
pH 
alkaline 
uncontroled 
acid 
acid 
acid 
The great difference in metabolism between the dextro and levo isomers may 
indicate that with levo N-ethylamphetamine there is less N-dealkylation to 
amphetamine or, that there is an active excretion If there is an active renal 
excretion present then the renal excretion curve must be biphasic, but in 
practice this is not observed Occasionally there are observations that dextro 
N-ethylamphetamine, given in high doses, shows a biphasic decline with 
ti/2 of 2 and 4 hr, while this phenomenon is not observed with the levo isomers 
(ti/2 7 hr) The sum of the percentages excreted of compound and metabolite 
under acidic urine conditions is about 100% for the levo isomers and 6 0 % for 
the dextro isomers 
There is good evidence to assume that there is little deammation of the levo 
isomer Beckett found data of 72-86% excreted totally after 24 hr after in­
gestion, our values range from 8 5 % to 9 5 % after 60 hr of excretion (table 4) 
The contribution of the excretion in the latter part of the elimination process 
is of course of minor significance than the in the f irst 24 hr, so that both data 
may be compared 
Table 4 
Halflife time of N-ethylamphetamine and its metabolite amphetamine and the 
percentages of both compounds excreted in the urine 
isomer 
(+) 
(-) 
subject 
C V 
F H 
W S 
H K 
P N 
A K 
t l , 2 
5 
2 5-4 
2 -4 
7 
7 
7 
t'/зА 
8 
6 5 
7 5 
9 5 
14 
13 
% E 
41 
44 
47 
97 
85 
82 
% E A 
21 
20 
21 
3 
10 
5 
k r/ke| 
0 4 1 
0 44 
0 4 7 
0 97 
0 85 
0 82 
kdea|/kel 
0 30 
0 30 
0 30 
0 04 
0 14 
0 07 
kdeam/kel 
0 29 
0 26 
0 23 
0 
0 
0 10 
t i/, half life (hr) of N-ethylamphetamine, A = amphetamine, % E percentage of the dose 
excreted 
- cumulative renal 
excretion (mg brtbe) 
15 
. - ~ — 29 2 % 
excretion rate (¿ig/min, log scale) 
100-
59bmg i.ilSOPROPYLAMPHETAMINE HCl 
sopropylampheramine 
Subject Ην Ρ 
Αβ 60 h 
figure 7: Renal excretion rate, urine pH, urine production and cumulative renal excretion 
of ( + ) N-isopropylamphetamine and its metabolite ( + ) amphetamine. The formation rate 
of amphetamine is fast. 
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N-isopropylamphetamine 
In the design of bio-active molecules often isopropyl groups are introduced 
with the idea that branched substituents are more resistant to biodégradation 
If, however, the H atoms at the a-C-position are of primary importance for 
metabolism this hypothesis is incorrect and the isopropyl group may easily be 
removed (Walle 1972). 
Dextro N-isopropylamphetamine is extremely rapidly eliminated from the 
body (ti), = 2-3 hr at pH 5). The metabolite ( + ) amphetamine is formed 
very fast and reaches its maximum in the renal excretion rate 1-2 hr after 
ingestion of the N-isopropylamphetamine The halflife time of the metabolite 
(6-7 hr) is identical with that obtained when amphetamine itself is ingested 
(see figure 7) The greatest differences in the metabolism of secondary 
amphetamines is found with dextro and levo N-isopropylamphetamine. 
The levo isomers on the contrary are hardly metabolized They are excreted 
unchanged for 90% and the ti/j of 7 hr is similar to that found with levo 
N-ethyl- and N-methylamphetamine. The metabolite amphetamine is excreted 
for about 10% with a b¡7 of about 10 hr. It can be concluded that the N-deal-
kylation of the dextro isomers is much faster than with the levo isomer. 
If the N-isopropylamphetamine molecule is concerned, and if the mechanism 
of the proton abstraction is correct, there are two equivalent protons that 
may serve as a centre for the attack by, for instance, an active oxygen atom 
or an enzyme. The chance that deamination or N-dealkylation takes place 
is one to one, and this is observed. In the case with N-ethylamphetamine, the 
protons that may be attacked were secondary and tertiary protons and it is 
known that the tertiary one can be removed easier than the secondary one. 
More information about this mechanism will be given with the stereochemical 
aspects and deuterium effects in this metabolism (chapters 5, 6). 
Table 5 
Halflife time of N-isopropylamphetamine, its metabolite amphetamine and the 
percentages of both compounds excreted in the urine. 
subject 
FR 
A B 
HK 
Η Ρ 
M K 
PN 
CV 
t l | 2 
2 
2 
5 
2,5 
6 
6 
7 
11
 НА 
6 
6 
9 
6 
9 
11 
9 
%E 
18 
9 
53 
29 
90 
81 
58 
% E A 
25 
20 
12 
20 
10 
15 
12 
kr/kel 
0 18 
0 09 
0 53 
0 29 
0 90 
0 81 
0 58 
k deol/k e l 
0 35 
0 30 
0 18 
0 30 
0 14 
0 20 
018 
^deam/kel 
0 47 
0 61 
0 29 
041 
0 
0 
0 26 
ti/2 halflife time (hr) of N-isopropylamphetamine, A = amphetamine, % E percentage 
of the dose excreted 
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N-Benzylamphetamine 
N-benzylamphetamine is not excreted unchanged in the urine, due to its very 
high lipid-solubility, tubular reabsorption is complete. The compound is meta-
bolized for a small percentage to amphetamine (10%) (fig 8) The possible 
metabolites excreted in the urine containing a nitrogen atom are amphetamine 
and benzylamine The latter compound is hard to detect in the unne 
because it is very rapidly metabolized by the MAO enzyme to benzaldehyde 
and benzoic acid. Beckett (1971) mentioned all the metabolites possible after 
incubation of the N-benzylamphetamine with rat liver supernatant (100CO g). In 
rat the ratio between the a-C-oxidation and N-oxidation between the stereo 
isomers is 1 : 1 This last finding also is valid in man and is very contradictory 
with the "normal" ratio of 3.5 : 1 obtained with N-alkyl substituted amphéta-
mines The consequences of this ratio between the two metabolic pathways is 
explained in chapter 10. 
Linné» PI CductlOU ІПІ/ІПІП -
5 -, 
cumulat ive rental 
• excret ion ^in£ b¿ase*) 
UT 
ren^l ечсгеЬсп rate u£/triin 
01 
чО I m i . d {*) benzvІлі-nphetíSmine HCl 
N С 
S u b i e c t PR 
Л 
d (+"* ¿unphetemine 
TJ.55hr 
Ί2 2ч Z-Ó - . 60 
t ime (h) 
figure 8 Renal excretion rate, urine pH, urine production and cumulative renal excretion 
of ( + ) N-benzylamphetamine and its metabolite (+ ) amphetamine The parent compound 
is not excreted at all, due to its high lipid-solubility Although the N-dealkylation is fast 
the metabolic capacity is small, because only 10% of the metabolite is formed 
80 
Table 6 
Halflife time of N-benzylamphetamme and its metabolite amphetam.ne and the 
percentages of both compounds excreted in the urine 
isomer 
(+) 
(-) 
subject 
PR 
BB 
PR 
BB 
t l / 2 
0 
0 
0 
0 
bhA 
6 
6 
6 
6 
% E 
0 
0 
0 
0 
% E A 
97 
67 
11 3 
22 
KIK\ 
0 
0 
0 
0 
kdeal/ kel 
0 14 
0 09 
0 15 
031 
kdeam'kel 
0 86 
0 91 
0 85 
0 69 
t i ( 2 halflife time of N-benzylamphetamine (hr), A = amphetamine, % E percentage 
excreted 
Biamphetamine. N-(1 phenylpropane-2) amphetamine 
In this molecule deamination and N-dealkylation become identical The 
dextro-dextro isomer on the contrary delivers dextro amphetamine only at a 
very slow rate and hardly 5 % is excreted in the urine The position on the 
enzyme site may be the limiting factor in the metabolism, but compounds as 
captagon and AN1 are very well metabolized The reason for this slow 
formation of amphetamine is obscure 
cumulative renal 
excretion (mg base ) 
excret on rate (tig/min I05 ecale) 
100-
50mg CAPTAGON 
О 
^ - r ^ X l o 1 — ©-'-ο-, 
amphetamine 
5ubjectC\ 
Ί β 
figure 9 Renal excretion 
rate, urine pH, urine pro­
duction and cumulative 
renal excretion of Capta­
gon and its metabolite am­
phetamine The ampheta­
mine is continuously for­
med during the elimination 
of both compounds which 
leads to an increase of the 
halflife time of amphetami­
ne (ti/2 7->-10hr) The 
longer halflife time of am­
phetamine implies that the 
compound stays longer in 
the body and may act for a 
longer period than when 
amphetamine itself is taken 
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Captagon· 7-(2-(-a-methyl-phenylethyl-amino)-ethyl)-theophylline 
Captagon is a molecule containing an amphetamine and theophylline sub­
stituent It was expected that amphetamine could be liberated After ingestion 
of 50 mg of captagon, which corresponds with 19 8 mg of amphetamine, amphe­
tamine is formed and excreted in the urine. The halfhfe of the amphetamine was 
10 hr, indicating that amphetamine is formed continuously and that the con­
version of captagon to amphetamine is a rapid process 2 5 % (μΜοΙ) is totally 
excreted (Domke 1970) (fig 9). 
AN1: a-Phenyl-a-N-(l-phenylisopropyl) amino-acetomtril 
AN1 is extremely fast metabolized to amphetamine 4 2 % amphetamine was 
formed, the halfhfe of amphetamine was 6 hr The cyano group has activated 
the benzyhc hydrogen atom, which due to this activation can be attacked 
much easier than in N-benzylamphetamine Four stereo isomers are possible 
with different metabolic pathways A N 1 , as is Captagon, was obtained com­
mercially, without information about the stereochemistry of the compounds 
(Marsel 1972) (fig 10) (See also chapter 10 for the stenc implications) 
urine production ml/mm 
10 
cumulat ive renal 
excretion (m£ base) 
10 
renal excretion rate ug/min 
M20m¿ AN1(d l ) 
oVc-c N c-(o) 
C = N 
01 
ТІ.бпг 
S u b j e c t M F 
COI 
60 
t i m e (h) 
figure 10 Renal excretion 
rate, urine pH, urine pro­
duction and cumulative 
renal excretion rate of AN1 
and its metabolite ampheta­
mine The amphetamine is 
extremely fast formed, the 
elimination rate is the same 
as that when amphetamine 
was taken The cyano 
group lowers the energy 
of the C-Η binding of the 
substituent, which causes 
an acceleration of the 
a-C-oxidation 
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Prenylamine 
Palm and Grober (1968) mentioned amphetamine as one of the numerous 
metabolites of prenylamine In man, no amphetamine was formed and excreted 
in the urine From the structure it can be concluded that the compound is 
bound strongly to the cytochrome P-450 and inhibits the metabolism of the 
amphetamines (See section IV, chapter 6) 
Table 7 
Percentage and halfhfe time of amphetamine formed from N-substituted 
amphetamines 
drug 
N-benzylamphetamine 
AN1 
captagon 
prenylamine 
biamphetamine 
% amphetamine 
10 
42 
25 
0 
5 
t '/ j 
6 
6 
10 
0 
8 
Threo and erythro phenmetrazine 
The renal excretion, blood concentration and saliva concentration show a 
very remarkable difference between the threo and erythro isomers of phenme­
trazine Threo phenmetrazine is excreted nearly for 1C0%, but the erythro 
isomer for only 4 0 % (fig 11) This very large difference is not observed in 
the apparent partition coefficient, nor in the correction factors used for the 
GLC procedure with fenfluramine as internal standard We obtained evidence 
that parahydroxylation of both isomers occurs only for 2 % There was no 
indication of ring opening in one of the metabolic routes, although the apiezon 
column is able to separate all derivatives of ephednnes After extraction of 
urine and blood these compounds could not be identified The threo and erythro 
isomers of phenmetrazine are well separated at the column in GLC and this 
is the reason that both isomers could be ingested together and studied under 
exactly the same circumstances 
Table 8 
Percentage of the dose excreted in the urine and half life time of threo and 
erythro phenmetrazine at pH 5 
compound subject dose (mg) % E t i ) 2 
threo- R D 
ES 
ЕЕ 
HK 
erythro- R D 
ES 
ЕЕ 
HK 
10 
10 
30 
30 
10 
10 
30 
30 
84 
42 
89 
95 
46 
20 
30 
40 
4 5 
3 5 
4 
4 
6 
4 
5 
4 
% E percentage of the dose excreted, ti/2 (hr) 
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figure 11: Renal excretion 
rate, urine pH, urine pro-
duction and cumulative 
renal excretion rate of the 
threo and erythro isomers 
of phenmetrazine under 
exactly the same circum-
stances The erythro iso-
mer is much less excreted 
unchanged than the threo 
isomer 
excretion rate i¿jg/min, log scale) 
100 
30m«; threo PHENMETRAZINE HCl 
30 m j erythro PHENMETRAZINE HCl 
Ί
threo phenmetrazine 
12 2Ί 
Conclusion 
Now an attempt can be made to quantify the deamination and N-dealkylation 
in the metabolism of secondary amphetamines. As mentioned before, the 
parahydroxylation of amphetamines may be neglected, with maximal renal 
excretion rate. Thus elimination of amphetamines is due to excretion of 
unaltered compound, deamination and N-dealkylation. We may therefore 
assume that the sum of the unaltered amphetamine excreted, deaminated 
and N-dealkylated product is equivalent to 100% of the ingested dose. 
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excretion 
ІОУо 
excretion 
100% 
excre bon 
10°/o 
<0>c (Ö>C-C-NH, * = ! ü " g - t - K 
о 
30% 
—у^—*• deamination 
< ^ 
С 
C-C-NH2 
phentermine 
<b)-C-Ç-N-C-C 
R-, R2 
@ьс ^ U / ~ C - C - N H Z »-30% 
R, I excretion 7 0 % 
R i r R 2 = H leopropylamphetamme 
Ri«H R2rD deureroisopropyl-amphetamine 
R1 = D R2=D deuteroisopropyl-deuteroamphetamme 
figure 12 competitive pathways in the elimination of amphetamines 
In this manner, the percentage of deaminated amphetamine, found after 
excretion of 7 0 % unaltered compound, is 3 0 % (fig 12) Similar results are 
found when amphetamine and phentermine are compared When these com­
pounds are simultaneously administered to the same person, 100% of the 
phentermine and 7 0 % of the amphetamine is excreted unaltered The total 
amount of amphetamine excreted is dependent upon the ratio of metabolic 
and renal clearance constants, k m resp k r which in turn are dependent upon 
the physico-chemical parameters of both the amphetamine and the enzyme 
system Since from each amount of amphetamine absorbed or metabolically 
formed, 7 0 % is excreted unaltered when amphetamine is a metabolite of 
some administered compound, the percentages of excretion, deamination and 
N-dealkylation of the original compound may be calculated (table 9) 
Phenylethylamine is excreted only 1-5% unaltered Comparison of this result 
to that of amphetamine plus its derivatives suggests that the deaminating 
enzyme is hindered when the aliphatic side chain is branched and/or that 
the deamination requires a hydrogen atom If the deamination did not require 
the presence of a proton then we would have expected some deamination 
of the phentermine Since the latter is excreted essentially unchanged, it may 
initially be assumed that the hydrogen atom is of importance The purpose 
of this investigation therefore was to determine the importance of the alkyl 
hydrogen with respect to N-dealkylation and deamination and whether its 
abstraction was the rate-limiting step 
When proton abstraction (C-Η bond rupture) is believed to be the rate-limiting 
step in the reaction sequence between a particular molecule and an enzyme 
system, the use of deuterium in place of hydrogen at the suspected position 
of proton abstraction may demonstrate the validity of the hypothesis, that is 
to say, if a deuterium isotope effect can be demonstrated, the corresponding 
C-Η bond exerts a determining role with respect to the rate-limiting step 
(Aebi 1967, Collins 1960, Rose 1961, Shiner 1960) In accordance with this, the 
hydrogen atom in question was replaced by a deuterium atom The occurrence 
of a primary deuterium effect indicates a slower rate of C-D bond rupture 
compared to C-Η bond rupture (chapter 6) 
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Table 9 
compound % deamination 
( + ) amphetamine 
N-methylamphetamine 
N-ethylamphetamine 
N-isopropylamphetamme 
N-dimethylamphetamine 
(—) amphetamine 
N-methylamphetamine 
N-ethylamphetamine 
N-isopropylamphetamine 
N-dimethylamphetamme 
30 
20 
30 
45 
10 
10 
10 
0 
0 
10 
* % of ingested dose, kr renal elea 
% dealkylation % excretion * kr к. 
— 
15 
30 
45 
50 
— 
10 
10 
15 
10 
70 
65 
40 
10 
40 
90 
80 
90 
85 
80 
k r > k , 
k r > k , 
kr = k, 
k r < k , 
kr = k, 
k r > k , 
k r > k , 
k r > k , 
k r > k , 
k r > k , 
constant, km metabolic clearance constant 
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CHAPTER 3 
METABOLISM OF TERTIARY AMPHETAMINES 
N-dimethy ¡amphetamine 
N-Dimethylamphetamine is rapidly metabolized into N-methylamphetamine 
(fig 13) The conversion of the tertiary N-dimethylamphetamine into the secon-
dary N-methylamphetamine is much faster than the conversion of the 
N-methyl- into the primary amphetamine As shown in chapter 2, the rate of 
metabolism of N-methylamphetamine to amphetamine is slow There is hardly 
a difference between the N-dealkylation of the dextro and levo isomers 
(100% N-dealkylation) The curve of the renal excretion rate of the second 
metabolite, amphetamine, is f lat-topped, indicating a slow process of formation 
On the other hand, the renal excretion curve of the first metabolite, N-methyl-
amphetamine, as formed from N-dimethylamphetamine, has a sharp maximum 
The halflife time of this first metabolite is 7-9 hr and this is of the same magni-
tude as that of N-methylamphetamine itself The percentages N-dealkylation 
and deamination of N-dimethylamphetamine can be calculated according to 
methods given in section I The results are given in table 10 
Table 10 
Percentage of N-dealkylation, deamination and excretion of the total elimi-
nation 
% dealkylation % excretion 
65 
40 
80 
70 
From table 10 it can be concluded that in N-dimethylamphetamine N-deal-
kylation is much more important than deamination, while in N-methylamphe-
tamine both processes are of the same magnitude 
In table 11 the percentages of excretion of N-dimethylamphetamine and its 
metabolites are given as the halflife times With levo N-dimethylamphetamine 
no amphetamine could be detected 
In comparison with the secondary N-methylamphetamine, the N-demethylation 
of one methyl group from the tertiary N-dimethylamphetamine proceeds 
much faster Is this difference due to the chemical stability of the compound 
or is the enzymatic reaction altered? It was observed that N-dimethylamphe-
tamme could be demethylated by KMn04 in KOH solution to N-methylamphe-
tamine while this product could not be further demethylated 
A second important observation is the lack of deuterium effect in the N-deme-
thylation In chapter 6 it is outlined that a measurable deuterium effect can be 
detected when the metabolic elimination is much faster that the renal elimi-
compounds 
+ N-methylamphetamine 
+ N dimethylamphetamine 
— N methylamphetamine 
— N-dimethylamphetamine 
% deamination 
20 
10 
10 
10 
 l 
15 
50 
10 
20 
87 
ut ine ml min - cumulative renal 
evi et ion (nimbase ) 
ιβ 
excretion rate (^.i^/min, log acale) 
100 
10 -Jj 
OOI 
50 mg ι.) DIMETHYLAMPHETAMiNE HCl 
- L Lx^ 
methylamphetdmine 
amphetamine 
U^ 
dimelhyldinph 
ôubject А В 
figure 13: Renal excretion rate, urine pH, urine production and cumulative renal excretion 
of ( + ) N-dimethylamphetamine and the metabolites ( + ) N-methylamphetamine and ( + ) 
amphetamine. The N-demethylation with tertiary amphetamines is much faster than with 
secondary amphetamines. 
88 
Table 11 
Halflife time of N-dimethylamphetamine and its metabolites and the per­
centages of the compounds excreted in the urine at pH 5 
isomer 
( + ) 
(-) 
subject 
T V 
C V 
A B 
A B 
P N 
H K 
K G 
% Е 
39 
31 
33 
45 
70 
86 
55 
% Е
М 
31 
24 
31 
41 
18 
11 
20 
% 
ЕА 
1 
3 
5 
6 
t ' h 
2-5 
5 
4 
3 
5 
5 
5 
1 , /2М 
8 
9 
8 
5 
11 
9 
9 
1 ,/2А 
10 
14 
9 
8 
— 
— 
— 
kr/kei 
0 39 
0 31 
0 33 
0 45 
0 70 
0 86 
0 55 
kdeal/ kel 
0 40 
0 35 
0 38 
0 55 
0 22 
0 14 
0 25 
kdeam/kel 
0 21 
0 34 
0 19 
0 
0 08 
0 
0 20 
% E percentage of the dose excreted, M = methylamphetamine, A = amphetamine, ti/2 
half life time (hr) 
nation In N-dimethylamphetamine this requirement is present, but we failed 
to show any deuterium effect This means that the rupture of the C-Η bond is 
not, as with N-isopropylamphetamine, involved in the rate-limiting step Thereby 
Jenner (1971) claimed that with N-dimethylamphetamine, a small amount of 
the corresponding N-oxide was excreted into the urine The conclusion is 
attractive that with the tertiary amines N-oxide formation is the rate-limiting 
step (fig 14) (See section IV, chapter 3). 
Me 
о 
OH 
1 1 
1 Me 
N ^ -v M e 
N 
" ^CHj 
M H 
CH, H figure 14 
The N-methylamphetamine formed is further metabolized by a-C-oxidation 
The N-dealkylation of the levo compound may be assumed to be the route of 
the N-oxide This N-oxide formation is independent of the steric configuration 
Hence, with the dextro isomers the same amount of N-oxide must be present, 
about 10% With the amount of N-oxide fixed at 10%, the percentages of 
deamination and N-dealkylation can be recalculated Both the deamination 
and N-dealkylation are split into a part due to a-C-oxidation and to N-oxidation 
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excretion n a t e C ^ / m m , log acate) 
1 0 0 305mg METHYL- ETHYL- AMPHETAMINE HCl (.) 
С Mc 
2Ь El· 
/ \ 
<S)-C-Ç-N-Me - --<^)-C-C-N-Et 
С
 А 
7h 
\ 
®-c-Ç-
¿ 
4 η 
% = ^ 
h 
Subject W V 
4 6 
figure 15: Renal excretion rate, urine pH, urine production and cumulative renal excretion 
of ( + ) N-methylethylamphetamine and its metabolites ( + ) N-ethyl-, ( + ) N-methylam-
phetamine and ( + ) amphetamine. The elimination of one of the substituents seems to 
be independent of the origin of the C-Η bindings. Thereafter the metabolite amphetamine 
is formed. 
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N-methyl-ethyl-amphetamine 
As observed with N-dimethylamphetamine one of the two alkyl groups is 
removed quicker than the other. From the metabolic data of N-methylamphe-
tamine and N-ethylamphetamine, the conclusion may be drawn that the ethyl 
group will be faster eliminated from the molecule than the methyl group. 
From table 12 it can be observed that the percentage of N-methylamphetamine 
excreted in the urine is higher than the percentage of N-ethylamphetamine. 
If we take into account that the metabolites undergo also N-dealkylation and 
deam,nation then the situation becomes diffuse. The large difference in per-
centage excreted between N-methyl- and N-ethylamphetamine may be caused 
by the fact that under acidic urine conditions deamination and N-dealkylation 
occur to the same extent, but with uncontroled urine pH, deamination relatively 
becomes more important. These two factors may be the reason that less 
N-ethylamphetamine is excreted unaltered in the urine than N-methylamphe-
tamine. From table 9 it can be derived that the N-dealkylation of N-ethylamphe-
tamine is two times faster than in N-methylamphetamine. Hence, when both 
groups are removed with equal rates, the amount of N-ethylamphetamine 
should be only half of the amount of N-methylamphetamine. The final con-
clusion must be that both groups are split off at a similar rate (fig 15) 
Table 12 
Halflife time of ( + ) N-methylethylamphetamine and its metabolites and the 
percentages of the compounds excreted in the urine. 
subject 
H H 
U V 
W.V 
dose 
5 
5 
30 
mg % E 
10 
3 
2G 
% E M 
18 
21 
25 
% E E 
7 
5 
12 
% E A 
6 
1 
10 
t l , 2 
3 
9 
2 
18 
21 
7 
t'l2E 
9 
11 
4 
24 
24 
7 
pH 
6-7 
6-7 
5 
% E percentage of the dose excreted, M = methylamphetamine, E = ethylamphetamine, 
A = amphetamine, ti )2 halfhfe time (hr). 
The experiment done under acid urine conditions shows a clear competition 
between the elimination of the methyl- and the ethyl group, from the compound 
N-methylethylamphetamine. The N-methylethylamphetamine is excreted in the 
urine and is very fast eliminated from the body. The halfhfe time of excretion, 
which reflects the blood concentration, is 2 hr 15-20 hours after intake of 
the compound it is completely removed from the body. The compound is con-
verted into metabolites of the "f irst order", the N-methyl and N-ethylampheta-
mine. The maximum in the excretion curve of both compounds is reached at 
the same time and is of about the same magnitude. This indicates that the 
rate of formation is of the same magnitude. The conversion of tertiary amine to 
secondary amine seems to be more important than the real difference in the 
rate of elimination of the methyl or ethyl group, and the difference in amounts 
totally excreted are mainly caused by secondary effects of deamination and 
N-dealkylation of the metabolites. 
Total amount excreted under acidic conditions is ± 70%. 
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figure 16: Renal excretion rate, urine pH, urine production and cumulative renal excretion 
of ( + ) N-methylisopropylamphetamine and its metabolites ( + ) N-isopropylamphetamine, 
( + ) N-methylamphetamine and ( + ) amphetamine The methyl group is faster eliminated 
than the isopropyl group 
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N-methyl-isopropyl-amphetamine 
When dextro N-isopropylamphetamine is ingested, the N-isopropylamphe-
tamine is eliminated extremely fast from the body and in the series of 
N-methyl-, N-ethyl-, and N-isopropylamphetamine it has the shortest halflife 
time. If N-dealkylation of tertiary amines occurs according to a similar 
mechanism as that of secondary amines, it may be anticipated that in 
N-methylisopropylamphetamine the isopropyl group will be removed much 
easier than the methyl group. It was therefore expected that only N-methyl-
amphetamine would be the metabolite, or major metabolite, and that little 
of the parent compound is excreted. From table 13 it may be seen that 
the metabolites are excreted to a similar degree. The amounts of metabolite 
N-methylamphetamine and N-isopropylamphetam.ne excreted are of the same 
level, but also in this case we have to take into account that the dextro 
N-isopropylamphetamine is faster eliminated than the dextro N-methylamphe-
tamine and that the percentage excreted in the urine does not give a correct 
picture of the competition in N-dealkylation of the methyl- and isopropyl 
group. If equal amounts of both metabolites were formed more N-methyl-
amphetamme would be excreted because the renal clearance is larger and 
N-isopropylamphetamine is more susceptible to biodégradation. Hence the 
methyl group must be split off faster (3 x) than the isopropyl group in order 
to give the metabolite a chance to be excreted in the urine. These findings 
indicate a different mechanism of oxidative N-dealkylation for tertiary and 
secondary amines. 
Under extreme acid urine conditions, pH 5, the excretion rate curves showed 
a phenomenon of interest (fig 16) The excretion curves of the N-methyliso-
propyl -and N-isopropylamphetamine did not show a straight line but there 
are clearly two parts in the excretion curve. During the first 10 hours of the 
experiment the excretion rate curve declines with a halflife time of 1.5 hr and 
thereafter with a halflife time of 7 hr. The same phenomenon is observed with 
the metabolite N-isopropylamphetamine. The maxima in the excretion rates are 
reached within two hours after the intake of the compound. This indicates 
that the N-methylisopropylamphetamine is extremely fast metabolized for the 
greater part to N-isopropylamphetamine, which in turn is converted fast to 
amphetamine. The curves of N-methylamphetamine and amphetamine showed 
a maximum of excretion that lasts for a few hours, at least 5-7 hours. This 
means that there is a very short steady-state level in the blood; the for-
mation of the metabolite is as fast as the elimination. The total amount of 
amphetamines excreted under strong acidic urine conditions is 70% and 
under moderate conditions 40-50%. 
Table 13 
Halflife time of ( + ) N-methylisopropylamphetamine and its metabolites and 
the percentages of the compounds excreted in the urine. 
subject 
F H 
K G . 
L S 
dose mg 
10 
10 
30 
10 
10 
19 
% E M 
14 
11 
17 
% E | 
10 
8 
22 
% E A 
9 
7 
12 
tl,2 
11 
7 
2-7 
[,/2М 
13 
10 
2-7 
t'l2l 
6 
10 
7 
t'/2A 
6 
10 
7 
pH 
6 
6 
5 
% E percentage of the dose excreted in the urine, M = methylamphetamine, I = isopro-
pylamphetamine, A = amphetamine, b¡7 halflife time of the parent compound (hr) 
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N-methyl-benzyl-amphetamine 
When ( + ) N-methylbenzylamphetamine is ingested only the metabolites 
N-methylamphetamine and amphetamine could be detected in the urine. The 
concentration in the urine of both metabolites is quite characteristic, the 
ratio is 1 : 1. The metabolite N-benzylamphetamme itself is not excreted and 
is converted to amphetamine for 10%. From these data, conclusions about 
the rate of the various competitive metabolic pathways, can only be very 
speculative. 
Table 14 
Halflife time of the metabolites of ( + ) N-methylbenzylamphetamine and the 
percentages of the compounds excreted in the urine. 
subject 
KG 
HH 
dose mg 
30 
10 
% E 
— 
% E M 
26 
12 
% E A 
24 
66 
t ' h l , / 2 M 
5 
10 
t'lJA 
5 
9 
pH 
5-6 
6 
% E percentage of the dose excreted, M = methylamphetamine, A = amphetamine, t i j 3 
halflife time (hr) 
Phendimetrazine 
The difference between the metabolic behaviour of threo and erythro phendime­
trazine cannot be studied as easily as with the phenmetrazines because the 
isomeric compounds and the isomeric metabolites are not fully separated at 
the Apiezon column. To avoid great errors in calculating peak areas, the com­
pounds are not given at the same time. The data of the amounts excreted 
totally of parent compound and metabolite show very large differences again. 
Both isomers of phendimetrazine were parahydroxylated, but only to a small 
extent (1%). There was no evidence for ring opening or other metabolic 
pathways; no other peaks than the original compounds and small amounts of 
the hydroxylated metabolites could be recognized. Only 16% of the threo 
compound is excreted unchanged and 18% of the metabolite threo phenme-
trazine (fig 17). Acid hydrolysis of the urine gives no phenmetrazine 
Table 15 
Halflife time of phendimetrazine and its metabolite phenmetrazine and the 
percentages of both compounds excreted in the urine. 
compound 
threo phendimetrazine 
erythro phendimetrazine 
subject 
EJ 
M D 
HB. 
AB. 
%E 
16 
15 
05 
0.7 
% E M 
18 
20 
24 
2.5 
t ' U 
3 
25 
25 
3 
4 ,
І 2 М 
5 
35 
45 
4 
% E percentage of the dose phendimetrazine excreted in the urine, % Едд percentage 
phenmetrazine excreted, ti/2 halflife of phendimetrazine, t i j 2 ^ halflife of phenmetrazine 
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from the conjugated compound The halfhfe time of the metabolite phenme-
trazine may be compared with the halfhfe time of phenmetrazine as parent 
compound (t i / , = 4 hr), thus indicating that the N-dealkylation is a rapid 
process When the nitrogen atom is a part of a ahcyclic ring, apparently no 
N-dealkylation (ring cleavage) occurs 
cumulative rendi 
excretion^mçbaee) 
excretion rate l^jug/mm log scale) 
100-
50m5 PHENDIMETRAZINE 
threo bitartrate 36mj base 
1 . ^ phenmetrazine 
phendimetrazine Subject E J 
•40 
figure 17 Renal excretion rate, urine pH, urine production and cumulative renal excretion 
rate of threo phendimetrazine and its metabolite phenmetrazine The N-demethylation is 
fast but only to a small extent 
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CHAPTER 4 
METABOLISM OF PHENTERMINES 
Phentermme 
Phentermine is excreted almost completely unchanged in the urine and only 
a very small amount is metabolized via parahydroxylation and N-oxidation 
(Cho 1972) 
Anens (1964) postulated that the lack of deammation is caused by the stenc 
hindrance at the carbon atom next to the nitrogen that should be eliminated 
but it is more likely the omission of the hydrogen atom that prohibits the 
deammation The halflife time of the excretion rate of pheiitermines, in subjects 
with acidic urine conditions, is higher than that of the corresponding amphe-
tamine When the pH of the urine is about 6, the halflife time of elimination is 
about 13 hr and the amount excreted unchanged over 60 hr is 50-80% Due 
to the higher percentage reabsorption in the tubuli, the metabolism gets 
more chances to play an important role in the total elimination than when 
the urine is acid and the renal excretion rate maximal (fig 18) 
Table 16 
Halflife time of phentermine and the percentage of the dose excreted in the 
urine under different pH conditions 
subject pH % E ti/2 
UV 
TV 
EA 
FR 
FH 
6-7 
6-7 
6 7 
5 
5 
45 13 
88 23 
50 19 
94 8 5 
100 9 5 
% E percentage of the dose excreted, t i / , halflife time (hr) 
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figure 18 Renal excretion rate, urine pH, urine production and cumulative renal excretion 
of phentermine Phentermme in this experiment was given orally while the ( + ) ampheta­
mine was administered rectally Phentermine was considered as a standard in order to 
investigate the rate of absorption after different routes of administration 
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figure 19: Renal excretion rate, urine pH, urine production and cumulative renal excretion 
of N-methylphentermine and its metabolite phentermine 
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N-methylphentermine 
N-methylphentermine is also excreted largely unchanged in man Walkenstein 
(1955) found with dogs and rats the parahydroxylation as the major metabolic 
route and N-dealkylation as a minor one N-dealkylation can be studied 
nicely with N-methylphentermine, because due to the lack of deamination, the 
total amount of phentermine excreted in the urine is caused by N-dealkylation 
From table 17 it can be derived that under mildly acidic urine conditions (pH 6) 
about 2 0 % is N-dealkylated Under acidic urine conditions the percentage of 
N-dealkylation is slightly decreased to 15% For N-methylamphetamine these 
figures are 2 5 % and 15% respectively From these figures it may be evaluated 
that the N-dealkylation of the methyl group is apparently independent of the 
deamination and that the reaction has its own rate constant Subject Η К has 
taken 10 mg of N-methylamphetamine and N-methylphentermine together and 
under acidic urine conditions nearly 100% of N-methylphentermine and 
metabolite phentermine and about 8 7 % of N-methylamphetamine and meta­
bolite amphetamine are excreted These results and those given in chapter 2, 
table 2 are used in the elucidation of the mechanism of the N-dealkylation of 
N-alkyl substituted amphetamines 
Table 17 
Percentage of dose excreted in the urine of N-methylphentermine and meta­
bolite and the halflife time of both compounds 
subject 
E A 
T V 
H K 
pH 
6 
6 
5 
% Ем p 
49 
75 
86 
% Ер 
20 
19 
14 
t ' I îMP 
20 
12 
6 
l , l2P 
30 
14 
11 
k r /ke | 
0 49 
0 75 
0 86 
kdeal/kel kdeam/kel 
0 20 — 
0 19 — 
0 14 — 
% E percentage of the dose excreted in the urine, MP = N-methylphentermine 
Ρ = phentermine ti|2 halflife time (hr) Deamination is impossible, so kd e a m/k e| does not 
exist 
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figure 20: Renal excretion rate, urine pH, urine production and cumulative renal excretion 
of N-isopropylphentermine and its metabolite phentermine 
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N-isopropylphentermine 
N-isopropylphentermine was used and studied as a reference compound in 
order to investigate the reason of the great difference in metabolism between 
dextro and levo N-isopropylamphetamine It was found that the levo N-iso-
propylamphetamine was deamined to a much smaller extent than the dextro 
N-isopropylamphetamine From the renal excretion data of the foregoing phen-
termines it was concluded that in N-isopropylphentermme no deamination could 
occur, that there are no steric isomers and that one of the isomers of N-iso-
propylamphetamines would behave like N-isopropylphentermine As can be 
observed from table 18, N-isopropylphentermine is excreted from 17-62% 
under acid urine conditions, but the amount of metabolite excreted is fairly 
constant 8-15% (fig 20) The latter figure can be compared with the percentage 
of N-dealkylation of N-methylphentermine, which occurs also for a 15% under 
acid urine conditions The half life time 7 hr can be compared with that of 
levo N-isopropylamphetamine, and levo amphetamine, but the maximum of 
the excretion rate is lower These observations may lead to the conclusion 
that a certain amount of N-isopropylphentermine is firmly bound to fatty 
tissues, so that only 17-23% can be excreted unchanged, or that there is an 
alternative mechanism for the elimination, for instance N-oxidation and para-
hydroxylation Perhaps that due to the steric interaction at the nitrogen atom 
the parahydroxylation as a competitive mechanism becomes important, but 
this hypothesis is the reverse of the observation that the N-dealkylation is 
regular and constant and occurs to the same amount as in N-methylphenter-
mine, which was excreted completely in the urine 
Table 18 
Percentages of the dose excreted in the urine of N-isopropylphentermine and 
its metabolite phentermine and the halflife time of both compounds 
subject 
M K 
FR 
A B 
PN 
H К 
pH 
5 
5 
5 
5 
5 
% Ε,Ρ 
27 
35 
17 
23 
62 
%Ep 
15 
12 
9 
11 
8 
^І2ІР 
6 
6 
5 
7 
75 
[,|2? 
8 
10 
8 
13 
13 
Mkel 
0 35 
0 35 
017 
0 23 
0 62 
k d e a l / k e l 
0 15 
012 
0 09 
011 
0 08 
% E percentage of the dose excreted, IP = N-isopropylphentermine, Ρ = phentermine, 
t i ) 2 halflife time (hr) 
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figure 21: Renal excretion rate, urine pH, urine production and cumulative renal excretion 
of 4-chlorophentermine and ( + ) 4-chloroamphetamine. Although there is hardly meta­
bolism of the 4-chlorophentermine, the compound is not excreted to a high extent 
unchanged. With 4-chloroamphetamine the high hpid-solubility of the compound in­
creases the percentage of deamination. 
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4-chlorophentermine 
The possibil ity of parahydroxylation, as observed by Walkenstein (1955), is 
ruled out by the substitution of a chlorine atom at the para position of the 
phenyl ring In 4-chlorophentermine N-dealkylation, deamination and parahy­
droxylation are not possible, so the compound ought to be excreted unchanged 
for 100% in the urine Jung and Tnggs (1968) showed that there was not a 
hundred percent excretion of 4-chlorophentermine in the urine Under acid 
conditions they found a similar percentage of excretion in the urine, as men­
tioned in table 19 (51-67%) (fig 21) Chlorophentermine does not show a relati­
vely sharp absorption peak in the renal excretion curve It is assumed that 
under acid urine conditions, the renal excretion can be compared with the 
blood concentration and that the renal excretion shows a maximum about one 
hour later than the blood concentration Under acidic urine conditions we 
found a very broad absorption maximum, the compound is slowly absorbed 
from the gastro-mtestinal tract, and at the same time, due to its highly 
lipophilic character, it is distributed over the tissues (Dubnick 1963) If it 
behaves analogous to 4-chloroamphetamine it is distributed mainly over fatty 
tissues The long halflife time shows that may be there is a slow release of 
the compound from the tissues 
Table 19 
Percentages of the dose excreted in the urine of 4-chlorophentermine and the 
halflife time 
subject pH % E ti и 
EA 
TV 
A B 
% E percentage of the dose excreted, ti/2 halflife time (hr) 
6 
6 
5 
28 
49 
65 
37 
38 
12 
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CHAPTER 5 
STEREO SELECTIVE METABOLISM OF AMPHETAMINES 
Introduction 
The dextro and levo isomers of amphetamine behave differently in their effect 
and metabolism In general, it is established that the levo amphetamine has no 
or weak central stimulant properties, concerning the motor activity, but the 
dextro isomer has The body has at its disposal several pathways of elimi­
nation and it may be assumed that when one of the pathways is blocked, 
the other, remaining, pathways become more important With levo amphe­
tamine, it is observed that the deamination is slower than with dextro amphe­
tamine The result is that levo amphetamine is excreted more unaltered than 
the dextro isomer (Gunne, 1967) With the aid of the following compounds, 
the N-isopropyl derivatives of phentermine, and both isomers of amphetamine, 
we have investigated the influence of the stereo chemical configuration of the 
α-carbon atom at the deamination and N-dealkylation of the dextro and levo 
amphetamines 
Results and discussion 
When the renal excretion rate is kept maximal by maintaining the urine acidic 
(pH 5), dextro amphetamine is excreted unchanged by most persons for about 
7 0 % but levo amphetamine for 9 0 % Gunne (1967) found a ratio between the 
renal excretion of dextro and levo amphetamine after ingestion of the racemic 
mixture of l/d = 1 25 When the excretion rate and total cumulative excretion 
of the dextro and levo isomers of N-alkyl substituted amphetamines are com­
pared, it may be observed that the halflife time of the renal excretion of all 
levo isomers studied is about 7 hr (section IV, chapter 4) At the same time, the 
percentage of N-dealkylation remains constant, 10% (see chapter 3) Con­
tradictorily, the dextro isomers show an increased metabolism with increase 
of the "size" of the substituent Comparison of the metabolism of levo N-iso-
propylamphetamine and N-isopropylphentermine may give an answer to the 
question whether the mechanism of the N-dealkylation of both compounds is 
of the same origin These two compounds are chosen, because no deamination 
is possible in N-isopropylphentermine and in both compounds the α-methyl 
group is presented to the active site of the cytochrome P-450 instead of 
preferred α-С-Н bond N-isopropylamphetamine and N-isopropylphentermine 
are ingested together by the same subject, in order to ensure that renal ex­
cretion and metabolism for both compounds were performed under identical 
circumstances The percentages of parent compound and metabolites are 
given in table 20 and table 21 
N-isopropylphentermine is a strongly lipophilic compound and this may explain 
why the renal excretion is rather irregular The metabolites, however, amphe­
tamine and phentermine, are excreted very well Thus, amphetamine and 
phentermine formed at the enzyme site, behave in the body like compounds 
which were ingested, excreted and metabolized as shown in previous experi­
ments It may be calculated that the average amount formed and excreted of 
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figure 22 Renal excretion rate, urine pH, urine production and cumulative renal excretion 
of ( + ) N-isopropylamphetamine and N-isopropylphentermine with its particular meta­
bolites while both compounds were ingested together, and eliminated under exactly 
the same circumstances 
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Table 20 
Percentages of the dose excreted in the urine of N-isopropylphentermine and 
its metabolite phentermine 
subject % E|p % Ep % N-dealkylation 
FR 9 12 
Μ К 27 15 
A B 17 9 average 11 % 
PN 23 11 
Η К 62 9 
% E percentage of the dose excreted, IP = isopropylphenternrne, Ρ = phentermine 
Table 21 
Percentages of the dose excreted in the urine of N-isopropylamphetamme and 
its metabolite amphetamine 
subject compound % E|A % EA % N-dealkylation 
FR ( + ) N-isopropylamphetamine 18 25 
A B 9 20 average 22% 
HP 29 20 
Μ К (—) N-isopropylamphetamine 84 11 
PN 81 15 average 12% 
Η К 53 12 
C V 58 15 
% E percentage of the dose excreted, IA = isopropylamphetamine, A = amphetamine 
the metabolite phentermine is 1 1 % of the dose, because phentermine itself 
is excreted for 100% unaltered (chapter 4) (fig 22) The amount of dextro 
amphetamine excreted as metabolite of dextro N-isopropylamphetamine is 
2 2 % This figure represents only 7 0 % of the amount of amphetamine formed 
Hence, the average amount of N-dealkylation of the dextro N-isopropylamphe-
tamine must be 2 8 % The amount of levo amphetamine excreted as metabolite 
from levo N-isopropylamphetamine is 12% This figure represents 9 0 % of the 
amount of amphetamine formed, so the amount of N-dealkylation of levo 
N-isopropylamphetamine must be 14% 
It is very tempting to conclude that the mechanism of N-dealkylation of levo 
N-isopropylamphetamine and N-isopropylphentermine is similar The next con­
clusion may be that both compounds have the same site of interaction with the 
enzyme The methyl group sticks in the enzyme site, there is a stencal hindrance 
which makes deamination impossible The α-С-Н bond is not available For all 
these kinds of nitrogen bases two possible routes of metabolism exist a-C-oxi-
dation and N-oxidation The dextro isomers of the amphetamines appeared 
to be very sensitive to the oxidation of the substituted alkyl group, while the 
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levo isomers and the phentermines do not show in their rate of metabolism 
any dependency upon this substitution When one wants to explain this 
phenomenon with the theory of a-C-oxidation, then for the levo isomers the 
rotation of the deprotonated amphetamine at the enzyme site should be rate-
limiting If one assumes that only the dextro isomers can be deaminated and 
N-dealkylated much faster by a-C-oxidation than by N-oxidation, and the levo 
isomers of amphetamines and phentermines are N-dealkylated and deaminated 
by initial N-oxide formation, then this assumption is not contradictory with the 
results obtained with the deuterated amphetamines and the incorporation of 
18
Ог as found by McMahon (1971) As was stated by Bickel (1971) a-C-oxidation 
and N-oxidation are competitive but also supplementary routes in the final 
reaction, deamination and N-dealkylation Thus if a-C-oxidation is hindered, 
by the lack of H atoms in the suitable direction, or due to stenc hindrance by 
large alkyl groups, then N-oxidation is the remaining route for N-dealkylation 
For secondary levo amphetamines and phentermines the amount of N-oxidation 
is constant and about 10% The next assumption can be that the N-oxidation 
is a rather unspecific process, thus with the dextro amphetamines there also 
is N-oxidation for 10% and the a-C-oxidation is added to the total process 
of metabolism Further evidence about the existence of both competitive 
mechanisms can be given by the activation energy of both mechanisms (sec­
tion IV, chapter 3) Due to the large differences in metabolic conversion be­
tween a-C-oxidation and N-oxidation, the activation energies should be quite 
different From the results given in section IV, chapter 3 it can be derived that 
the conclusion obtained by the experiments described here, is right 
CHAPTER 6 
DEUTERIUM ISOTOPE EFFECTS IN THE METABOLISM 
OF N-ALKYL SUBSTITUTED AMPHETAMINES IN MAN 
Introduction 
The results given in chapters 1, 2 and 5 all elicit a strong indication that the 
rupture of the α-С-Н binding is the rate-limiting step in metabolism of the 
dextro isomers and that the levo isomers might be deammated by the alter­
native N-oxidation route Therefore the particular hydrogen atom was replaced 
by a deuterium atom What could be expected was the following 
a) If the C-H/D bond rupture is the rate-limiting step, then with N-isopropyl-
amphetamine a significant deuterium effect will be observed in the meta­
bolism This effect will only occur with dextro isomers 
b) With levo isomers and the supposed N-oxide mechanism, two possibilities 
may exist 
1) The attack of the oxygen at the nitrogen atom is rate-limiting The result 
will be no deuterium effect 
2) The attack of the N-0 binding at the C-Η binding is the rate-limiting step 
The result will be a deuterium effect If this mechanism occurs without any 
help or interference of the enzyme, there will be no stereo selectivity in the 
deamination 
Results 
The results obtained give clear evidence as to the involvement of the tertiary 
hydrogen in both the N-dealkylating id deaminating sequence It should be 
recognized that, in the human body, several elimination mechanisms may mask 
a small deuterium effect 
The excretion rate, of the unaltered compound, which is maintained constant 
and maximal by maintaining the urine acidic, can be of importance For 
example, when the hydrogen compound is excreted 50% unaltered and the 
deuterium compound is excreted 50 5% unaltered, the conclusions resulting 
from the cumulative excretion, may be that there is no isotope effect, whereas 
many observations may show a statistical significant effect Other factors, such 
as the partition volume and the excretion rate of the deuterium and hydrogen 
compound may be different The partition volumes and the excretion rates both 
depend upon the pKa value of the compound and this value may differ maximal 
0 05 between the 2 compounds (Elison 1961) (table 22) 
The deuterated compounds are more ionized than the hydrogen compounds 
at the pH of the blood (7 40) Since the nonionized form of amphetamine is 
reabsorbed in the renal tubulus, the deuterated compounds are, or can be, 
more rapidly excreted than the hydrogen compounds If the latter is true then 
the difference in excretion rate must be constant during the whole period of 
excretion and the deuterium content of the urine samples must gradually 
decrease 
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Table 22 
pKa values of N-alkyl substituted amphetamines 
drug pKa 
amphetamine 
deuteroamphetamine 
N-methylamphetamine 
N-tndeuteromethyamphetamine 
N-isopropylamphetamme 
N-deuteroisopropylamphetamine 
N-deuteroisopropyldeuteroamphetamme 
N-dimethylamphetamine 
N-di-trideuteromethylamphetamine 
9 83 
9 88 
9 90 
9 95 
1031 
10 36 
10 38 
9 97 
10 08 
± 
±2 
± 
± 
± 
± 
•+: 
± 
± 
0 01 
001 
0 02 
0 02 
001 
001 
0 01 
0 01 
001 
The retention time of the compounds on the Apiezon-KOH column reflects 
the hpid-solubility of the compounds The deuterium compounds tend to 
decrease the retention time and due to this observation it is unlikely that 
the lipid-solubility and the related partition volume have increased 
When one is dealing with a deuterium effect in the metabolism, (deamination 
or the N-dealkylation), the enzymatic process must be slower for the deute­
rium compound due to the higher force constant of the C-D bond Therefore, 
the gradual increase in the deuterium content to the hydrogen content in the 
urine at subsequent time intervals will be less, or even a decrease may be 
found 
In our study a continuous increase of the percentage deuterium in the samples 
was found indicating a necessary manifestation of the deuterium effect in the 
metabolism The observation that the deuterated compound is excreted totally 
to a higher extent is secondary and is caused by factors other than the dif­
ference in metabolism The increase of the percentage deuterium of the 
samples may be a large one, for instance with N-deuteroisopropylamphetamine 
or a small one, as with deuteroamphetamine 
( + ) deuterated amphetamine vs ( + ) amphetamine (table 23) (fig 23) 
Observation of the deuterium percentage of amphetamine in the first urine 
sample after ingestion of both compounds ( 5 0 % H, 5 0 % D), and the deuterium 
content in one of the last urine samples (48 hr) indicates an appropriate in­
crease of 1 5 % (Accuracy of the determination is ± 2%) 
Table 23 
Difference in excretion and metabolism of ( + ) deuteroamphetamine and ( + ) 
amphetamine 
subject dose mg % D dose % D start % D end % H excr % D excr Л % excr Л % pH 
JG 
FH 
FH 
HP 
12 
10 
12 
12 
50 8 
50 1 
50 4 
50 0 
45 
50 
53 
54 
60 
68 
62 
61 
79 
71 9 
70 7 
54 
68 9 
90 
88 4 
75 3 
101 15 5 
181 18 5 
17 7 9 5-6 
20 3 7 5-7 
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co-
io 
β 
б 
— cumulative renal 
excret ion ^mg - base) 
f—-^^τ^-
e x c r e t i o n rate (¿ag/min¡ log sca le) 
100 
10 4 m f ( « ) DEUTEROAMPHETAMINE HCl 
10 05mj(») AMPHETAMINE MCI 
CCI 
_ Τ Ί deuteroamphetarnine 
f igure 23: Renal excretion rate, urine pH, urine production and cumulative renal excretion 
of ( + ) amphetamine and ( + ) deuteroamphetarnine. The deuterium content of the urine 
samples shifted from 5 0 % in the first samples to 6 0 % in the last ones (table 23). The 
difference in excretion rate between D- and H-amphetamlne is small, due to the fact 
that the renal clearance of the unaltered compound is much more important than the 
metabolic clearance (table 9). 
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From these data it can be concluded that there is a small deuterium effect. The 
composition of deuterium and hydrogen compound in the first urine samples 
determines the total cumulative excretion data Foreman (1969) has shown with 
deuterated amphetamine a distinct deuterium effect with respect to meta­
bolism by homogenized rabbit liver The rabbit and human metabolize amphe­
tamine in the same way, but from table 9 it can be seen that when the renal 
excretion k r is more important than the metabolic clearance k m the deuterium 
effect measured is small 
Table 24 
Differences in metabolism and excretion between ( + ) N-methylamphetamine 
and ( + ) N-tndeuteromethylamphetamine 
subject 
W V 
L S 
J G 
dose mg 
7 7 
7 0 
7 5 
% D dose 
50 1 
50 0 
50 2 
% D start 
54 
55 
56 
% D end 
54 
55 
56 
% H excr 
69 
74 
61 3 
% D excr 
88 
90 
75 7 
A % excr 
19 
16 
144 
0 
0 
0 
pH 
5 
5 
5 
( + ) N-trideuteromethylamphetamme vs ( + ) N-methylamphetamme (table 24) 
With N-methylamphetamine, the deuterium content of the urine samples varies 
between 52 and 5 6 % throughout the total period and essentially there is no 
shift in the percentage deuterium The total amount of N-tndeuteromethyl-
amphetamine excreted is higher than the amount of N-methylamphetamine 
excreted 
( + ) N-di-tndeuteromethylamphetamine vs ( + ) N-dimethylamphetamme (table 
25) 
Dimethylamphetamine does not show a deuterium effect in the N-dealkylation 
of the first and second methyl group The deuterium content of the urine 
samples vanes but no deuterium shift is observed 
Table 25 
Differences in metabolism and excretion between ( + ) N-dimethylamphetamine 
and ( + ) N-ditndeuteromethylamphetamine 
subject 
JG 
J B 
JH 
M H 
dose mg 
20 
21 
146 
138 
% D dose 
50 1 
50 0 
50 1 
50 2 
% D start 
50 
50 
50 
59 
% D e n d 
60 
61 
57 
60 
% H excr 
18 
18 
6 
17 
% D excr 
27 
24 
9 
25 
Δ % excr 
9 
6 
3 
8 
10 
11 
7 
1 
pH 
5 
5 
5 
5 
(—) N-dimethylamphetamine and (—) N-ditndeuteromethylamphetamine 
M Η 15 50 0 55 60 18 26 8 
The accuracy in % D by means of massfragmentometry is ± 5% 
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íy-L_ri_ 
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Subject J G 
J 6 -4Ö 
figure 24 Renal excretion rate, urine pH, urine production and cumulative renal excretion 
of ( + ) N-deuteroisopropy'amphetamine and ( + ) N-isopropylamphetamine There is a 
remarkable deuterium effect 
112 
( + ) N-deuteroisopropylamphetamine vs ( + ) N-isopropylamphetamine (table 
26) (fig 24) 
This compound elicits a rather large difference between the hydrogen and 
deuterium compound The deuterium content increases from 48% to 90% in 
all the subjects, but in some subjects the deuterium shift begins or is measu­
rable only 10 hr after ingestion When the urine is acidic (pH 5), the total 
amount of N-isopropylamphetamine excreted in the first 10 hr determined the 
total cumulative excretion and for this reason the differences between deute­
rium and hydrogen cumulative excretion are very small, in spite of the great 
deuterium shift The dextro isomer shows this effect, but the levo isomer does 
not From table 9, chapter 2 it can be seen that for the dextro isomer the 
metabolic processes of elimination are much more important than the renal 
excretion and that with levo N-isopropylamphetamine the relationship between 
renal and metabolic clearance is reversed 
Table 26 
Differences in metabolism and excretion between ( + ) N-isopropylamphetamine 
and ( + ) N-deuteroisopropylamphetamine 
subject 
T V 
JG 
JS 
JG 
C V 
( - ) N-i 
JS 
PR 
JG 
dose mg 
13 
15 
15 
15 
15 
% D dose 
50 0 
49 5 
49 5 
50 0 
50 0 
isopropylamphetamine and 
15 
16 
17 
50 0 
25 1 
52 0 
% D start 
48 
48 
48 
48 
48 
% D end 
90 
89 
82 
90 
80 
% H excr 
137 
8 35 
8 75 
5 0 
12 1 
% 
(—) N-deuteroisopropy(amphetamine 
51 
53 
52 
51 
53 
53 
63 2 
57 3 
5 4 0 
D excr 
142 
9 90 
10 14 
6 50 
124 
63 5 
66 5 
56 8 
Δ % excr 
0 5 
1 55 
1 39 
1 50 
0 30 
0 30 
9 2 
2 8 
42 
41 
34 
42 
32 
0 
0 
0 
pH 
5 
5 
5 
5 
5 
5 
5 
5 
Table 27 
Difference in metabolism and excretion between ( + ) N-isopropylamphetamine 
and ( + ) N-deuteroisopropyldeuteroamphetamine 
subject 
C V 
T V 
JB 
( - ) N 
F H 
H H 
dose mg 
44 1 
43 0 
42 3 
% D dose 
49 5 
50 0 
51 3 
isopropylamphetamine and 
41 6 
40 0 
50 0 
50 1 
% D start 
50 
45 
40 
% D end 
80 
75 
77 
(—) N-deuteroisopn 
52 
51 
54 
52 
% H excr 
7 95 
3 14 
1 70 
% D excr 
6 02 
2 04 
1 25 
apyldeuteroamphetamine 
88 
82 
76 
80 
A % excr 
1 93 
1 10 
0 45 
12 
2 
A % 
30 
30 
37 
2 
1 
pH 
5 
5 
5 
5 
5 
( + ) N-deuteroisopropyl-deuteroamphetamme vs ( + ) N-isopropy¡amphetamine 
(table 27) (fig 25) 
According to the results with N-deuteroisopropylamphetamine it was expected 
that the halflife time of N-deuteroisopropyldeuteroamphetamme would be 
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cumulative renai 
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löopropylamph. ¡ 
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figure 25: Renal excretion 
rate, urine pH, urine pro­
duction and cumulative 
renal excretion rate of 
( + ) N-deuteroiospropyl-
deuteroamphetamine and 
( + ) N-isopropylampheta-
mine There is a deuterium 
effect of the same magni­
tude as mentioned in figure 
24. 
doubled. The experiments, on the contrary, do not show a further increase in 
ti/2 of the N-dideuteroisopropylamphetamine. The reason for this may possibly 
be the fol lowing: 
The purpose of the experiments was to prove that both tertiary hydrogen 
atoms in N-isopropylamphetamine are chemically identical for the enzyme. 
Therefore they were replaced by deuterium atoms in order to show that the 
hydrogen atoms in question are involved and are rate limiting. We have com­
pared H-isopropyl- with D-isopropylamphetamine and found an increase in 
ti/2 from 2 hr to 4 hr for the deuterium compound. From above experiments 2 
hypotheses may follow: 
114 
Hypothesis I. The enzymes deaminate and dealkylate the H- and D-isopropyl-
amphetamine with the same affinity, thus, the difference in excretion rate and 
ti/2 is caused by the C-D bond rupture. 
Hypothesis II. The enzyme can perform one metabolic action with the com­
pound and after that action the compound leaves the enzyme action site. 
If both N-dealkylation and deamination occurred at the same time, no amphet­
amine would be found as metabolite When two different enzymes are involved, 
then the dideuterated N-isopropylamphetamine must be metabolized at a 
slower rate than the monodeuterated N-isopropylamphetamine When we are 
comparing N-isopropylamphetamine with the N-dideuteroisopropylamphetamine 
and take into account hypothesis II, then it does not matter whether the C-D 
bond of the amphetamine moiety is broken or the C-D bond of the isopropyl 
moiety is broken. When the isopropyl group has been removed, the metabolite 
shows the normal deuterium effect. 
Discussion 
The results clearly el.cit a deuterium effect in the metabolism of the dextro 
isomers of the amphetamines With the levo isomers no deuterium effect could 
be observed This may be due to the low metabolic rate, but the results are 
even less positive than with dextro amphetamine. With dextro amphetamine the 
ratio kr/km is very unfortunate to show a metabolic effect Thus with o-C-oxi-
dation the C-Η binding is ruptured in the rate-limiting step. Some remarks 
should be made about the metabolism of the levo isomers. Assuming the two 
possibilities of N-oxide formation mentioned in the introduction, the lack of a 
measurable deuterium effect may indicate that the attack of the oxygen at 
the nitrogen atom is slow and rate-limiting. The second possibility, the rate-
limiting attack of the N-0 bond at the C-Η binding, without any help of the 
enzyme can be ruled out, because then the origin and energy of the C-H 
binding that is attacked will play an important role, as observed with the 
dextro isomers The situation will be similar to the dextro isomers and this is 
not observed. Measuring activation energies, it is shown that the activation 
energy of the levo isomers is a factor 1.8 that of the dextro isomers (section 
IV, chapter 3). This study also has shown that there is no exchange of hydrogen 
from the amphetamine moiety to the alkyl group and vice versa This finding 
supports the mechanism of McMahon (1971) of the oxygen insertion 
CHAPTER 7 
STEREOCHEMISTRY IN THE N-DEALKYLATION OF 
N-ALKYL SUBSTITUTED EPHEDRINES IN MAN 
Introduction 
The stereochemistry at the u-C-atom and the oxygen insertion in the rate-
limiting step, introduces the question of the importance of the stereochemistry 
at the ß-C-atom. Substituents at this place may interfere or hinder the 
a-C-oxidation. Ephedrines show the same metabolic pathways as the amphet-
amines. With the amphetamines the stereochemical configuration of the tertiary 
C-Η binding is the key in the deamination and N-dealkylation. When the in­
teraction of this C-Η group with the enzyme is hindered it affects deamination 
and N-dealkylation. The hydroxyl group of the ephedrines may also hinder 
deamination and N-dealkylation. To show any difference in metabolic behaviour, 
the extent of metabolism to total excretion should be significant, so the 2S 
(dextro configuration of the amphetamines) configuration was chosen. The 
ephedrines are less lipid-soluble than the corresponding amphetamines. The 
most pronounced difference in metabolic behaviour was expected for the 1R, 
2S and 1S, 2S N-isopropylnorephedrine. 
Results 
From table 28 it can be observed that there exists a remarkable difference 
between the N-dealkylation of the 1R, 2S and I S , 2S isomers of N-isopropyl­
norephedrine. With these isomers metabolism is the main route in the total 
elimination, so differences in metabolism are easy to observe. The finding 
that the 1S, 2S configuration is more excreted unchanged than the 1R, 2S 
configuration has serious consequences for the metabolism of the amino-
propiophenones. These compounds are reduced to the corresponding ephedri­
nes to a considerable extent. The results found with 1S, 2S ephedrines are in 
agreement with those published by Wilkinson (1968). 
?' 
H —C—NH-R 
H - - C - O H 
nor-ephedrincfs ) 
erytro-1R,25 
H 
MO 
CH3 
I 
-C —NH-R 
I 
-C —H 
nor-ephedrine(6) 
threo-1S.2S 
R= H, methyl, ethyl, isopropyl 
CH3 
I 
-C—NH-R 
I 
-c —H H 
25-amphet".mine (s) 
figure 26: Structural formulas and configuration of ephedrines. 
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Table 28 
Differences between renal excretion, N-dealkylation and deamination of 1R, 2S 
and 1S, 2S N-alkyl substituted norephedrines. 
compound 
1R, 2S norephedrine 
N-methyl-norephednne 
N-ethyl-norephednne 
N-isopropyl-norephedrme 
IS,2S norpseudoephednne 
N-methyl-norpseudoephednne 
N-ethyl-norpseudoephednne 
N-isopropyl-norpseudoephedn 
(percentage dose) 
excretion N-dealkylation deamination 
75 — 25 
60 15 25 
40 25 30 
20 50 30 
95 — 5 
85 7 8 
60 15 25 
40 20 40 
CHAPTER 8 
KINETICS OF METABOLISM AND RENAL EXCRETION OF 
N-ALKYL SUBSTITUTED AMINOPROPIOPHENONES 
Introduction 
The metabolism of aminopropiophenones shows 4 competitive pathways for 
eliminating the compound from the body. The metabolic routes that take place 
are parahydroxylation, reduction, deamination, N-dealkylation, but also there 
is excretion of the unchangsd compound and the metabolites by the kidneys 
Schreiber (1968) produced evidence for all these reactions in the metabolism 
of N-diethylaminopropiophenone, but stated also that the parahydroxylation is 
a minor pathway. Beckett (1959) examined the excretion of 4-chloroethylamino-
propiophenone and its metabolites and found that the total amount excreted 
of non-acid compounds was about 50% When examining the N-alkyl-
substituted aminopropiophenones and their metabolites excreted into the urine, 
it is observed that all the compounds show a particular metabolic behaviour 
Results 
Aminopropiophenone is partly reduced to norephedrine (32%) The norephe-
drine formed is excreted mainly due to its low lipid-solubility (chapter 7). 
N-methylaminopropiophenone is mainly demethylated to aminopropiophenone 
(60%) N-Ethylaminopropiophenone is excreted mainly unchanged into the 
urine (45%) and there is litte N-dealkylation and reduction (fig 27) 
N-isopropylaminopropiophenone is mainly excreted into the urine unchanged, 
but the rapid decrease of the compound from the body resembles the rapid 
elimination of N-isopropylamphetamine (chapter 2 + 6). 
The compounds N-ethyl-, N-propyl-, N-isopropyl- and N-butylammopropio-
phenone all have nearly the same pKa value (table 29) and lipid-solubility, and 
this may be the most important factor in the metabolism and renal excretion 
competition 
Table 29 
pKa values, apparent and true partition coefficients of some N-alkyl substituted 
aminopropiophenones. 
compou 
aminopropio 
N-methyl-
N-ethyl-
N-propyl-
N-isopropyl-
N-butyl-
N-dimethyl-
N diethyl-
nd 
phonone 
pKa 
816 
7 59 
8 40 
8 46 
8 45 
8 47 
8 09 
8 78 
TPC h e p ¡ 
0 500 
27 4 
28 2 
157 
4 60 
525 
TPC c h | 
214 
2750 
3050 
15400 
40 5 
15000 
APChepi 
0 22 keto 
0 Ю е п о І 
0 05 
2 25 
2 25 
122 
0 78 
21 
A P C c h , 
48 keto 
20enol 
195 
225 
244 
1200 
6 90 
600 
APChepi I S l n e apparent partition coefficient at pH 7 40 in the system heptane/water 
(Teore I bufrer) 
TPCchi is the true partition coefficient in the system chloroform/water 
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figure 27: Renal excretion rate, urine pH, urine production and cumulative renal excretion 
of N-ethylaminopropiophenone and its metabolites N-ethylnorephednne and aminopropio-
phenone. The reduction and N-dealkylation of the secondary aminopropiophenones arc 
minor pathways. 
119 
N-Dimethylaminopropiophenone is reduced (40%) and excreted (25%) un-
changed in fairly equal amounts and to a small extent demethylated (fig 28) 
N-Dimethylnorephednne also is slightly demethylated to N-methylnorephednne 
and mainly excreted unchanged (Wilkinson 1968) 
N-Diethylammopropiophenone is mainly reduced (20%) and N-dealkylated (25 
% ) The N-dealkylated product N-ethylaminopropiophenone is mainly excreted 
unchanged (40 % ) and also the N-diethylnorephednne formed is mainly 
excreted unchanged and for a small part N-dealkylated to N-ethylnorephednne 
(fig 29) 
N-Diethylaminopropiophenone has no big excretion of the unaltered compound 
(2%) This can be explained by its high lipid-solubility and the comparatively 
low lipid-solubility of the metabolites formed, resulting in an increased elimina-
tion from the body 
The observed quantitative difference in the way of metabolism of amino-
propiophenones compared to that of amphetamines can be explained as 
follows 
For the deamination and N-dealkylation a H atom is needed and this H atom 
is directly involved in the rate-limiting step of this oxidative deamination 
(chapter 6) When the H atom is not available, as with phentermme, the 
oxidative reaction is blocked, and the compound is excreted unchanged in the 
urine for 100% Aminopropiophenones show a keto-enol tautomerism This 
means that for a certain fraction of the total amount of aminopropiophenone 
present in the liver or metabolic site of the enzyme, the required H atom is 
present 
The metabolic fate of the aminopropiophenones in still rather obscure The 
influence of the carbonyl group may be activation of the a-H-atom The same 
behaviour is observed with AN1 (chapter 2), with ßF- and ßß-difluoroampheta-
mines (Fuller 1972) and with N-cyanoethylamphetamine (Beckett 1972) The 
result was a lowering of the bond energy of the α-С-Н binding and an in­
creased extent of deamination (table 30) 
Table 30 
compound % deamination 
+ amphetamines 30 
— amphetamines 10 
aminopropiophenones 50 
β β difuoroamphetamine 70 
The reduction of aminopropiophenones is rather irregular (table 31) The exact 
mechanism is not known yet, but some characteristics about this mechanism 
may be derived from the results mentioned by Testa (1973) and those of the 
ephednnes In chapter 7 it was outlined that the 1S, 2S configuration, with the 
OH-group and Η atom directing into the enzyme site is less metabolized and 
excreted to a higher extent than its 1R, 2S isomer It was mentioned already 
in chapter 1 that metabolism serves the logic of an increase of the total 
elimination rate At the risk of committing teleology, it may be predicted that 
also the reduction of aminopropiophenones will be stereo specific in order to 
ensure maximal elimination 
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figure 28: Renal excretion rate, urine pH, urine production and cumulative renal excretion 
of N-dimethylaminopropiophenone and its metabolites N-methylephedrine and ephedrine. 
The metabolite aminopropiophenone is not found in the urine. This means that N-dimethyl-
aminopropiophenone is first reduced to N-methylephedrine, which in turn is demethylated 
to ephedrine. 
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Table 31 
Percentage of competitive metabolic routes in the metabolism of N-alkyl 
substituted aminopropiophenones 
compound 
ammopropioplienone 
N methyl-
N cthy!-
N-isopropyl-
N dimethyl-
N-diethyl-
excretion 
5 
25 
45 
50 
30 
2 
reduction 
35 
— 
3 
— 
60 
15 
N-dealkylation 
— 
60 
2 
— 
— 
25 
deamination 
60 
15 
50 
50 
10 
58 
Beckett and Testa (1972) pubi shed an extended method of Gordis (1969) for 
the separation of stereo isomers of phenylethylanrnes by der.vatization with 
l-prolyltrif luoroacetylchlonde Testa (1973) published the stereochemical com­
position of the metabolites of N-diethylaminoprop ophenone after reduction 
Reduction of this compound results in threo N-diethylnorephednne (80% 1S, 
2S, 18% 1R, 2R and 2 % erythro isomers) Thus, that particular metabolite is 
formed which needs less "metabolc care" 
The N-dealkylation by the mechanisms α C-oxidation and N-oxidation do not 
convert the configuration of the 1S, 2S N-diethylnorephedrme (McMahon 1971) 
From table 31 it may be seen that N-ethyl- and N-isopropylaminopropiophe-
none are hardly reduced to the corresponding alcoho's Hence, N-ethylnore-
phednne must be formed by N-dealkylation of N-diethylnorephednne ex­
clusively In the chain of N-dealkylation with the parent compound N-diethyl-
norephednne in the 1S, 2S configuration (98%) there must be retention of 
configuration, the metabolites N-ethyl- and norephedrine should be present 
predominantly in the 1S, 2S configuration The results of Testa show the 
interesting phenomenon that there is conversion and racenvsation during this 
N-dealkylation process to a considerable extent 
Table 32 
Stereochemistry of the ammo alcohols excreted in man as N-diethylanvnopro-
piophenone metabolites under condition of acidic urine (Testa 1973) 
compound 
N-diethy I norephedrine 
N-ethylnorephednne 
norephedrine 
% E 
158 
14 1 
26 0 
I S , 2S 
80 
58 
12 
% in the 
IR, 2R 
18 
20 
46 
configuration 
1S, 2R 
1 
7 
3 
IR, 2S 
1 
15 
39 
% E percentage of the dose excreted 
The decrease in the ratio 1S, 2S/1R, 2R during the N-dealkylation might be 
explained by the assumption that the rate of metabolism in the 1S, 2S con­
figuration is faster than with the 1R, 2R configuration (table 32) The results 
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figure 29: Renal excretion rate, urine pH, urine production and cumulative renal excretion 
of N-diethylaminopropiophenone and its metabolites, N-ethylaminopropiophenone, 
N-diethylnorephedrino and N-ethylnorephedrine. The metabolite N-ethylnorephedrine is 
formed predominantly from N-diethylnorephedrine, because N-ethylaminopropiophenone 
is hardly reduced (fig 27). 
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given in chapter 7 eliminate this explanation. The conversion of 1S, 2S in 
1R, 2S requires the deprotonation of the Η atom, thus creating a flat inter­
mediate. 
It is questionable, whether the conversion can be reconciled with the 
mechanisms of o-C-oxidation and N-oxidation. The constant and low per­
centage of the 1S, 2R configuration may mean that this isomer is not formed. 
The 2R configuration inhibits a-C-oxidation. The isomer 1R, 2S must be formed 
from the 1S, 2S or 1R, 2R configuration. The possibility for this conversion is 
the fol lowing: 
The percentage 1S, 2S decreases in relation to 1R, 2R, so that as a result 
the percentage of 1R, 2S increases. The configuration at carbon atom 1 con­
verts ( 1 S - ^ 1 R ) . 
Conversion of the configuration at carbon atom 2 may be ruled out by the 
McMahon mechanism of a-C-oxidation of oxygen insertion with retention of 
configuration. Let it be assumed that the 1S, 2S configuration of the ephednnes 
cannot be metabolized at all, N-dealkylation of the 1S, 2S configuration of 
substituted ephednnes only takes place for 15-20%. Because both the OH 
group and Η atom interact with the enzyme, a result may be conversion of the 
configuration at carbon atom 1 to the 1R, 2S configuration. The latter is the S 
( + ) configuration of amphetamine which is suitable for a-C-oxidation (25-50%, 
table 28). T h s means that the percentage of N-dealkylation of the 1S, 2S 
configuration and the percentage of conversion are similar. From table 32 and 
28 it can be derived that the percentage of N-dealkylation of N-ethyl- and 
N-isopropylnorephednne are of the same magnitude (20%) as the amounts of 
convers'on between the succeeding steps in the N-dealkylation of N-diethyl-
norephedrme (20%). Maybe these values agree by coincidence and this ex­
planation is too speculative. An attempt will be made to prove this tentative 
mechanism by measuring activation energies of the N-dealkylation of the 
different isomers. 
CHAPTER 9 
KINETICS OF METABOLISM AND RENAL EXCRETION OF 
N-ALKYL SUBSTITUTED CYCLOHEXYLISOPROPYLAMINES 
Introduction 
Substitution in the propane chain of amphetamine results in a great difference 
in metabolic routes and their partial contribution in the total metabolic elimina-
tion Also it is observed that these substituents do not alter the physico-
chemical properties of the amphetamine derivatives very much (section II) 
Substitution in the aromatic ring however, results in big changes in the lipid-
solubility and also in the rate of elimination Fenfluramine (Beckett 1967), 
4-chloroamphetamine (Fuller 1967) and 2-methoxyamphetamine are much more 
metabolized and slower excreted than the amphetamine Hydrogen substitution 
in the aromatic ring, relatively do not alter the lipid-solubility very much 
Hence it was aspected that the metabolic feature of cyclohexylisopropylamines 
should be more or less similar to that of the amphetamines In the literature 
relatively little is known about the metabolism of these drugs, though the 
N-methyl derivative is used as anti obesity drug The aim of the investigation 
was to study the influence of the hydrogen substitution on the metabolic 
pattern The metabolic fate of the "saturated amphetamines" in man was 
compared with the known metabolic pathways of amphetamines and ephe-
drines 
Results and discussion 
A Excretion of the unchanged compound 
After ingestion of cyclohexylisopropylamine or an N-alkyl substituted derivative 
by man, a very small amount of the parent compound was excreted unchanged 
in the urine In table 33 the amounts excreted are given as well as the per-
centages obtained with the corresponding amphetamines (fig 30) 
Table 33 
Excretion of unchanged amphetamines and cyclohexylisopropylamines in the 
urine of man 
compound 
cyclohexylisopropylamine 
N-methyl-
N-ethyl-
N-isopropyl-
amphetamme 
N-methyl-
N-ethyl-
N-isopropyl-
o/ /o 
S confi 
7 
7 
4 
1 
70 
65 
40 
10 
of the dose excreted 
time 
guration t i ( 2 (hr) 
3 
3 
3 5 
0 5 
7 
7 
5 
3 
unchanged 
of elimination 
R config 
6 
7 
4 
3 
90 
80 
90 
85 
and 
urat 
halflife 
ion t i / , (hr) 
3 
5 
3 
1 
8 
7 
7 
7 
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figure 30: Renal excretion rate, urine pH, urine production and cumulative renal excretion 
of N-methylcyclohexylisopropylamine (propylhexedrine) and its metabolites cyclohexyli-
sopropylamine and cyclohexanolisopropylamine. The metabolic processes are very fast, 
the renal excretion rate of the metabolites reach a maximum after 2-3 hours. 
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From table 33 it can be derived that concerning the saturated amphetamines, 
there is no striking difference in metabolic behaviour between the various 
derivatives and between the different stereochemical configurations of those 
derivatives All compounds are very well metabolized and the renal excretion 
of the unchanged compound is of minor importance This is in contrast with 
the amphetamine series, where substantial amounts of unchanged compounds 
are excreted For the derivatives with the S configuration, the proportional 
excretion of the unchanged compound decreases with increasing alkyl sub­
stituent However th s excretion is constant for the R configuration (chapter 2) 
The detection system used, makes it possible to detect the parahydroxylated 
metabolites of the saturated amphetamine in contrast to parahydroxyamphe-
tamme In spite of this possibility, no trace of hydroxylated metabolite of 
cyclohexylisopropylamine was found It must be concluded that the deamina-
tion is an extremely fast metabolic route in the metabolism of this parent com­
pound Most likely deamination and ring hydroxylation are competitive path­
ways for elimination With the amphetamines « C-oxidation and renal excretion 
are the two metabolic routes 
В Hydroxy metabolites 
In comparison with the amphetamine metabolism, the most striking observation 
in the metabolism of saturated amphetamines is the hydroxylation of the 
cyclohexyl ring The hydroxylation is prevaeling when the size of the sub­
stituent increases, concomitantly with increase of the lipid-solubility The 
degree of hydroxylation also depends upon the stereochemical configuration, 
but the ratio of hydroxylation of R and S configuration is constant (fig 31) 
The results are summarized in table 34 
Table 34 
% of the dose excreted as ring hydroxylated metabolites into the urine of man 
compound 
cyclohexylisopropylamine 
N-methyl-
N-ethyl-
N-isopropyl-
- ) S 
0 
60 
37 
55 
configuration 
( + ) R 
0 
10 
55 
85 
S/R 
0 60 
0 67 
064 
The differences in percentage of the hydroxy metabolites in the R and S 
configuration might be explained with the aid of the competitive metabolic 
pathways, on the understanding that the S-compound is more susceptible to 
a-C-oxidation than the R-form Deamination is so fast that N-dealkylated 
metabolites are hardly excreted unchanged in the urine (1-5%) As reported 
earlier, for amphetamines both reactions were extremely dependent upon the 
R- and S configuration The same behaviour can be found with saturated 
amphetamines, the effect in some way is masked by the hydroxylation 
Dring (1970) showed for some species the amounts of parahydroxylation of 
S- and R amphetamine, and he found the same differences in hydroxylated 
products, due to the difference in deamination of the amphetamine (table 35) 
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urine ml/min 
ю 
β 
ч -
2 
cumulative renal 
excretion mg base 
90% 
6 0 % 
urine pH ρ/ 
50 η · · 
5 5 ί 
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10 
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С- С- NH-C • 
SC-) Ь 
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Subject NA,J L 
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f igure 31 Difference in renal excretion rate between the R ( + ) and S (—) configuration 
of the metabolite N-isopropyl-cyclohexanolisopropylamine The R ( + ) configuration 
( t i / , 4 hr) is much slower metabolized (N-oxidation) than the S (—) configuration 
(a-C-oxidation) The equal maximum renal excretion rate of both metabolites indicates 
that the rate of hydroxylation is independent of the stereochemical configuration of 
the side chain 
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Table 35 
Aromatic hydroxylation of amphetamine antipodes in various species (after 
Smith and Dring 1970) 
% of the dose excreted as p-hydroxyamphetamine 
S P e C i e S
 S ( + ) R ( - ) R.S( + . - ) 
man 
guinea pig 
mouse 
rat 
1 1 
14 
48 
0 
3 9 
17 
63 
1 
2 8 
60 
С The liydroxylattng enzyme system 
Considering the metabolism of cyclohexylisopropylamines and amphetamines 
the question arises whether one enzyme performs both a-C-oxidation and ring 
hydroxylation, or different enzymes, or different active sites of one enzyme 
system are responsible for the conversion What is the reason why with in­
creasing size of the N-alkyl substituent with saturated amphetamines the ring 
hydroxylation increases while with amphetamines the a-C-oxidation increases 
An explanation may be that with increasing size of the substituent, the lipid-
solubility increases too and that "a certain part" of the enzyme can be reached 
while with amphetamines the nature of the C-Η bond and therefore the rate of 
the a-C-oxidation is altered This may be acceptable when one assumes that 
for all derivatives the rate of aromatic hydroxylation is low The lipid-solubili-
ties were measured, but it turned out that the corresponding derivatives of 
saturated and non saturated amphetamines have a fixed ratio of their partition 
coefficient (table 36) 
Table 36 
pKa values and partition coefficients of amphetamine, cyclohexyhsopropylamine 
and derivatives 
compound 
amphetamine 
N-methyl-
N-ethyl-
N-isopropyl-
cyclohexy I isopropy lamine 
N-methyl-
N-ethyl-
N-isopropyl-
pKa 
9 9 0 
1010 
10 23 
10 14 
10 50 
10 60 
10 80 
10 60 
TPChepi 
1 88 
5 1 4 
38 6 
117 
190 
92 0 
550 
1180 
T P C c h l o r 
146 
565 
1790 
4460 
770 
1860 
8350 
12900 
A P C h e p t 
0 005 
0 0 1 5 
0 060 
0 2 1 
0 0 1 5 
0 058 
0 22 
0 74 
A P C c h ! o r 
0 48 
1 10 
2 67 
8 09 
0 61 
1 17 
3 3 4 
8 10 
TPC true partion coefficient 
APC apparent partition coefficient 
hept system heptane-water (Teorell buffer, pH 7 4) 
chlor system cr.loroform-water (Teorell buffer, pH 7 4) 
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The different saturated amphetamines are about three times more lipid-soluble 
than the corresponding amphetamines This difference in solubility does not 
explain the different enzymatic attack at the molecule The difference between 
the two rmg systems is the origen of the C-Η bond that is attacked aliphatic 
and aromatic, and the "shape" of the molecule The phenyl ring is stabehzed by 
its resonance energy of 36 kcal/mol If one enzyme is postulated for hydro-
xylation of both phenyl ring and cyclohexyl ring then the resonance energy 
may act as a threshold Due to its high activation energy of the hydroxylation 
of the phenyl ring, the a-C-oxidation get a chance to occur as an alternative 
metabolic pathway The cyclohexyl ring behaves like an aliphatic chain, in 
wh ch the most outstanding C-Η bond with the lowest energy is hydroxylated 
It may be that different enzyme systems (mechanisms) are metabolizing these 
amphetamines The compound Ferrocenyl sopropylamine exerts to be an ex­
cellent inhibitor of the metabolism of amphetamines in rat (section IV, chapter 
5) Ferrocenylisopropylamine binds very strongly to the cytochrome P-450 
(table 37) and in this way inhibits the a-C-oxidation But, even when the 
ferrocenylisopropylamine was added in an excess of 50 times the concen­
tration of saturated N-isopropylamphetamine in rats, the compound failed to 
inhibit the metabolism of "saturated N-isopropylamphetamine" From this 
observation it must be concluded that the hydroxylation of the cyclohexyl ring 
is mediated by an other mechanism than a-C-oxidation The binding affinities 
of the amphetamines and its saturated analogues are found to be of the same 
magnitude in rats This means that the difference in structure of the phenyl-
and cyclohexyl ring has no influence at the interaction drug-cytochrome P-450 
In table 37 the binding affinities of the amphetamines and related compounds 
are given 
Table 37 
Binding affinities of amphetamines, cyclohexylisopropylamines and related 
compounds to hepatic cytochrome P-450 of the rat 
compound Ks value molar type 
amphetamine (S) 
amphetamine (R) 
N-isopropylamphetamine 
N-isopropylamphetamine 
cyclohexyl isopropy lamme 
N-isopropyl- (S) 
benzphetamine (S) 
ferrocenylisopropylamine 
N-isopropyl-
DPEA 
Imipramine 
desmethyhmipramine 
amitnptyl ine 
(S) 
(R) 
(S) 
5 0 x 1 0 3 
4 5 x 1 0 3 
5 0 x 103 
4 1 χ I O 3 
4 0 x 1 0 3 
5 0 x I O 3 
5 5 x 1 0 " 
1 4 x 1 0 * 
5 0 x 1 0 * 
1 4 x 1 0 * 
2 2 x 1 0 7 
2 7 x 1 0 * 
2 5 x 1 0 7 
I 
I 
von Bahr (1970) 
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figure 32: Renal excretion rate, urine pH, urine production and cumulatice renal excretion 
of cyclopentamine. The compound is excreted like N-methylamphetamine Cyclopen-
tamme. ti/2 = 7 hr, 70% totally excreted unchanged and 5% a-C-oxidation N-methyl-
amphetamine: ti/2 = 7 hr, 70% excreted unchanged and 10% a-C-oxidation Even the 
relationship dose HCl = цдг/тіп maximum excretion rate exists 
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Lewander (1968) reported the inhibition of both parahydroxylation (95%) and 
deamination (50%) of amphetamine by desmethyhmipramine The Ks value of 
Imipramine and desmethyhmipramine is of the same magnitude of that of 
ferrocenylisopropylamme (Von Bahr 1970), (table 37) This finding supports 
the idea that if the enzyme is blocked by these strong bounded compounds, 
all metabolic possible pathways that can be performed by the occupied enzyme 
entity, are blocked The same results were obtained by inhibition of the 
amphetamine metabolism by the compound DPEA (Glasson 1972) It is postu­
lated by Brodie (1971) and Udenfnend (1971) that cytochrome P-450 hydroxy-
lates the aromatic nucleus by the epoxyde mechanism Such a mechanism can 
not be involved for the hydroxylation of the cycloalkyl ring 
What are the requirements for an enzymatic hydroxylation of cycloalkyl rings? 
Is the activation energy of the rupture of the C-Η bond the dominating factor 
or are there also any stenc requirements? It is possible to replace the 
cyclohexyl ring by a cyclopentyl ring without alteration of metabolic pathways 
This should be possible if only the activation energy mentioned is determinant 
for the hydroxylation The compound N-methylcyclopentylisopropylamine, 
cyclopentamine, is demethylated and excreted into the urine like N-methyl-
amphetamine (fig 32) In man no ring hydroxylation could be observed The 
cyclopentyl ring behaves like a phenyl ring, both ring systems appeared to 
have strong influence at the metabolic routes The cyclopentyl ring is a planar 
ring system, chemically stable and without ring tension It must be concluded 
that the hydroxylating enzyme can easily attack molecules with a certain 
flexibility in the C-Η bond that can be attacked This is the case with aliphatic 
carbon chains and alicyclic ring systems A cyclopentyl ring is planar and 
rigid and the same holds for the phenyl ring 
D N-cycloalkyl substituted amphetamines 
With amphetamines the mam metabolic pathway in man is the a-C-oxidation 
and with the saturated amphetamines a-C-oxidation competes with ring 
hydroxylation Also the "f lexibi l i ty" of the ring is demonstrated In N-cycloalkyl 
substituted amphetamines, all these competitive pathways are possible In 
Table 38 
Metabolism of N-cycloalkyl substituted amphetamines Comparison of the 
availability of the tertiary C-Η bond of the substituent for attack by the 
cytochrome P-450 
compound 
( + ) N-isopropylamphetamine 
( + ) N-cyclopentylamphetamine 
( + ) N-cyclohexylamphetamine 
( + ) N-cycloheptylamphetamine 
/o dose excreted % dose excreted 
unchanged as amphetamine 
10 40 
3 30 
1 5 
0 5 
% dose excreted 
as ring 
hydroxylated 
metabolite of 
N-cycloalkylamph 
0 
0 
18 
0 
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order to get information about relative rate constants of a-C-oxidation and 
alicyclic ring hydroxylation, the dextro isomers of the fol lowing compounds 
were investigated N-cyclopentyl-, N-cyclohexyl-, and N-cycloheptylampheta-
mme (S + ) In this series the tertiary C-Η bond of the cycloalkyl group has 
the same outstanding position as the corresponding tertiary C-Η in the am­
phetamine moiety The rate of formation of the metabolite amphetamine give 
indication about the stencal hindrance of the bulky ring system when the 
compound is attacked by cytochrome P-450 for a-C-oxidation In table 38 com­
pounds are compared with 2 tertiary C-Η bonds available for a-C-oxidation 
by cytochrome P-450 
From table 38 it can be derived that all possible metabolic pathways do occur 
Cyclopentylamphetamme The amount amphetamine formed and excreted in 
the urine indicated that the tertiary C-Η of the cyclopentyl group can be 
attacked very easily by the cytochrome P-450 It is almost the same situation 
as observed with N-isopropylamphetamine The ring system exhibits no or 
very few stencal hindrance in the interaction with the enzyme The tertiary 
C-Η binding can be attacked by the cytochrome P-450 when this group is 
adjacent to the nitrogen atom However, in IM-methylcyclopentylisopropylamine, 
this particular C-Η group is not attacked at all (see fig 32) This means that 
the a-C-oxidation only occurs in the aliphatic side chain and that the nitrogen 
atom must be a "target" atom for the enzyme Therefore it is also less probable 
that a-C-oxidation is responsible for hydroxylation of alicyclic ring systems 
Cyclohexylamphetamme The low amount amphetamine formed as metabolite 
from N-cyclohexylamphetamine indicates that the C-Η bond is still accessible 
for attack by the cytochrome P-450, but also that other metabolic pathways 
reduce the significance of this contribution to the total elimination With 
N-cyclohexylamphetamine, the main metabolite excreted in the urine is 
N-cyclohexanolamphetamine The total amount was about 18%, and the OH 
group was distributed over the ring as follows 0 8 % C2, 2 2 % C3 and 15% 
C4 The situation is the same as observed with the "saturated amphetamines" 
Again, a-C-oxidation and alicyclic ring hydroxylation are the competitive 
metabolic pathways 
Cycloheptylamphetamine As compared to N-cyclohexylamphetamine the size 
of the ring has no influence at the rate of formation of amphetamine It was 
not possible to detect alicyclic ring hydroxylated metabolites The metabolic 
routes of this compound are not clear 
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CHAPTER 10 
METABOLISM OF N-CYCLOALKYL SUBSTITUTED AMPHETAMINES 
UNEXPECTED DIFFERENCES BETWEEN DEXTRO 
AND LEVO ISOMERS 
Introduction 
N-alkyl substituted amphetamines are well metabolized The difference in 
metabolism between the stereo isomers is quite characteristic, the dextro 
isomers are metabolized predominantly by a-C-oxidation and the levo isomers 
by N-oxidation The N-oxidation delivers amphetamine much slower than the 
a-C-oxidation, hence the amount formed and excreted in the urine never 
exceeds the amphetamine generated by the latter mechanism The N-oxide 
formation is the rate-limiting step and hence all levo isomers of the N-alkyl 
substituted amphetamines are metabolized at the same rate and the same 
percentage of product formation The C-Η bond in tne N-alkyl group can 
rotate freely and is always available for the attack by the enzyme With 
N-cycloalkyl substituted amphetamines, the aim of this investigation was to 
look after the limitation of the availability of this tertiary C-Η binding for 
attack by cytochrome P-450 
Results 
Amphetamine is formed as metabolite from the dextro and levo isomers of 
N-cycloalkyl substituted amphetamines The percentages of amphetamine ex­
creted in the urine are given in table 39 It can be seen that the results of 
both isomers of N-cyclobutylamphetamine are quite contradictory with the 
results found with N-alkyl substituted amphetamines (fig 33 and fig 34) The 
finding that the levo isomer produces more amphetamine than the dextro 
isomer is quite surprising The findings are confirmed with N-cyclopentyl- and 
N-benzylamphetamine, though less dramatically The renal excretion curve of 
levo N-alkyl substituted amphetamines show a plateau for the metabolite (—) 
amphetamine, fol lowed by the decline with a halflife time of 7 hr With (—) 
N-cycloalkylamphetamines the renal excretion rate of (—) amphetamine shows 
a sharp maximum and a long halflife time of 13 hr, which is comparable 
with the amphetamine formed from captagon This observation means that 
there is a continuous formation of amphetamine and that the conversion rate 
(Vmax or Qmax) is not rate-limiting 
Discussion 
The explanation of the remarkable behaviour of levo N-cycloalkyl ampheta­
mines requires a totally new assumption in the approach of the interaction 
between the amphetamines and cytochrome P-450 With the cyclobutyl ring 
there is ring tension which activates the tertiary C-Η bond The activation 
energy of the N-dealkylation is therefore diminished With ( + ) and (-) isomers 
the N-dealkylation might be enhanced due to this decreased activation energy 
This implies that the a-C-oxidation must be fast and that also the N-oxide bond 
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Table 39 
Percentage of the dose excreted in the urine of parent compound and meta­
bolite amphetamine of N-cycloalkyl substituted amphetamines 
compound 
( + ) N-cyclobutyl-
(—) N-cyclobutyl-
( + ) N-cyclopentyl-
(—) N-cyclopentyl-
( + ) N cyclohexyl-
( + ) N-cycloheptyl-
( + ) N-benzyl-
(—) N-benzyl-
subject 
H S 
H S 
K W 
JB 
H S 
J B 
H H 
T P 
J B 
K W 
T P 
T V 
PR 
B B 
B B 
PR 
dose mg 
156 
22 0 
23 3 
155 
29 7 
30 0 
169 
31 5 
32 3 
42 4 
47 1 
23 8 
26 0 
40 0 
45 5 
40 8 
47 9 
2 4 
2 8 
25 5 
12 
26 
0 7 
4 3 
16 
145 
0 1 
0 8 
0 6 
0 1 
0 1 
0 1 
0 1 
0 1 
% E A 
185 
186 
45 
50 
27 
15 
37 
20 
17 
16 
2 2 
6 4 
7 5 
9 7 
6 7 
22 
11 3 
% E H 
20 
15 
% E percentage of the dose excreted, A = amphetamine, H = ring hydroxylated meta­
bolites 
has enough energy to attack the tertiary C-Η binding However, the formation 
of the N-oxide is the rate-limiting step and the result must be comparable 
with the N-alkyl substituted amphetamines It was expected that the differences 
between ( + ) and (—) N-cyclobutylamphetamine would be enhanced There 
must be an explanation wh'ch is more acceptable for the phenomena observed 
With N-alkyl substituted amphetamines, the stereochemistry may result in the 
conclusion that the N-atom is the target or centre in the interaction with the 
enzyme and that thereafter the phenyl ring moves to a place to ensure a 
maximal interaction Key-lock position The ring system may be the determining 
factor in this orientation With N-cycloalkyl substituted amphetamines there are 
two ring systems in order to orientate the molecule to the proper position for 
u-C-oxidation This competition between the ring for the bmd'ng place is 
showed clearly in the ratio of the metabolic routes 
The exact position at the enzym site of the amphetamines can only be guessed, 
but the S configuration is most suitable for metabolism The fact that the ring 
plays a role might be stressed by the fact that not every amine is metabolized 
by cytochrome P-450 For instance Walle and Gaffney (1972) showed that 
isopropylamine, liberated from isoproterenol circulates freely in the body and 
is excreted in the urine unchanged Furthermore cyclopentamine is metabolized 
like N-methylamphetamine and cyclohexylisopropylamine is also metabolized 
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figure 33 Renal excretion rate, urine pH, urine production and cumulative renal excretion 
of ( + ) N-cyclobutylamphetamine and its metabolite ( + ) amphetamine The metabolite ю 
formed continuously during the total elimination process The halfhfe time of ampheta­
mine is enhanced (9 hr) 
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figure 34 Renal excretion rate, urine pH, urine production and cumulative renal excretion 
of (—) N-cyclobutylamphetamine and its metabolite (—) amphetamine The metabolite is 
formed continuously during the total elimination process, the t i / 2 of (—) amphetamine 
is enhanced In contrast with N-alkyl substituted amphetamines the metabolite did not 
show a plateau in its renal excretion rate (see section IV) 
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by α-C-oxidation The enzyme does not discriminate between the origin of the 
ring systems The tertiary C-Η bonds in the rings are not attacked by the 
enzyme when the distance from the N-atom is too far, they are attacked by the 
a-C-oxidation when they are in the a-C-position (fig 35) 
Ус-C-N-C 
H с 
Q^-N-C-C-^o) figure 35 
The ring and the nitrogen atom seem to be keys in the interaction with the 
enzyme The ratio between the a-C-oxidation and N-oxidation of the dextro 
and levo isomers of N-alkyl substituted amphetamines is 3 5 1 for both 
deamination and N-dealkylation 
For N-cyclobutylamphetamine this ratio also occurs for the deamination, but 
the N-dealkylation is decreased dramatically to 0 41 This large difference 
between the deamination and the N-dealkylation is contradictory with the data 
obtained with the N-alkyl substituted amphetamines 
The hypothes s can be made that also the cycloalkyl ring may direct the 
amphetamine molecule in the proper position for a-C-oxidation This possibil ity 
will favour the metabolism of the levo isomers With dextro N-cyclobutylamphe-
tamine, both tertiary C-Η bindings are in the correct position for a-C-oxidation 
The two positions for localisation at the cytochrome P-450 result in the same 
products (fig 36) The high amount of metabolism gives also a low renal 
excretion of the unchanged compound 
''
 H H
 '- ' M CHj figure 36 
enzyme enzyme 
With levo N-cyclobutyl amphetamine, the R-configuration inhibits a-C-ox'dation, 
while N-oxidat on only gives small amounts of amphetamine The increased 
reactivity of the С H binding does not influence the formation of the N-0 
binding When the cyclobutyl group is the predominant nng in the orientation 
process, the C-Η binding is always in the proper position for a-C-oxidation 
The amphetamine moiety cannot be metabolized due to the R configuration 
The reactivity of the C-Η binding results in a high amount of deamination and 
the levo amphetamine formed, is less metabolized The increased percentage 
of excretion of the unchanged compound and this high percentage of ampheta­
mine formation support the hypothesis With N-cyclopentylamphetamine the 
tertiary C-Η binding in the cyclopentyl group has lost its activation due to the 
loss of ring tension, so the differences between the ( + ) and (—) levo isomers 
are less pronounced When the hypothesis of the ring orientation at the cyto­
chrome P-450 is valid, then with every molecule with two rings, the ratio of 
amphetamine formed from levo and dextro isomers at least should be 1 1 
This ratio is found with the N-benzylamphetamine and N-cyclopentyl ampheta­
mine Beckett (1971) mentioned also this ratio for the isomers of N-benzyl-
amphetamine when they were incubated with rat liver microsomes 
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SECTION IV 
THE ROLE OF THE ENZYME CYTOCHROME P-450 IN 
THE METABOLISM OF AMPHETAMINES 
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CHAPTER 1 
CHARACTERISTICS OF CYTOCHROME P-450 
Introduction 
One of the most important pathways in the metabolic degradation of drugs is 
oxidation It can be stated that nearly all oxidative processes of strongly 
lipophilic drugs are carried out by a single system of enzymes However, for 
the oxidation of drugs several metabolic pathways are available, such as 
parahydroxylation of aromatic ringsystems, a-C-oxidation and N-oxidation 
The basic principle of these oxidations is the introduction of one atom of 
oxygen from a molecule oxygen into the substrate At the same time there is 
oxidation of a reduced agens, the NADPH Hayaishi (62), Mason (57) and 
McMahon (69) were able to prove with , 8 0 2 that the oxygen atom that is 
built in into the substrate, was derived from atmospheric 0 2 Mason introduced 
for this type of oxidative degradations the term mixed function oxygenase 
NADPH + H+ + RH + 0 0 ^ - NADP+ + ROH + H 2 0 
The terminal oxydase in this reaction is cytochrome P-450 
Cytochrome P-450 
Just like all cytochromes the cytochrome P-450 is a protohaem and part of a 
protein One of the most characteristic properties of haemo-proteins (cyto-
chrome-c, hemoglobine, myoglobine) is their absorption spectrum which shows 
three maxima at the following nm 
u 550-565 nm 
β 520-535 nm 
γ 400-420 nm, the Soret band 
The position and intensities of the maxima are dependent upon the occurrence 
of particular ligands, the fern or ferro configuration (Hill 1970) and electronic 
configuration (low spin and high spin) A characteristic property of cytochrome 
P-450 is that its spectrum is similar in the reduced and oxidized form This 
is contradictory with the spectra of other cytochromes This behaviour is the 
mam reason why this pharmacon-metabolizing enzyme has only recently been 
discovered In 1958 Garfinkel and Klingenberg proved the existence of the 
CO binding pigment with the absorption maximum of 450 nm In order to 
distinguish this pigment from the well-known pigment cytochrome b5, this CO 
binding pigment was called reticulochrome, but later on Omura (1962) changed 
this name in cytochrome P-450 In the last decade it appeared that this pigment 
does not occur only in mammalian liver but also in the liver of a number 
of lower animals (insects) and even in moulds, yeast cells and bacteria The 
amount of cytochrome P-450 present corresponds in most cases very well 
with the capacity of the liver to metabolize pharmaca 
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At present it is generally accepted that cytochrome P-450 is an essential part 
of the oxidative enzyme system, present in the microsomes So, it appeared 
that an increase or decrease respectively of the abundance of cytochrome 
P-450 in the liver, due to an exposure to certain drugs, in each case was 
accompanied by an increase or decrease of the rate of oxidation of the xenobio-
tics by hepatic microsomes Cytochrome P-450 is not only found in liver mi­
crosomes but also in the microsomes of mitochondral fraction of the adrenal 
cortex In the latter case the enzyme is involved in the hydroxylation of 
steroids which are normal body constituents In contrast with the oxidative 
system in the liver, the system in the adrenal cortex mitochondria is not able 
to transform exogenous substrates 
Microsomal oxidation 
In general it is accepted that the endoplastic reticulum contains two catalyzing 
components which play a role in the oxidation system a flavoproteine and cy­
tochrome P-450 The flavoprotein (Fpl) is similar to the NADPH cytochrome 
с reductase, an enzyme described by Honecker (1950) Cytochrome с only 
is an artificial electron acceptor, in reality this f lavoprotein mediates the elec­
tron transport to the cytochrome of the oxidative system in the microsomes 
the cytochrome P-450 A better name for this enzyme should be NADPH cy­
tochrome P-450 reductase In the adrenal cortex with respect to this electron 
transport there is another enzyme playing a role, a non-haem iron protein 
(FeSH) This haem is called the factor X by many authors The existence of 
X has not been proved unambiguously (fig 1) Cytochrome P-450 must be in 
the reduced state in order to be able to bind molecular oxygen, to activate it 
and to perform the oxidation 
in the endo plasmatic reticulum of the liver 
NADPH ->• Fp -*- Χ ->- cyt P-450 
adrenal cortex mitochondria 
NADPH -*• Fp ->- Fe-SH ->- cyt P-450 
r 
r 
RH + 0 2 
->- ROH + H 2 0 
RH + 0 2 
- > ROH + H 2 0 
figure 1 Composition of the oxidative system 
In fig 2 the total electron transport processes are shown The most impor­
tant points in the flow scheme are successively 
A The moment, at which there is binding between the pharmacon-substrate 
and the cytochrome P-450, in the oxidized (fern) form 
В The complex is reduced The quantity NADPH present delivers the reduc­
tion equivalents that are needed These equivalents are transferred by the 
flavoenzyme (Fp1) Point В in the reaction chain is also the point at wh'ch the 
reductase-haemoprotein reaction can be measured, by the occurrence of a 
reduced cytochrome P-450 complex in the presence of carbon monoxide (ab­
sorption maximum at 450 nm) 
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figure 2 Microsomal elec­
tron flow scheme for the 
oxidation of xenobiotics in 
the liver The haemoprotein 
cytochrome P-450 is written 
as P-450 RH and ROH are 
resp substrate and meta 
oolite (after Schenkman, 
1972) 
It is assumed that the reduction of the fern-cytochrome P-450-substrate com­
plex is the rate-limiting step in the total reaction of the mixed function oxyge­
nase 
С At this point the reductase activity can be measured independently of the 
total electron transport system, by conducting electrons to an exogenous elec­
tron acceptor, cytochrome с This is the reason why first the misleading name 
of NADPH-cytochrome-c reductase was given to this flavoprotein 
D In step D molecular oxygen from the air is bound by the cytochrome P-450 
The mechanism through which the oxygen is "act ivated" is rather obscure It 
has been proposed that a singlet oxygen molecule is formed from which one 
atom is inserted in the substrate molecule and the other atom reacts to water 
(Politzer 1971) The oxygen can be replaced by the carbon monoxide, which 
leads to an inhibition of the oxidation process 
E The metabolites in statu nascendi are uncoupled of the reaction chain 
At this stage the overall reaction can be measured It can be stated that the 
total reaction sequence can be characterized by measuring the parameters 
at the points indicated With the above scheme in mind one may think that 
the stoichiometric ratio in the reaction is one to one, as is observed with the 
electron transport in the mitochondria This is not true in this case, the various 
components occur at different concentrations Estabrook (1971) postulated 
that one molecule of flavoprotein is surrounded by about 20 molecules cyto­
chrome P-450 in the membrane of the endoplasmatic reticulum Thereby the 
well known cytochrome b5, which is involved in the desaturation of fatty 
acids, contributes to the electron transport The proper mechanism of this 
electron transport is not clear, there exist many hypotheses and speculations 
Isolation of the enzyme 
For a good characterization of cytochrome P-450 it is clear that the enzyme 
should be isolated and purified as far as possible It is important to know 
that the enzyme is a part of the membrane structure Isolation by means of 
solubilization (by detergents or proteinases) includes the danger of conver­
sion into an inactive form of the enzyme, which has an absorption maximum 
at 420 nm It is believed that this inactivation is caused by the rupture of the 
binding between the cytochrome P-450 and the microsomal lipids, with as 
a result that the substrate cannot be bound anymore Without any doubt the 
narrow structure relationship with the membrane is the main complexmg factor 
which hampers the research of this enzyme 
NADPH 
н,о 
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Microsomal difference spectra 
It is difficult to measure the absolute spectrum of cytochrome P-450 The 
enzyme is part of the membrane and another microsomal component, cyto-
chrome b5, interferes with the absorption spectrum Cytochrome b5 should 
be eliminated from the measurement or from the preparation Sato (1969) 
prepared "cytochrome P-450 particles" through selective elimination of the 
cytochrome b5 under protection by glycerol against mactivation Remmer 
(1969) enhanced selectively the microsomal concentration of cytochrome P-
450 relative to cytochrome b5 and obtained by difference spectral measure-
ment of such microsomal preparation with "normal" microsomes the absolute 
spectrum of cytochrome P-450 It appeared that when a substrate, like hexo-
barbital, was added to the sample cuvet, there was a shift of the maximum 
in the absorption curve to a lower wavelenght When both spectra are sub-
tracted (cyt + hexobarb — cyt) the result is the so-called difference spectrum 
This difference spectrum can be obtained much easier by dividing the same 
microsomal preparation over two cuvettes, adding the substrate to the sample 
cuvet and solvent to the reference cuvet and by subtracting both spectra 
from each other (double beam spectrophotometer) The shift of the absorption 
maximum in the absolute spectrum may be explained by an electron flow in 
the enzyme as a result of the interaction between pharmacon and substrate 
There exist two types of difference spectra One spectrum with the maximum 
at 390 nm and a minimum at 420 nm (type I) and a spectrum in which maximum 
dnd minimum are reversed (type II), depending upon the substrate offered to 
the enzyme The direct reason for this difference in interaction between the 
two classes of substrate is not clear When the absolute value of the absor-
bance differences are plotted against the concentration of substrate used, 
a hyperbolic curve is obtained The hyperbolic form of the curve is suggest-
ing that the substrate interacts in a way which is similar to the substrate 
dependency in enzyme activities (Schenkman 1971) The data can be plotted 
double reciprocally, in analogy to a Lineweaver-Burk plot By means of ex-
trapolation the concentration of the substrate can be estimated at which the 
half maximal spectral difference occurs This constant is called spectral dis-
sociation constant, Ks This Ks is a direct measure for the affinity between 
substrate and cytochrome P-450 (Michaelis-Menten constant) For most of the 
compounds from which the interaction with cytochrome P-450 is investigated, 
it reveals that this Ks value is similar to the Km value, measured with meta-
bolic conversion This agreement provides strong evidence that cytochrome 
P-450 is the place in the total oxidation process where the substrate binds 
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CHAPTER 2 
THE ORIGIN OF THE OXYGEN 
Introduction 
The oxygen needed for the enzymatic oxidation is originated from the air 
(Mason 1957, McMahon 1969) What is the mechanism of the binding of the 
oxygen molecule by the cytochrome P-450, and its transformation into two 
activated oxygen atoms provided with an energy content sufficient for attack 
at the a-C-atom or N-atom? Molecular oxgen can be excited to the first and 
second activated level of the two valence electrons by UV light and a sensi­
tizer, like Eosine, or Methylene Blue (Politzer 1971, Kasha 1971). The sensi­
tizer converts the UV light into light with an energy capable for activating 
the oxygen molecule from the ground state to the f irst and second activated 
state with an energy of 22,5 kcal/mol (singlet 'Ag) and 37.5 kcal/mol (triplet 
'2>д) above that of the familiar oxygen in its triplet state. (3Σ g) These two 
figures reveal that this energy content is higher than the activation energies 
required for a-C-oxidation and N-oxidation and data given by Schenkman 
(1971) (10-20 kcal/mol) (chapter 3) It may be assumed that cytochrome P-450 
is capable to generate the energy to create the singlet oxygen. This singlet 
oxygen is able to attack double bonds in molecules (fig 3). (Duynstee 1971, 
Garssen 1971, Politzer 1971). 
= с — - * ,с — с ^ • c -ç 
pere pox de 
ϊ 
O-O ООН 
-с-с-сн с-с=с' 
I I I I I 
I I figure 3 Tentative mechanism for the 
-C*C-C reaction of singlet oxygen with alkenes 
О О 
If the singlet oxygen plays an essential role in fi-C-oxidation or N-oxidation 
of the amphetamine, cytochrome P-450 has to create a double bond in the 
transition state of the amphetamine-cytochrome complex. 
This possibility fulfils the requirements for this reaction: 
1. stereochemical limitations at the a-C-atom 
2. oxygen from the air 
3. deuterium effect in the rupture of the α-С-Н binding 
4 stenc hindrance by groups substituted at the |3-C-atom 
5 no differences in binding affinity between isomers of amphetamines to the 
cytochrome P-450. 
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Reactions with singlet oxygen 
In vitro, when the schiff base of amphetamine and aceton was subjected to 
the attack of singlet oxygen, generated by methylene blue, light of 254 nm and 
oxygen, amphetamine and aceton were the reaction products 
/ Q V O L J L °*254nm . <OVC-¿-NH24=O 
\^y methylene blue = У z Τ 
methanol С 
X^/ methylene blue \ ü / I 
methanol *-
The ty2 of the reaction varied between 2-5 hr, depending upon the concen-
tration of methylene blue The reaction was much slower without methylene 
blue, or oxygen while the schiff base itself was stable in the water free so-
lution Also the schiff base of methylbenzylketone and isopropylamme, resulted 
after irradiation with light of 254 nm in the presence of oxygen and methylene 
blue in the starting materials (fig 4) 
The reaction was fol lowed by GC-MS, while the controle solutions without 
one of the participants of the reaction, were stable A direct comparison be-
tween the rate of the reaction between the two schiff bases was not possible, 
though all products could be separated at the GC-column The mixture of the 
two schiff bases immediately resulted in the hydrolysis of the compound M 
Both schiff bases seem to protonate each other From the experiments it may 
be concluded that singlet oxygen is capable to react with the C-N double bond 
of the amphetamine schiff base N-isopropylamphetamine did not react under 
these circumstances Hence cytochrome P-450 may create a double bond by 
hydrogen abstraction, and singlet oxygen may react with the transition state 
complex 
figure 4 The reac-
tion of singlet oxy-
gen with a schiff 
base 
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CHAPTER 3 
ACTIVATION ENERGIES OF a-C-OXIDATION AND N-OXIDATION OF 
N-ALKYL SUBSTITUTED AMPHETAMINES BY RAT LIVER 
MICROSOMES DEUTERIUM EFFECTS AND STEREO CHEMISTRY 
Introduction 
In section III it has been described that the dextro isomers of N-alkylsubsti-
tuted amphetamines are metabolized predominantly by a-C-oxidation, where­
as N-oxidation is the main mechanism in the metabolic conversion of the 
levo isomers The aim of the present study was to see if the stereochemistry 
and deuterium effect as observed in the metabolic elimination of amphetami­
nes in man, is also valid when these compounds are subjected to metabolism 
by rat liver microsomes It was investigated, whether the marked difference 
between the two oxidative mechanisms is reflected in a further parameter of 
the reaction, namely the energy of activation, which represents the energy re­
quired for the enzyme-substrate complex to reach the transition state leading 
to the formation of N-dealkylated or/and deaminated products 
+ p, 
+ P2 
When ES is considered as the only enzyme-substrate complex in both reac­
tions N-dealkylation (P,) and deamination (P2), the total rate of the formation 
of the products can be described by the following equation 
d(P,+P2) _ ( k + k ) [ E S ] ( 1 ) 
dt 3 1 3 
and the maximal velocity by 
Чпах = ( ^ V u o t a i 1 И 
'nVmax = ln(k 3 l + k 3 2 ) + l n [ E t o t a | ] (3) 
where Et,,,,] is the total amount of enzyme involved The relationship between 
maximal reaction velocity and temperature may be given by 
d!nV„ 
=
 d l n ( k 3 1 + k 3 2 ) - k31 . E £ , k32 4 32- (4) 
d T d T k 3 1 + k 3 2 R T V k32 R T 
where EA31 and E
A
32 are the activation energies of N-dealkylation and dea­
mination, respectively, Τ is the absolute temperature, R the gas constant 
(1 987 calories per degree per mole) 
Assuming that 
^ and ^ 2 
к
зГ
к32 V ' * 
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are independent of the temperature, the integration of equation (4) gives· 
^ i EA -L- 'Ьг E A 1 1 
max" 
'nVm„=constant _ i - J 3 ! _ . 3f + _ ^ _ . Εχ . _ J _ ( 5 ) 
The term 
/ _ _ ! * 3 1 _ F^ ^ 3 2 P A 
may be considered as the apparent energy of activation (EA) of the overall-
reaction, irrespective as to whether к з і > к 3 2 or к з г ^ к э ь 
Consequently 
Іп
 т м =
 constant ь (6) 
RT max 
and 
log V_-. = constant _ c (7) 
m a x
 2.303 RT 
This apparent energy of activation can be obtained from the Arrhenius-plot 
E* 
log Vmax against 1/T. The slope of the line is . 
2 303 R 
Experimental 
Because it is known that subsaturating concentrations of the substrates can 
influence the observed energy of activation (Schenkman 1972, Gibson 1953), 
in the present study values of E A were based upon V l l l t l 4-values. Therefore 
Lineweaver-Burk plots at different temperatures were made and V IM,,4-values 
were derived by extrapolation. The preparation of the microsomal suspensions 
from rat liver, the methods for the in vitro incubations, and for the gas chro­
matographic analysis of the metabolites are described in chapter 5 of this 
section. 
Results and discussion 
N-isopropylamphetamine 
In figure 5 and 6 the metabolic scheme of N-isopropylamphetamine is outlined 
and it can be observed that methylbenzylketone (MBK), a metabolite from the 
deamination, has a considerable concentration when derived from the S ( + ) 
isomer while the R (-) isomers generates the MBK at a much lower level 
The deuterium effect in figure 5, in particular concerns the formation of MBK 
in contrast to the findings in figure 6, which show a clear deuterium effect 
in respect of the MBK formation. These findings can be explained assuming 
that with the S ( + ) isomer as substrate, the oxidative degradation is mainly 
based on a-C-oxidation In the oxidative degradation of the R (-) substrate 
N-oxidation prevails. In the measurement of activation energies, the formation 
of both metabolites, amphetamine and MBK, are considered Hence the ac-
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r jH iver microsomes lOmin incubated at 12° with 0.5 mM S(*)N-isopropyl amphetamine HCl 
mbk _ 
S(*) N-deuteroieopropyl-
deutero amphetamine 
COLUMN 20% dpiezon 5 % KOH^awhrom Q Ô O - Ô O m 
figure 5- Gas chromatogram of the reaction products of ( + ) N-isopropylamphetamine 
after incubation by rat liver microsomes. 
rat liver microsome» 10mm incubated at 22°C w i t h 0 . 5 m M Ri-JN-isopropylarrphelamine HCl 
R(-) N-i*opropy lamphetamme 
amph 
R(-l N-deuteroisopropyl 
deutero amphetamine 
H H 
&Г 
^VC-Ç-N-Ç-C • (о\-с-с-нн. 
methyl benzyl keton (mbk ) 
COLUMN 20% лрімоп 5% KOM gatcbrom Q60-80m 
figure 6. Gas chromatogram of the reaction products of (—) N-isopropylamphetamine 
after incubation by rat liver microsomes The compound MBA, N-methylbenzylamine, 
is used as internal standard. 
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tivation energy obtained is derived from the overall reaction. The activation 
energy of S ( + ) N-isopropylamphetamine metabolism was found to be 11,8 
kcal/mol. The activation energy of R (-) N-isopropylamphetamine metabo­
lism was found to be 17.9 kcal/mol. With S ( + ) N-deuteroisopropyl-deutero-
amphetamine, the activation energy was increased to 18.6 kcal/mol while with 
the R (-) isomer it remained constant, 18 8 kcal/mol. These results substan­
tiate that when a-C-oxidation is involved in the metabolism of amphetamines 
a much lower activation energy is required than in the case of N-oxidation. 
(fig 7). The deuterium effect as found with these experiments is compatible 
with the deuterium effect obtained in the metabolism of the same compounds 
by man (section III, chapter 6). 
N-isopropylphentermine 
In section III, chapter 5, it was attempted to prove that N-isopropylphentermi-
ne and (-) N-isopropylamphetamine were metabolized by N-oxidation by means 
of the formation rate of the metabolite amphetamine (12%) and phentermine 
(11%). N-isopropylphentermine, on basis of its structure, can only be meta­
bolized by means of N-oxide formation. The activation energy measured in the 
present study appeared to be 17.9 kcal/mol. This value corresponds very 
well with the relatively high activation energy of (-) N-isopropylamphetamine. 
nmoles/min Ιηχξ 
5 0 -
20 
10 
5 -
Δ S(*)N-isopropylamphetamine 
О PHN-isopropylamphetamine 
— ι 1 1 1 1 1 — 
3 3 0 ЪЧО 350 
figure 7 Arrhenius plot for the 
a-C-oxidation of ( + ) N-isoporopyl-
amphetamine and N-oxidation of 
(—) N-isopropylamphetamine by rat 
liver microsomes 
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N-benzy ¡amphétamine 
No significant difference in activation energy of N-dealkylation was found for 
the S ( + ) and R (-) isomers of N-benzylamphetamine (resp 14 9 ± 0 2 and 
15 3 ± 0 6 kcal/mol) Strikingly, as described in section III, chapter 10, also 
no differences in t1/) and cumulative renal excretion rates were found between 
the S ( + ) and R (-) isomers of N-cycloalkyl substituted amphetamines and 
N-benzylamphetamine This is explainable when the substituent is regarded as 
the determinant factor in the orientation of the amphetamine derivative at the 
cytochrome P-450 In that case both with S ( + ) and R (-) isomers the a-C-H 
binding in the substituent is available for a-C-oxidation The enhanced ac-
tivation energy may be explained by the different energy of the C-Η bond 
that is broken in the rate limiting step The values of activation energy found 
in this study are of the same magnitude as the value of a-C-oxidation of ben-
zylic C-Η binding given by Bardsley (1973) (16,3 kcal/mol) Another possible 
explanation could be that the phenyl ring of N-benzylamphetamine accounts 
for roughly 4 0 % in the orientation and the substituent for 6 0 % (based on the 
combined contribution of N-oxidation and a-C-oxidation to the overall reac­
tion) 
Table 1 
Activation energies to reach the transition state in the enzyme-substrate com­
plex for some amphetamine like compounds 
compound 
( + ) amphetamine 
N-methyl-
N-isopropyl-
N-benzyl-
N-dimethyl-
N-methylethyl-
N-methyhsopropyl-
( + ) N-deuteroisopropyldeuteroamphetamme 
(—) amphetamine 
N-methyl-
N-isopropyl-
N-benzyl-
N-dimethyl-
(—) N-deuteroisopropyldeuteroamphetamine 
N-isopropylphentermine 
activation energy 
kcal/mol ( ± S E ) 
11 6 _* 0 7 
11 8 =L 09 
149 ± 02 
185 i . 09 
178 ± 01 
185 + 05 
186 ± 06 
178 ± 1 4 
179 + 14 
153 ± 0 6 
189 ± 1 7 
188 J; 07 
179 ± 0 6 
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N-dimethylamphetamme 
In man, N-dimethylamphetamine is converted as fast as N-isopropylampheta-
mine into its metabolite N-methylamphetamine, thus it was expected that the 
activation energy for this conversion was of the same magnitude However, 
the activation energy found with rat liver microsomes was relatively high, 
18,5 kcal/mol for both isomers The rapid conversion of both compounds can 
be compared, but the mechanisms that are underlying may be quite different 
As has been described in section III (chapter 6) N-ditrideuteromethylampheta-
mine did not show any deuterium effect in its conversion to N-methylampheta-
mme, though metabolism is the major pathway in the total elimination In sec-
tion III (chapter 3) it was also mentioned that in ( + ) N-methylethylampheta-
mine, the methyl as well as the ethyl group were removed at nearly equal rates, 
while with ( + ) N-methylisopropylamphetamine the methyl group is removed 
even three times faster than the large isopropyl group So there is no sign of 
any steric relief in the enzyme- substrate complex Most likely this process im-
plies another rate limiting step, the N-oxidation The relatively high activation 
energy of ( + ) N-methylethylamphetamine and ( + ) N-methyhsopropylampheta-
mine supports this concept (17 8 =t 0 1 and 18 5 ± 0 5 kcal/mol resp ) Thereby 
Jenner (1971) showed that N-oxides of N-dimethylamphetamine were excreted 
in the urine of man (15-25%) At the enzyme site and in the interaction drug-
enzyme this behaviour can be rationalized as follows In secondary N-alkyl 
substituted amphetamines the n-C-H and N-group presents the key-lock po-
sition for a-C-oxidation With the levo isomers this is not possible at all 
and with the 1S.2S isomers of N-alkyl substituted ephedrmes it is difficult, 
due to the interaction of the OH group With tertiary amphetamines, the small 
hydrogen atom at the nitrogen is replaced by a "bulky" methyl group, which 
in turn interacts with the enzyme and hinders the «-C-oxidation in such a way 
that only the alternative N-oxidation is available for N-dealkylation 
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CHAPTER 4 
FACTORS INFLUENCING THE METABOLIC CLEARANCE 
a) The limitation of the metabolic rate 
The rate of formation of the metabolite is given by the equation (chapter 3) 
Î 
substrate A + enzyme 
k i 
k-i 
complex 
EA 
к, product 
Ρ 
* enzyme 
Ί 
d P 
d t k 2 + k 3 
С E 
О) 
The assumption is made that the concentration of the enzyme system remains 
constant during the whole period of metabolic conversion of a particular sub­
strate and that this substrate is in equilibrium with the enzyme (k2/k, = Ks) 
The whole metabolic process depends upon the concentration (C) of the sub­
strates, the enzyme and upon k3 which represents the overall rate constant 
When all enzyme molecules are involved in the reaction, then k3 (EA)ma4 is 
t n e
 Vm.\ o r Ο'ι,,,χ ' n general, Q'11U4 is the conversion rate of the substrate in 
mg/h and Ks is the dissociation constant of the drug-enzyme complex Thus 
the rate of metabolic clearance in the liver of a substrate can be described 
as follows 
Q: d Q _ 
d t " m a x ' K s + С 
dividing by Ks gives 
t 
Ks 
dQ - QU* 
d t 
(2) 
(3) 1 + С 
K s 
The concentration С is given by the dose D and the volume of distribution V 
The decrease in the concentration is given by 
d C 
d t 
1 Qr 'max 
V K s 1 + С (4) 
K s 
Q'm-i-/ ^s represents the metabolic clearance constant km, which equals the 
total body clearance kc! when renal excretion may be neglected 
Then 
'el and к el 
V 
4 e l T el 
When these two factors are substituted in equation 4, the decrease in con­
centration is given by 
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dC _ _kgi_ С 
dt ν 1 + С 
Ks 
After integration and when 
t = oo С = О Qel = D 
t = О С = D/V Qei = О 
equation 5 gives 
C= _ D _ e K s v \e T e l ( 6 ) 
V 
This means that at the time the concentration of the drug at the enzyme 
site becomes of the magnitude of the Ks value, the system is overloaded and 
elimination cannot proceed via first order kinetics When the concentration of 
the drug is far below the Ks value equation 6 is reduced to 
J_.D_ _ j _ t 
η D
 0
 K s V
 a
 Tel T ei
 m 
С = M e e = constant e l'J 
V 
In this case the elimination proceeds via the first order process as described 
in section I For example Amphetamine can be administered to a subject 
in a dose of 25 mg The volume of distribution in man is about 200 I and the 
blood concentration may be maximal 0 9 μΜ The dissociation constant of 
the enzyme-amphetamine complex is Ι Ο 3 M This means that the concen­
tration С is a factor 1000 less than the Ks value So, elimination of ampheta­
mine always occurs via a first order process Even doses up to 500 mg amphe­
tamine can be handled in this way Working with the isolated perfused rat 
liver with 100 ml blood in the circulation system, a dose of 25 mg might be 
too high (25 mg/ 100 ml + Vr liver) for a first order metabolic elimination 
b) Metabolism of levo isomers of N-alkyl substituted amphetamines 
The observed differences in the metabolism of dextro and levo isomers of 
N-alkyl substituted amphetamines may be understood with the acceptance of 
two mechanisms, a-C-oxidation and N-oxidation The metabolic conversion can 
be fol lowed by measuring the blood concentration or the renal excretion rate 
of the metabolite amphetamine When the rate of metabolism is fast, the renal 
excretion rate will show a maximum This is observed with dextro isomers The 
levo N-alkyl substituted amphetamines are thought to be metabolized into 
amphetamine via N-oxidation N-oxidation is a slower process than «-C-oxi-
dation, however a constant rate difference between the two metabolic pro­
cesses cannot alter the shape of the curve of the renal excretion rate of the 
metabolite amphetamine It is observed from figure 8 and table 2 that the 
renal excretion rate of the metabolite (-) amphetamine shows a plateau value 
at 1 5 μg/mιn for about 18 hr and thereafter the renal excretion rate declines 
with a halflife time of 7 hr The half life time of 7 hr all levo isomers have in 
'el 1 + С (5) 
Ks 
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c u m u l a t i v e renal 
ечсгеЬоп (ΓΠ£ baeej 
3 0 
e x c r e t i o n r a t e (^ug/min, log e c a l e ) 
i o d ­
io-
I O 
0 01 
rU 
61 3mg i - ) l 8 0 P C O P Y L A M P H E T A M I N E HCl 
J\ 
Ьл 
Til leopropylamphetamine 
- J 1. 
amphetamine 
5 u b j e c t С V 
figure 8 Renal excretion 
rate, urine pH, urine pro­
duction and cumulative 
renal excretion, blood and 
saliva concentration of 
(—) N-isopropylampheta-
mine and its metabolite 
(—) amphetamine Note 
that the renal excretion 
rate of the metabolite is 
constant for about 24 hr 
«a 
common Another characteristic feature of the excretion curves of levo isomers 
is that the curves of parent compound and metabolite cross each other only 
after a very long time (50 hr) (table 2) The main process in the elimination of 
levo amphetamines is renal excretion, metabolic clearance via N-oxidation is a 
slow and minor process (10 - 15%) The plateau value in the renal excretion 
rate and in the blood concentration suggests that an equilibrium between for­
mation and elimination is reached This situation occurs when the cytochrome 
P-450 is "overloaded" and cannot perform N-oxidation via a first order pro-
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Table 2 
The plateau concentration as indication for the limitation of metabolic capacity 
of the enzyma for the conversion of levo isomers of N-alkyl substituted amphe­
tamines 
compound 
( + ) amphetamine 
N-methyl-
N-ethyl-
N-isopropyl-
N-dimethyl-
(—) amphetamine 
N-methyl-
N-ethyl-
N-isopropyl-
N-dimethyl-
P'mhr 
6 
3 
3 
4 
16 
10 
18 
15 
Cm(pl) 
0 75 
8 2 
4 8 
13 
1 2 
1 4 
1 50 
4 5 
cross 
36 
13 
4 
10 
50 
50 
40 
25 
t'/2 
6 
7 
3 
3 
4 
7 
7 
7 
7 
7 
t'/im 
12-7 
8 
8 
10 
12-7 
14-7 
20-7 
10 
p l m plateau in the renal excretion rate of the metabolite amphetamine (hr) 
Cm(p|) renal excretion rate at the plateau (μς/ιτιιη) 
cross crosspoint of the renal excretion rate curve of parent compound and metabolite 
t'/2 halflife time of the parent compound 
t 1 / 2 m halflife time of the metabolite amphetamine 
cess The result is a constant formation of (-) amphetamine, while the concen­
ti ation of the parent compound declines predominantly by renal excretion 
Thus the situation may be compared with an infusion at constant rate The 
plateau value reached is given by 
С / , - Q ™ Q1 - J^Çc kmel , „ 
m H ~ ~k m ~ ~лГ~ к (8) 
1
 '
 Kmel Δ ΐ K m r 
where in Q',„ is the rate of formation of the metabolite and km (| the elimination 
constant of the metabolite For the levo isomers the ratio k,m|/k l n r is nearly 
1 (100/90) Thus in the plateau the formation rate of the metabolite equals 
the renal excretion rate The metabolite itself is eliminated predominantly 
(90%) by renal excretion and this is the reason why at the end of the plateau, 
the renal excretion declines again with a halflife time of 7 hr From these 
results the conclusion must be drawn that the metabolite is formed at a con­
stant and maximal rate, Q' r i M 4 The maximal conversion rate in general is 
reached when all enzyme entities are occupied, thus when the system is 
saturated or overloaded From paragraph a, it can be derived that the system 
gets into trouble when the concentration of the compound is of the same 
magnitude as the Ks It has been supposed that in the total body, this situation 
never will occur, because the blood concentration is a factor 1000 lower than 
the Ks value measured by means of spectrometry It is questionable however, 
whether the blood concentration in the total circulation is a real measure for 
the concentration of the substrate in the lipoidal membranes of the endoplas-
matic reticulum in the liver, ι e at the enzyme site In the present case one can 
imagine that although the blood concentration of the levo isomer is far below 
the Ks value, the concentration at the enzyme site gradually increases as a 
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consequence of a low rate of conversion This situation may be compared to 
the infusion mentioned above With dextro isomers the rapid conversion 
prevents such an accumulation in the hepatic membranes Thereby the ques­
tion arises in how far the Ks value, measured in vitro and representing binding 
to cytochrome P-450 in a microsomal preparation, can be related with meta­
bolic processes in vivo Until to date the whole chain of events in the meta­
bolic processes of levo isomers in the liver is still obscure 
с Inhibition of the metabolism of amphetamines 
When two compounds are offered simultaneously to the liver and the metaboli­
zing enzyme system, and these two compounds will be metabolized via the 
same metabolic route (mechanism), the compounds may interfere in each 
others metabolism although the Ks values are quite different It is imaginable 
that when one of the two is bound 1000 times stronger than the other, the 
enzyme site will be occupied and the metabolism of the other is inhibited 
This behaviour is observed when ferrocenylisopropylamine is added together 
with N-isopropylamphetamine to the isolated liver system, or in rats in vivo, 
in order to be metabolized Ferrocenylisopropylamine with a Ks value of 1,2 χ 
10 6M appeared to inhibit the metabolism of N-isopropylamphetamine (Ks = 
10 3 M (chapter 5) 
The inhibition can be observed in a prolongation of the half life time This in­
crease can be expressed mathematically 
t i „ = 0 69 V,/ke| = 0 69 V,/km = 0 69 V, K s /Q' m (9) 
The ti/2 of the compared in the presence of the inhibitor is given by 
t . h | = 0 69 V f /Q' m Ks (1 + Ι/Κ,) (10) 
wherein I is the blood concentration of the inhibitor 
tifa / tifa = 1 + Ι/Κ, (11) 
From the ratio of the halflife time of the compound without and in the presence 
of the inhibitor, the inhibitory constant, the dissociation constant of the in­
hibitor at the enzyme site can be calculated (Ki) 
" l = 
I 
V21 _ ì (12) 
y2 
The halflife time of N-isopropylamphetamine in the isolated perfused rat liver 
is increased from 20 mm to 200 mm when the inhibitor, ferrocenylisopropyl-
amine, is present 
Inhibition occurs at a blood concentration of the ferrocenyl compound 
of 10 ug/ml (46 χ 10 6 M) 
Thus К, = 46x10 6 /(10-1) = 5 1 x 1 0 6 M 
From the spectral analysis as described in chapter 5, the Ks value of ferro­
cenylisopropylamine was found to be 1,2 χ 10 6 M 
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CHAPTER 5 
IN VIVO AND IN VITRO INHIBITION OF THE METABOLISM 
OF AMPHETAMINES 
Introduction 
In section III the influence of substitution in the alkyl side chain on the meta­
bolism of amphetamines was studied Substitution in the aromatic ring, for 
instance hydrogen substitution (III-9) chances the metabolic behaviour drastic­
ally It became of interest to extend the variations in the substitution to 
replacement of the aromatic ring by a ferrocenyl group The compounds tested 
to this respect are ferrocenylisopropylamine (FIPA) (I) and its N-isopropyl sub­
stituted analogue, non benzenoid aromatic analogues of amphetamine 
V-^-CHrC-NH, (OVc-C-NHz 
Fe ' M V=-/ H 
г II 
FIPA has been reported to have little activity on the central nervous system 
(Loev & Flores, 1961) Current theory concerning pharmacological recep­
tors postulates that agonist molecules must satisfy certain stereoelectronic 
prerequisites in order to interact effectively with a particular receptor (Ariens, 
1971) Ferrocene, although aromatic is non-benzenoid and presents a con-
s derable physicochemical and stereochemical departure from benzene be­
cause of its cylindrical character It might therefore be expected not to elicit 
a pharmacological response similar to that of amphetamine Drug-metaboli-
zing enzymes, on the other hand, have less structural specificity than pharma­
cological receptors, and are able to metabolize a variety of substrates In 
these respects FIPA presented a unique compound for study Although FIPA 
is an analogue of a potent pharmacologically-active agent, it is non-physiolo-
gical as it contains an iron atom sandwiched between two cyclopentadiene 
rings, a structural arrangement which results in a considerable difference in 
bulk between FIPA and amphetamine 
In the present investigation, the influence of FIPA on the metabolism (N-
dealkylation) of certain amphetamine derivatives was studied Demonstration 
of competitive inhibition of the metabolism of amphetamine derivatives by 
FIPA would indicate that this compound had an affinity for the enzyme system 
concerned and might present substantial stencal hindrance to the approach of 
other substrates The effects of ( ± ) F I P A on the metabolism of ( + )N-isopropyl-
amphetamme and ( + +)biamphetamine were therefore studied These com­
pounds were chosen because of their short metabolic halflives (N-isopropyl-
amphetamine, 20 mm, biamphetamine, 10 mm) compared to amphetamine (200 
mm) as within the limits of experimental procedure, it is easier to demon­
strate inhibition of metabolism (increase in V/2) with compounds that normally 
have a short half life time 
Studies were carried out in vivo in rats, and in vitro with isolated perfused 
rat liver and hepatic microsomal suspensions Cytochrome P-450, the terminal 
oxidase in the oxidative transformation of drugs, is generally believed to be 
the site for substrate interaction (Schenkman, 1970) Studies concerning the 
binding to this enzyme system, were, therefore, included 
161 
Material and methods 
Animals 
Adult male rats weighing 200-260 g were used Phenobarbital-treated animals 
received 75 mg/kg sodium phénobarbital intraperi toneal^ in saline daily for 
5 days In the in vivo experiments rats were injected intravenously with soin 
of ( + ) N-isopropylamphetamine HCl and ( ± ) ferrocenylisopropylamine HBr 
in saline Blood samples (0-5 ml) were taken at regular intervals from the 
orbital plexus 
Isolated perfused rat liver experiments 
Livers (9-14 g) were surgically removed from rats and perfused with Schimas-
sek (1962) soin as modified by Alvarez (1971) The liver and oxygenated 
(95% 0 2 , 5% C 0 2 ) perfusate were maintained in a humidified chamber at 
37c Preparation of perfusion fluid was as follows 100 ml human blood was 
centrifuged, the plasma removed by suction, and the remaining cells washed 
three times with Schimassek soin The washed erythrocytes (10 ml) were 
mixed with 3 g bovine albumin, 0 150 g glucose and enough Schimassek soin 
to make 100 ml This prep of artificial blood was carried out under aseptic 
conditions One litre of Schimassek soin contained the following salts NaCI 
137 mM, KCl 2 68 m M, CaCI2 1 80 m M, MgCI 2 0 49 m M, NaHCO, 11 9 m M. 
NaH 2 P0 4 H 2 0 0 67 mM, i twas steril ized by filtration 
The isolated liver was perfused with 100 ml perfusion fluid at a rate of 12 
ml/mm (Cardiac Suction Unit pump, type 913, New Electronic Products Ltd, 
London) The perfused isolated liver prep was allowed to equilibrate for 1 h 
prior to an experiment Liver function was monitored by the vol of bile pro-
duction Test compounds were dissolved in perfusion fluid, and, at regular 
time intervals, 0 5 ml samples perfusion fluid were treated as indicated in the 
g I с analysis 
Preparation of microsomes 
Rats starved overnight, to remove liver glycogen, were killed by decapitation 
under light ether anaesthesia The livers were rapidly excised, portions were 
weighed, finely minced and transferred into 9 vol ice-cold 0 25 M-sucrose 
Homogenates were made using a Teflon-glass Potter-Elvehjem type homogeni-
zer After sedimentation of nuclei and cell debris by centrifugaron at 500 g, 
the supernatant was centrifuged at 18 000 g for 10 mm, the microsomal frac­
tion was isolated by centr i fugaron of the 18 000 g supernatant at 105 000 g for 
60 mm The microsomal pellet was washed once to remove contaminating 
haemoglobin and carefully re-suspended in isotonic KCl soin (0 15 M), con­
taining 0 05 M-Tris-HCI (pH 7 5) 
Determination of microsomal N-dealkylation 
The microsomal suspension was used as the enzyme source for the measure­
ment of N-dealkylation of ( + ) N-isopropylamphetamine in vitro Incubations 
were carried out at 37 , under air, as described earlier (Henderson & Kersten 
1970) Incubation media contained 5 χ 10-'M Tris-HCI (pH 7 5), 8 χ 10 4 M-
M g C l j , 8 χ 10 6 M-MnCI,, 5 χ 10 - 3 M-sodium isocitrate, isocitric dehydroge­
nase 20 μg/ ml (Sigma type IV, capable of generating 5 5 μπηοΙ NADPH/min/ 
mg at 37"), 13 χ 10 5 M-NADP, and ( + )N-isopropylamphetamine as indicated 
The mixture was premcubated at 37 for 10 mm, to ensure reduction of all 
NADP The reaction was started by addition of the microsomal suspension, 
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equivalent to 4 mg protein per ml. After incubation for 30 mm, the reaction 
medium was made alkaline with KOH and extracted with ether. The amount of 
amphetamine formed was determined by g.l.c. Blanks containing all reaction 
components including heat-denatured enzyme were similarly treated to detect 
non-enzymic formation of metabolites. 
Microsomal difference spectra 
For the measurement of difference-spectra the above microsomal suspension 
was diluted with 0.15 M-KCI-0 05 M-Tris-HCI (pH 7.5) to a concn. of about 
1 mg microsomal protein per ml and was divided between two cuvettes. The 
substrate dissolved in 0.15 M-KCI-Tris-HCl (pH 7.5) was added to the sam­
ple cuvette, and an equal vol. of buffer was added to the reference cuvette 
At varying substrate concn , difference-spectra were recorded with a Beck-
man DB-G spectrophotometer. When FIPA was used as a modifier of the 
spectral changes (Leibman, 1969) induced by ( + )N-isopropylamphetamme, it 
was added to the microsomal suspension in both cuvettes. 
Ail spectra were measured at room temp, in the absence of NADPH. Micro­
somal protein concn. were determined by the method of Lowry (1951). 
Gas chromatographic analysis 
An internal standard, N-methylbenzylamine (10 цд) was added to 0.5 ml sam­
ples of perfusion fluid, and the resulting soin, made alkaline with 2 ml 2 0 % 
KOH, extracted with 10 ml freshly distil led ether, and the ether extract cone 
to 100 μΙ in a stream of dry air. The cone, extract (5 μΙ) was injected into the 
g.l с and the concn. of the test compounds and their metabolites cale, relative 
to the internal standard. The g.l.c. instrument was a Hewlett Packard Model 
402, with flame ionization detector, and a Mosely recorder model 7127 (1 mV 
full scale deflection) The operating conditions were as fol lows: 2 0 % Apiezon 
5 % KOH on Gaschrom Q 60-80 mesh, or 3 % Carbowax 2 % KOH on Gas-
chrom Q 60-80 mesh, in a column 1.80 m by 3 0 mm diam ; carrier gas f low 
rate: N 2 , 20 ml per mm, H.,, 30 ml per mm; air, 150 ml per mm; temp.: oven 
160' ; flash heater 200 ; detector 200 . 
Synthesis 
All compounds were prepared according to previously published methods 
(Loev and Flores, 1961, Section II) and their purity established by m.p., i.r., 
u.V., n.m.r. and mass spectral data 
Results 
A. In vivo metabolism in rats 
The results of these experiments are presented in table 3. Rats rapidly elimi­
nate N-isopropylamphetamine and the half life time for this compound is ap-
prox 30 mm. FIPA had a halflife time of approx. 200 mm (120-300 mm), which 
is similar to that of amphetamine itself. Administration of (±)FIPA, in suitable 
concn., together with ( + ) N-isopropylamphetamine caused a change in the half-
life time of the latter to 85-100 mm (table 3, fig 9). In order for this effect to 
become manifest, the blood concn. of FIPA had to be of the same order as 
N-isopropylamphetamine. This was due to the large difference in the fictive 
volume of distribution (Vr = Dose/Blood concn. at zero time) between the two 
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Compounds, for, as can be seen from the data in table 3, FIPA has a Vf 
approx 6 times greater than N-isopropylamphetamine The prolongation of the 
half life time of N-isopropylamphetamine by FIPA indicates that the latter com­
pound hinders the elimination of the former in vivo 
Table 3 
Elimination of ( + ) N-isopropylamphetamine and ferrocenylisopropylamine by 
the rat 
The f.ctive volume, Vf = D/C0 = dose/blood concn at t = 0 
Vf ferrocenylisopropylamine / Vf ( + ) N-isopropylamphetamine = 5 8 
rat 
A 
A 
В 
A 
A 
В 
A 
В 
compound 
( + ) N-isopropylamphetamine 
( + ) N-isopropylamphetamine 
( + ) N-isopropylamphetamine 
( ± ) N-ferrocenylisopropylamine 
( ± ) N-ferrocenylisopropylamine 
( ± ) N-ferrocenylisopropylamine 
( + ) N-isopropylamphetamine 
ferrocenylisopropylamine 
( + ) N-isopropylamphetamine 
plus 
ferrocenylisopropylamine 
dose 
(u mol) 
5 95 
1 48 
4 25 
39 2 
139 
3Θ7 
3 96 
139 
4 25 
149 
t'/2 
(mm) 
25 
30 
30 
180 
120 
300 
85 
130 
100 
120 
Vf 
(ml) 
503 
580 
576 
4080 
2880 
2770 
775 
576 
/4Ä/' 
К 
RditA 
I 019 m¿ (t)isoprOpyldmphetjMTiine 
• 078m¿ fernxenyi-
[ isoprcpyUmine^i) 
v t y2 .25min 
ι FIPA 
R«*bA 
3 61 m¿ ferrocenylip amine ( ΐ ) ι ν 
¿rf ter 1 hr 
Qlm¿ (t) isopropylamphebAmme и 
A, isopropylrfmphet<nwine W t/2а 5 
o íerrocenylіэоргору temine (i)t Уг . 150 
О 20 40 60 80 100 60 0 20 40 60 fiO 100 120 140 
min 
(a) (b) 
figure 9 Blood concentration of ( + ) N-isopropylamphetamine and ( ± ) ferrocenyl­
isopropylamine after intravenous dosage to rats Rat A was injected intravenously with 
( + ) N-isopropylamphetamine and ( ± ) ferrocenylisopropylamine (FIPA) and blood 
concentrations of the compounds were estimated at different time intervals In the 
experiment shown in (a), ( + ) N-isopropylamphetamine (0 79 mg) and ( ± ) ferrocenyl­
isopropylamine (0 78 mg) were injected but the amount of FIPA was too low for 
inhibition The t'/á °f ( + ) N-isopropylamphetamine (25 mm) was the same as observed 
in control experiments In (b) inhibition of elimination of (+ ) N-isopropy.amphetamine 
(0 70 mg) is shown after intravenous administration of a suitable dose of FIPA (6 61 mg), 
injected 1 h before ( + ) N-isopropylamphetamine in order to avoid interference by the 
distribution phenomenon as shown in (a) 
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В Isolated perfused liver experiments 
The results of these experiments are presented in tables 4 and 5 The halflife 
times of metabolism and the fictive volumes of distribution of a number of 
amphetamine derivatives are given in table 4 Amphetamine and its N-methyl-
and N-ethyl derivatives have metabolic t1/2 values of between 100 and 200 
mm In contrast to this, the higher homologues, ( + )N-isopropylamphetamine, 
( + ) N-benzylamphetamine and ( + + ) biamphetamine, have metabolic t1/2 
values of between 5 to 20 mm The N-alkyl amphetamines as a group are 
N-dealkylated in the isolated liver prep to amphetamines as shown schema­
tically below 
<§ъ f > C-C-Ν <§ь С-С-Ν 
FIPA was hardly metabolized during the period of the experiment and therefore 
has a long metabolic V/2 of the order of 300 mm When FIPA and N-isopropyl-
amphetamine were added in equimolar amounts to the perfused liver system 
the metabolic t '/ 2 of the latter was changed from 20 mm to approx 200 mm 
(fig 10 tables 4 and 5) indicating a considerable inhibition of metabolism 
ISOLATED PERFUSED RAT LIVER 
MSA"' 
loo • 
001 
72m¿ N-isopropyUmphet*rifi€ HCL(+) 
\ isopropyUmphelAmne 
\ t % .20mm 
525m¿ N-iaopropylrfrriphetíimine HCL(+) 
620 m¿ ferroc#nyliíOpropyUmirw HBr (i) 
\ isopropylatnphetamine 
• \ H i . f fmn 
|+ferrocffnyl isopropyUmine 
20 60 100 140 180 220 260 500 
(a) 
10 50 50 TO 90 110 150 150 
m 
(Ь) 
figure 10 Metabolism of ( + ) N-isopropylamphetamine in the isolated perfused liver 
(a) Metabolic conversion of ( + ) N-isopropylamphetamine into amphetamine 
( + ) N-isopropylamphetamine HCl (72 mg) was added to the perfusion system 
(b) Inhibition of metabolism of N-isopropylamphetamine and amphetamine 
( + ) N-isopropylamphetamine HCl 5 25 mg) and (=L) ferrocenyhsopropylamine HBr 
(6,20 mg) were added to the perfusion system In order to elicit a clear-cut inhibition, 
ferrocenyhsopropylamine was added about 40 mm after the ( + ) N-isopropylamphe-
tamine 
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Table 4 
Halflife times of metabolism and fictive volumes of distribution of some amphe-
tamines in the isolated perfused rat I,ver 
Vf ferrocenylisopropylamine / Vf ( + ) N-isopropylamphetamine = 5 8 
exp compound 
4 (+ ) N-isopropylamphetamine 
21 ( + ) N-isopropylamphetamine 
28 ( + ) N-isopropylamphetamine 
13 (—) N-isopropylamphetamine 
14 (+ ) N-benzylamphetamine 
15 (—) N-benzylamphetamine 
23 ( + + ) biamphetamine 
29 ( + + ) biamphetamine 
30 ( + + ) biamphetamine 
31 ( + + ) biamphetamine 
17 (H—) biamphetamine 
19 ferrocenylisopropylamine 
20 ferrocenylisopropylamine 
21 ferrocenylisopropylamine 
23 ferrocenylisopropylamine 
31 ferrocenylisopropylamine 
28 N-isopropyl ferrocenylisopropylamine 
30 N-isopropyl ferrocenylisopropylamine 
Dose 
(umol/hver) 
29 6 
40 6 
27 6 
36 0 
24 8 
24 0 
20 0 
185 
190 
28 2 
20 6 
186 
26 0 
28 6 
28 0 
24 8 
25 8 
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ty2 
(mm) 
20 
20 
20 
43 
13 
20 
20 
5 
5 
5 
27 
400 
200 
120 
200 
130 
50 
40 
Vf 
(ml) 
129 
115 
192 
129 
187 
175 
167 
100 
120 
125 
185 
900 
700 
775 
600 
300 
500 
1000 
liver 
w t (g ) 
124 
144 
11 7 
144 
109 
133 
9 4 
9 7 
105 
9 3 
9 9 
106 
7 7 
144 
9 4 
9 4 
11 7 
105 
Table 5 
Inhibition of metabolism of ( + ) N-isopropylamphetamine and ( + + ) bi-
amphetamine by ferrocenylisopropylamine in isolated perfused rat liver 
exp compound 
20 (+ ) N-isopropylamphetamine 
plus 
ferrocenylisopropylamine 
21 ( + ) N-isopropylamphetamine 
plus 
ferrocenylisopropylamine 
28 ( + ) N-isopropylamphetamine 
plus 
N-isopropyl ferrocenylisopropylamine 
23 ( + + ) biamphetamine 
plus 
ferrocenylisopropylamine 28 0 200 600 9 4 
Dose 
(umol/hver) 
24 7 
26 0 
40 6 
28 6 
27 6 
25 8 
20 0 
t'/2 
(mm) 
240 
200 
200 
120 
200 
50 
160 
Vf 
(ml) 
145 
700 
775 
192 
500 
liver 
w t (g ) 
77 
144 
11 7 
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The result of this inhibition was a fairly constant concn of amphetamine (by 
N-dealkylation of N-isopropylamphetamine) over a long period of time Similar 
results were obtained when FIPA was combined with N-benzylamphetamine 
and biamphetamine 
When N-isopropyl FIPA was added to the perfused liver prep , FIPA was 
detected as the metabolite, which suggests that FIPA is reversibly bound to 
the metabolizing enzyme system 
С Effect of ferrocenylisopropylemme on the microsomal N-dealkylatton of 
( + )N-isopropylamphetamme 
The influence of ( ± ) F I P A on the oxidative N-dealkylation of ( + )N-isopropyl-
amphetamine was investigated by incubating the compounds in suspensions 
of rat liver microsomes The rates of enzymic conversion of ( + )N-isopropyl-
amphetamine were measured at constant substrate concn with varying concn 
of inhibitor Data were treated according to Dixon (1953) and the results are 
shown in fig 11 The results indicate a competitive inhibition of microsomal 
N-dealkylation by ( ± ) F I P A The inhibitor constant (K.) was calculated to be 
4 1 χ 10<> M 
(fiinolea/mj-.h) 
ferrocenylisopropylamine (10 6 M ) 
figure 11 Dixon plot of the effect of ferrocenylisopropylamine on the N-dealkylation of 
( + ) N-isopropylamphetamine by hepatic microsomes 
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D Interactions at the level of cytochrome P-450 
Addition of ( + )N-isopropylamphetamme and ( ± ) F I P A to microsomal suspen­
sions derived from rat liver produced characteristic spectral changes Two 
distinct types of difference spectra were observed with these compounds 
( + ) N-isopropylamphetamine caused a type I spectrum, which is shown in fig 
12, the absorbance changes at the max (395 nm) and at the trough (425 nm) 
appeared to be related to the concn of substrate Double reciprocal plots of 
these data were made according to the method of Lineweaver and Burk, and 
an apparent dissociation constant ( K J of 0 96 ± 0 18 χ 10-'1 M was obtained 
for ( + )N-isopropylamphetamine This value corresponds very well with the 
apparent Km of 0 67 χ 10
 Λ
 M, determined during the microsomal N-dealkyla-
tion experiments (±)FIPA, on the other hand, gave a type II difference spec­
trum with a peak and a trough at 425 and 395 mm, respectively (see fig 13), 
an apparent K„ of 1 24 ± 0 15 χ 10 - 6 M was calculated from a Lineweaver-Burk 
plot (fig 14) The value of this spectral dissociation constant is of the same 
Δ absorbance 
0 0 V 
0 02 
-0 ΟΣ­
Ο 0 4 -
(+) isopropylamphetamrne 
a 5 10"ЧМ 
3Ô0 4 0 0 420 4 4 0 460 460 
wavelength ( nm J 
figure 12 Type I spectral changes obtained on addition of (+ ) N-isopropylamphetamine, 
at different concentrations, to hepatic micrcsomcs of rats pretreated with phénobarbital 
3β0 400 4 2 0 
η 
0 0 2 -
-
0 0 2 -
d , 
^ b ^ ^ 
^^Ζ^~~Ά - - Γ < ^ - ^ = = = 
^ ^ Ξ Ξ ^ ^ Ξ ^ ^ ferroccnylisoprop/íjmine 
a 5 · 10"7 M 
b 1 · 10 6 M 
с 3 · 10 6 M 
d 5 · 10 6 M 
4 4 0 4 6 0 4β0 
wavelength ( n m ) 
figure 13 Type II spectral changes observed after addition of different concentrations 
of ferrocenylisopropylamme to hepatic microsomes of rats pretreated with phénobar-
bital 
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order of magnitude as the K, measured for ( ± ) F I P A (4 1 χ 10 β Μ ) determined 
during the inhibition of microsomal N-dealkylation of ( + )N-isopropylampheta-
mine 
Preliminary studies revealed that FIPA is deaminated, although slowly, to fer-
rocenylacetone by microsomal preparations from rat liver in the presence of 
NADPH This may indicate that FIPA itself can also serve as a substrate for 
microsomal oxidation and probably binds to cytochrome P-450 at the active 
site As mentioned previously, N-isopropyl-FIPA is N-dealkylated to FIPA 
Since deamination and N-dealkylation are considered to be the result of one 
cnzyrrt'c action, a-C-oxidation (Beckett, 1971, Parli, 1971), the relatively fast 
N-dealkylation of N-isopropyl-FIPA and the simultaneous inhibition of N-iso-
propylamphetamine (table 5) also support the idea that these ferrocenes bind 
at the active site of P-450 Since the K, can be regarded as an inverse 
measure of the affinity of a particular substrate for cytochrome P-450, the 
large difference in the spectral dissociation constants of ( + )N-isopropyl-
amphetamine and ( ± ) F I P A substantiates the view that the latter compound 
would act as a competitive inhibitor 
ДаЬзогЬапсе
-1 
120 η 
0 5 0 05 10 
\Jerrccenylicopropylumine\ - 1 (10~ 6 M ) 
figure 14 Lineweaver-Burk plot of the spectral changes induced by addition of 
ferrocenyhsopropylamine to rat liver microsomes 
The effect of (-t)FIPA upon the binding of ( + )N-isopropylamphetamine to 
cytochrome P-450 was also studied In these experiments difference spectra 
were recorded after the addition of increasing amounts of ( + )N-isopropyl-
amphetamme, in the presence of a constant concn of ( ± ) F I P A (the inhibitor 
was added to the microsomal suspensions beforehand) A double reciprocal 
plot was made of the sum of the absorbance changes at the peak and the 
trough against the concn of ( + ) N-isopropylamphetamine (fig 15) It may be 
seen that the ( ± ) F I P A acts as a competitive inhibitor, the K, of ( + )N-iso-
propylamphetamine was changed from 0 83 χ Ю - 1 M in the control experiment, 
to 1 45 and 4 15 χ 10 ¿ M in the presence of 1 0 and 5 0 χ 1CK· M (±)FIPA, 
respectively Analogously to the classical competitive inhibition model in 
enzymology, a dissociation constant of ( ± ) F I P A (spectral K,) can be calcula­
ted and amounts to 1 30 χ 10 - 6 M on average This value is quite similar to 
the K.-value of ( ± ) F I P A (1 24 χ 10 « M) 
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Discussion 
The data presented herein clearly demonstrate that FIPA competes for sites 
on the enzymes that normally metabolize amphetamine derivatives This further 
indicates that the enzymes are capable of accommodating very bulky sub­
strates, in fact, in the present study, FIPA demonstrated a 1000-fold greater 
affinity to the enzyme system when compared with ( + )N-isopropylampheta-
mme It would be reasonable to assume at this point that the ferrocenyl moiety 
contributes substantially to this increase in binding energy 
FIPA was also a competitive inhibitor for the N-demethylation of aminopynnc 
(v-C-oxidation), and it remains to be determined whether or not FIPA is a 
general inhibitor of microsomal oxidations 
In the in vivo situation, the relative Vr values of FIPA and N-isopropylampheta-
mme determine the effectiveness, via distribution, of the former compound as 
a competitive inhibitor of liver N-dealkylation The Vf ratio of FIPA/N-isopro-
pylamphetamine is approximately 6, indicating that the ferrocenyl derivative is 
much more widely distributed throughout the body tissues This corresponds 
very well with the work of Dratz, (1964), in which it was shown that radio-
actively labelled ferrocene initially concentrates in fat tissue in large quanti­
ties However, as partition experiments in our laboratory indicate that N-iso-
propylamphetamine is at least 10 times more lipid-soluble than FIPA (sec 
table 6), the difference in the Vf values might be explained by selective 
binding 
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figure 15 Effect of ferrocenylisopropylamine upon the spectral changes induced by 
addition of ( + ) N-isopropylamphetamine to rat liver microsomes (Lineweaver-Burk 
plot) Livers of phénobarbital treated rats were used The microsomal suspension 
contained 1 mg of protein/ml Apparent Ks values of (+ ) N-isopropylamphetamine 
are shifted to higher concentration by the presence of ferrocenylisopropylamine 
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9 90 
0 14 
9 70 
9 85 
0 005 
021 
0 075 
4 00 
0 48 
8 09 
2 33 
99 0 
1 88 
117 
150 
1130 
140 
4460 
466 
28000 
Table 6 
Apparent and true partition coefficients of amphetamine, ferrocenyhsopropyla-
mine, and derivatives 
compound pKa APCh* APCcM* TPCht TPCch,t 
amphetamine 
N-isopropylamphetamine 
f errocenyhsopropy lamine 
N-isopropylferrocenyl-isopropylamine 
*APC = apparent partition coefficient, 
tTCP = true partition coefficient, 
h = N-heptane-water (Theorell buffer, pH 7 4), 
chi = chloroform-water (Theorell buffer, pH 7 4) 
Increase of the FIPA/N-isopropylamphetamine molar ratio, as in our in vivo 
experiments, results in a proportionate increase in the initial FIPA concen-
tration obtained in the liver, which permits the compound to exert a measu-
rable inhibition of metabolism Dratz, (1964) has also shown that after rapidly 
attaining high concentrations in fat tissue, ferrocene then attains (1 or 2 days 
after oral administration) concentrations in the liver which are higher than 
these in the fat 
Use of isolated perfused liver preparations obviates the problems inherent in 
the in vivo situation (viz the relative distribution patterns of the compounds 
being examined) and permits study on a more controlled level Indeed, as 
can be seen from the in vitro data, once the effects of distribution are re-
moved, FIPA exerts its competitive inhibition at concentrations considerably 
lower than those of the substrate N-isopropylamphetamine 
The results in vivo and in vitro substantiate each other, and indicate that, 
although FIPA has considerable differences in structure from the arylalkylami-
nes that are normally metabolized by the hepatic microsomal enzymes, it 
nevertheless demonstrates a considerable affinity for these enzymes This is 
another example of the less rigid structural specificity of drug-metabolizing 
enzymes, when compared with pharmacological receptors 
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CHAPTER 6 
A CONCEPT OF THE SUBSTRATE-CYTOCHROME P-450 
INTERACTION 
Introduction 
The effect of a drug in the body may be considered as the interaction with 
different receptors (Ariens 1972) When two or more drugs are ingested, the 
effect may be different from the sum of the effects of those drugs alone, the 
compounds may interfere with each other There may be interaction at the 
level of the receptor, as is outlined extensively by Anens (1971, 1972), or 
there is an interaction at the level of the metabolic enzymes The concen-
tration of the drug in the blood may be regarded directly related to the con-
centration in the biophase, thus all factors affecting the blood concentration 
also may change the effect The interference at the level of metabolism by 
drugs was demonstrated by the finding that in a combination of two drugs, the 
one prolonged the action of the other (Mannering 1971) Subsequently, it was 
found that concurrently with the prolonged action, the blood concentration was 
elevated and metabolic degradation was inhibited At this time many com-
pounds may be regarded as inhibitors of the metabolism of other compounds 
However, beyond the idea that a considerable number of drugs are metaboli-
zed via one single enzyme system in the liver, there is no suitable theory 
which explains why certain compounds are such pre-eminent inhibitors With 
the aid of the compound ferrocenylisopropylamine, which showed up to be 
an inhibitor of the amphetamine metabolism, it has been attempted to state 
some empiric rules for the prediction of possible inhibition when two drugs 
are combined 
Inhibition 
It has been observed during the past few years that the metabolism of amphe-
tamine is inhibited by the following drugs Desimipramine (Dingell 1969), 
Methylphenidate (Dayton 1972) Haloperidol and Clorpromazine (Lemberger 
1970) Nor- and Protriptyline (Lewander 1969), Chlordiazepoxide, Diazepam 
(Lewander 1969) Imipramine (Lewander 1969, Bickel 1966, Kakemi 1971) Iprin-
dole (Freeman 1972) and DPEA (McMahon 1961 and Glasson 1972) All these 
compounds also appeared to inhibit the N-demethylation of aminopynne, 
ethylmorphme etc (O'Malley 1972, Mannering 1971) In this study we have 
shown that ferrocenylisopropylamine interferes with a-C-oxidation (chapter 4) 
Taking into consideration the great variety of inhibitors and the large group 
of compounds of which the metabolism can be blocked, there must exist 
some logic in the interactions underlying the mechanism of inhibition 
Drug-enzyme interaction 
The enzyme cytochrome P-450 can be regarded as isolated in some way in 
rough microsomal preparations like the 9000 g supernatant derived from liver 
homogenates This fraction can be subjected to spectral measurements with-
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figure 16 Structural formulas of some inhibitory compounds (Mannering 1971) 
and without drug, and then a εο-called difference spectrum is obtained 
(chapter 1) This difference spectrum is only obtained when the drug interacts 
with the enzyme In table 7 the dissociation constants of the amphetamine-
enzyme complex are given There is no obvious difference between the Ks 
values of dextro and levo isomers, cyclohexyl or aromatic ring systems, nor 
hydroxy or keto substitution in the s de chain The first interaction with the 
enzyme might be the same, thereafter physico-chemical properties of the drug-
enzyme complex, as bond force, stenc configuration, activation energy are 
determining the question whether the compound will be metabolized or not 
Also the compounds that inhibit the metabolism of the amphetamines and 
other substrates elicit an interaction with cytochrome P-450, but the Ks value 
is much lower, indicating a higher binding affinity When two drugs are added 
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simultaneously to the enzyme, both may compete for a binding place and may 
show real competition (chapter 4) The question arises how great must be the 
difference between the Ks values of two drugs, so that a substantial inhibition 
of the metabolism of one of them becomes manifest All drugs which are 
known to inhibit the metabolism of amphetamines have Ks values of 10 e M, 
while amphetamines themselves show Ks values of approximately 10 * M 
This means that the inhibitory drugs bind to the enzyme 1000 times stronger 
than amphetamines do Lewander (1960) did not found any inhibition of the 
amphetamine metabolism by barbiturates, nor did we (Yih 1972), the ratio 
between Ks values is 100 It appeared also that hexobarbital did not inhibit 
the N-dealkylation of N-diethylaminopropiophenone (Breimer 1972) 
The inhibitor 
As mentioned above, the interaction between drug and enzyme depends upon 
the physico-chemical properties of both components Because it is assumed 
that only one enzyme is involved the structure of the inhibitors may exert the 
requirements for strong binding Observing the structure of the inhibitory 
compounds SKF-525 A, Imipramine, amitnptyline, orphenadnne, diazepam, fer-
rocenylisopropylamine, DPEA, one may draw the conclusion that there must 
be present two aromatic rings tied up by one carbon atom In this way a more 
or less flat structure is obtained with an extended π-electron cloud It seems 
as if a large flat structure is required, because also trans 1-2-THC and lyne-
strenol (O'Malley 1972) fulfil the requirement and show a high affinity for 
the enzyme Apparently the inhibitory drugs have polar groups, nitrogen and 
oxygen atoms It is unlikely that the number of π- and free electrons of the 
inhibitory compounds in the first instance are responsible for the strong 
binding A more suitable parameter should be the number of C-C and C-N 
binding distances between the nitrogen and ring system (s) This concept wil l 
be discussed in more detail in the next heading 
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Table 7 
Ks values of amphetamine like compounds and inhibitory drugs Possible 
parameters for binding affinity. 
compound 
(-¡-), (—) amphetamine 
N-methylamphetamine 
N-ethylamphetamine 
N-isopropylamphetamine 
( + ), (—) H-amphetamine 
N-isopropyl-H-amphetamine 
norephedrine 
norpseudoephedrme 
fencamfamine 
methylphenidate 
phacetoperan 
pipradrol 
ammopyrine 
aniline 
benzphetamine 
imidazole 
pyridine 
iproniazid 
ethylmorphine 
N-isopropylferrocenyl 
isopropylamine 
hexobarbital 
cannabidiol 
1-6 tetrahydrocannabinol 
cannabinol 
tranylcypromine 
1-2 tetrahydrocannabinol 
SKF-525 A 
DPEA 
Lilly 18947 
ferrocenylisopropy lamine 
desmethylimipramine 
Imipramine 
orphenadnne 
amitriptyline 
ipnndole 
piperonylbutoxyde 
Ks (M) type π-electrons 
5 
5 
5 
5 
5 
5 
4 
4 
5 
6 
6 
4 
3 
3 6 
5 5 
1 5 
1 6 
2 5 
3.0 
5 0 
8 0 
5 9 
1 3 
1.2 
1.2 
1 8 
5 0 
5 0 
6 0 
1.2 
2.7 
2 6 
2 0 
2 7 
5 0 
χ 1 0 3 
χ 10-3 
х Ю
3 
χ 1 0 3 
χ 1 0 3 
x10- 3 
χ 1 0 3 
χ 1 0 3 
χ 10-1 
χ 1 0 4 
χ 10-4 
χ 10-" 
χ 10" 
χ ΙΟ"
4
 1 
χ 10-4 
χ 10" 
χ 1 0 ' I 
χ 10-4 
χ 1 0 5 
x 1 0 · 5 I 
χ 1 0 5 
χ 10-5 
χ 1 0 s 
χ 1 0 5 
x 1 0 5 
χ 1 0 s 
χ 1 0 ' 
χ 1 0 ' I 
ХІ0" 6 
χ I O 6 I 
χ I O 6 
χ 10·6 
χ 1 0 ' I 
χ 1 0 7 I 
χ 1 0 4 I 
I 6 
6 
6 
6 
0 
0 
6 
6 
6 
6 
6 
6 
8 
6 
12 
4 
6 
6 
-
8 
8 
10 
8 
12 
6 
8 
14 
12 
12 
8 
12 
12 
12 
14 
8 
6 
dista 
3 
3 
3 
3 
3 
3 
3 
3 
3 
3 
3 
3 
4 
1 
3 
0 
0 
3 
-
3 
0 
0 
0 
0 
3 
0 
6 
4 
4 
3 
5 
5 
5 
4 
5 
10 
nee reference 
Schenkman (1967) 
Schenkman (1967) 
Lu (1970) 
Davies (1968) 
Topham (1970) 
Schenkman (1967) 
Jansson (1972) 
Kupfer (1972) 
Kupfer (1972) 
Kupfer (1972) 
Kupfer (1972) 
Cohen (1971) 
Schenkman (1967) 
Schenkman (1967) 
McMahon (1961) 
von Bahr (1972) 
von Bahr (1972) 
von Bahr (1972) 
Franklin (1972) 
distance: the number of C-C and C-N bindings between the nitrogen atom and the 
aromatic nucleus. 
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Localisation of the amphetamines at cytochrome P-450 
The stereo specificity in the metabolism of amphetamines implies that there 
is a preferable situation in the interaction amphetamine-enzyme. On this basis 
the two mechanisms involved, the «-C-oxidation and N-oxidation may be ex­
plained. Concerning the metabolism of the N-cycloalkyl substituted ampheta­
mines, it can be concluded that with the dextro isomers amphetamine is al­
ways liberated from the molecule, thus ind.eating that the α-С-Н bond of the 
substituent is accessible for oxidation (section III, chapter 10). When the dex­
tro and levo isomers of N-cycloalkyl substituted amphetam nes are subjected 
to n-C-oxidation, the astonishing situation is observed that the levo isomer 
generates more amphetamine than the corresponding dextro isomer. These 
results are contradictory to the findings with N-alkyl substituted ampheta­
mines (section III, chapters 2 and 10). This behaviour can be explained if 
one assumes that the nitrogen atom is the trigger in the coupling between 
ihe amphetamine molecule and cytochrome P-450 Thereafter, the phenyl ring 
turns to the most favoured position, the molecule is fixed at the cytochrome 
and subsequently a-C-oxidation or N-oxidation can be performed Apparent­
ly the alkyl group does not contribute to the orientation of the molecule. The 
differences in the rate of N-dealkylation can be explained by different bond 
energy of the α-С-Н bond of the substituent. The ring system appears to be 
a predominant factor in the orientation. With N-cycloalkyl substituted amphe­
tamines there are two ring systems which may serve as trigger in the orien­
tation of the molecule With dextro N-cycloalkyl amphetamine, the cycloalkyl 
ring may fix the molecule and the α-С-Н bond of the cycloalkyl ring and the 
n-C-H bond of the amphetamine moiety both are suitable for o-C-oxidation 
Thus, both deamination and N-dealkylation may occur, dextro amphetamine 
is formed and metabolized again (fig 17) 
S(*) s« 
/ H н \ , 'Ή н \ 
a-C-oxidation a. C-oxidation 
With the levo isomers two ways are open: 
1) The phenyl ring is the trigger, the configuration is unsuitable for a-C-oxi-
dation and amphetamine can be formed only slowly. 
2) The cycloalkyl ring is the trigger, the α-С-Н bond of this ring is always 
in the proper position for attack (a-C-oxidation) but this is not the case with 
the levo configuration of the α-С-Н bond in the amphetamine moiety. Hence, 
only a-C-oxidation at the cycloalkyl group occurs and the result is a high 
amount of amphetamine formed. The levo amphetamine formed is also less 
metabolized than its antipode (fig 18). 
N-oxidation R-
α С-oxidation 
figure 17 In the S ( + ) configura­
tion both a-Η atoms are available 
for attack by the enzyme 
figure 1Θ In the R (—) configura­
tion only the α-H atom of the 
substituent is available For attack 
by the enzyme when the ring of 
the substituent is the trigger in 
the orientation of the compound 
at the enzyme 
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As a result of these observations in the metabolism of the amphetamines 
the compound may be regarded as a compass-needle, the rings are moving 
until they reach the areas in which the interaction is effective At the cyto­
chrome an area may bo imaginable in which only a-C-oxidation can be per­
formed In man the participation of a-C-oxidation in the total elimination of 
nitrogen bearing molecules decreases when the molecule becomes larger and 
more stretched For instance orphenadnne, Imipramine and amitriptyline are 
N-demethylated to a small extend, but at the same time the hydroxy metaboli­
tes are present in substantial amounts while for the amphetamines they may 
be neglected It may be assumed therefore that there must exist an addi­
tional area which is responsible for the parahydroxylation Hence, when the 
substrate molecule has such dimensions that, if the nitrogen atom is the cen­
tre of the movement, the aromatic ring sticks in the area of the hydroxylation 
If we are counting the C-C- and C-N binding distances between the nitrogen 
atom and the phenyl rings in the inhibitory molecules (Ks = 10 ° M) it can be 
observed that apparently there must be 4-5 distances in order to give this 
high affinity The two aromatic rings are responsible for the high affinity A 
second effect is that in this position a substantial hydroxylation occurs Am­
phetamine accounts for only 3 distances The only compound with a high affi­
nity which seems contradictory to this hypothesis is ferrocenylisopropylamine 
Only 3 distances from the nitrogen atom to the aromatic nucleus There must 
be an additional requirement to ensure binding affinity When models are 
constructed of the inhibitors it is seen that the two aromatic rings, connected 
by one carbon atom are not in a plane With ferrocenylisopropylamine the 
aromatic nucleus is cylindrical Now the following topographical chart of the 
enzyme site performing a-C-oxidation and parahydroxylation may be con 
structed The area may be described plastically as an islet on which the 
u-C-oxidation may be performed in a lake of hydroxylation Our hypothesis 
is compatible with the finding of Lewander (1968) who reported that Imiprami­
ne was able to inhibit both deamination and parahydroxylation of ampheta­
mine in rat (fig 19) 
figure 19 An artists impression of the topography of the enzyme cytochrome Р-4Ь0 
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A refinement of the localisation of the area of a-C-oxidation 
The stereochemistry in the metabolism of amphetamine derivatives reveals 
that the configuration of the o-C-H bond in the amphetamine moiety is the 
decider whether a-C-oxidation can be performed or not The availability of 
an α-С-Н in the substituent is of secondary importance Probably the place of 
the reaction is strongly limited Evidence herefore may be obtained from the 
observed stencal hindrance by the ß-hydroxyl group in ephedrmes and the 
cyclohexyl ring in fencamfamine The high activation energy of N-dealkylation 
of N-dimethylamphetamine which is consistent with the concept that a-C-
oxidation is impossible gives rise to the opinion that the area, performing 
a-C-oxidation, is strictly limited In the tertiary N-dimethylamphetamine, the 
methyl group requires much more space than the proton in the corresponding 
secondary N-methylamphetamine This makes it understandable that in general 
tertiary amines are metabolized by cytochrome P-450 via N-oxidation 
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CHAPTER 1 
DOPE AND DOPING CONTROL 
Introduction 
Amphetamine and its structure analogues mentioned in section III and IV are 
also used in sports with the intention to modify performance of the competitor 
The very intention in general is called doping because it is very difficult to 
establish objectively whether the drug taken has modified the performance in 
a positive sense It should be stressed that the definition of doping reflects 
these difficulties 
definition 
Doping is defined as the administering or use of substances in any form alien 
to the body or of physiological substances in abnormal amounts and with ab­
normal methods by healthy persons with the exclusive aim of attaining an 
artificial and unfair increase of performance in competition Furthermore, vari­
ous psychological measures to increase performance in sport must be re­
garded as doping This definition of the counsel of Europe is widely used by 
many sporting authorities Too widely, because this definition includes many 
obscure statements such as substances alien to the body, exclusive, unfair, 
abnormal etc "Alien to the body" this term is not correct, how are insecti­
cides taken as stimulants, present in wholesome fruit to be classified etc Fur­
thermore the term "al ien" would be correct if all substances normally circula­
ting in the human body are known Thus Coffeine should be considered as 
dope In addition one should also take into consideration the quantity present 
of drug in the body That means if somebody has used ephednne nose drops a 
week before a competition he may be charged of having doping when highly 
sensitive detection methods are used The definition has to be extended to 
use of adequate amounts of substances of or classes of substances men­
tioned by name If the use of certain chemical substances is suspected, ade­
quate methods of control should be available to establish the illicit use Those 
who control the illicit use should have good knowledge of pharmacokinetics 
of the drugs indicated as doping in addition to their analytical expertise "Ab­
normal amounts" depends strongly upon country and habituation The term 
"unfair" has certain connotations of unrealistic heroism and is a heritage 
from the Old Greek Olympiads "Unfair" had better be related with the degree 
of observance of the rules of each branch of sport which all competitors have 
accepted The idea of good sportsmanship can only exist if there is an equal 
reward for the two competitors, the winner and the loser In our days the 
rewards of both competitors in many cases are out of balance In professional 
sports there are too many interests, determining the match, so that the term 
good sportsmanship is only fictive and a matter of morality, ι e what can just 
be tolerated or not Some professional football plays are regarded as a small 
war with their own rules about what can be tolerated Even in pure amateurism, 
the desire to win may be very strong In fact this is the driving force for 
competition but each competitor at each time has to consider at what cost he 
184 
wants to win This cost includes all means and all training needed to achieve 
the performance desired by himself, the trainer or the nation 
The performance (P) is related with characteristic properties belonging to the 
athlete such as force (F), skill (S), motivation (M), concentration (C) and talent 
or intelligence (I) for every particular sport Thus 
Ρ = f (F S M С I ) 
The different factors can be influenced by local circumstances, training and 
may be by drugs With anabolic steroids the muscle mass and there with the 
force may be enhanced The skill can only be increased by continuous training 
and motivation can be increased by the height of the reward, but also by 
drugs which block signals originating from boredom, fear or hate Concen­
tration may be regarded as the product of selective elimination of signals of 
information that enter the athlete during the performance and that is not strict­
ly required for the performance proper It is often thought that concentration 
can be related with the percentage of faults in a certain action This may be 
true when the action itself is so difficult that all attention is required, but this 
in general is not the case in topsport as badminton, table tennis, tennis or 
soccer etc There is such an abundance of skill that each movement can be 
done blindly Therefore drugs which modify the selective elimination process 
in the brain may severly influence the factor concentration 
In the term concentration a second parameter can be recognized, the reaction 
rate After the observation of a certain action of the opponent one ought to 
react Thus the processes are subsequently observation, analysis of the op­
ponent's action, thinking about the return, movement to the place of action, ac­
tion, and analysis of its action With amphetamines the time course of most 
processes can be decreased depending on the dose The most desirable si­
tuation is that the time of movement to the place of action and performance of 
the return is shortened whereas the mam components in the overall action, 
the thinking and analysis, remain unchanged When too much amphetamine is 
taken, all processes are enhanced and the thinking becomes abortive, which 
can be compared with the panic situation due to time pressure well known in 
ball and shuttle games Thus one may conclude that drugs may be taken in 
order to live up to expectations, despite the knowledge about the possibil i­
ty of overdosing, toxicity, addiction and death Though each human being has 
the right to kill himself with drugs, this is not the basis of competition in 
sport On the other hand the rewards may be so great that it is worth taking 
the risk and for this reason the community opens the way of illicit drug taking 
The prohibition alone of taking drugs does not eliminate this undesired phe­
nomenon 
The conflicting opinions about the effect of doping on performance serves the 
opinion that the prohibition is the least harmful of all evils operating in sport 
Once there is agreement that chemicals are not allowed in sporting events, 
methods of doping control should be established Adequate control should 
involve both analytical, chemical and pharmacokinetic expertise An omission 
in the present regulations of doping control is the lack of limits for each 
classified drug, beyond which a test is positive Thus with the doping control 
as a given fact some remarks can be made about this control itself and how 
it can be improved 
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doping control 
To avoid a misinterpretation of the true value of the word doping and doping 
control, the definition mentioned before is replaced by the prohibition of the 
use of classified drugs. Beckett and Donike, in several articles written before 
the XXth Olympiad in Munich, have described the technical course of actions, 
required for a water thight doping control, in great detail. The philosophy in 
the articles is how and how accurately can we find back and identify the 
classified drugs in the urine or blood of the competitor. It is not easy to 
perform a watertight doping control. Sampling and transport of the samples, 
analysis and interpretation of the results, all require a high degree of confi­
dence and expertise. To date the doping control only requires the identification 
of the classified drugs and ignores important parameters as biological half-
life time, renal excretion rate and dose-effect relationships. 
In the previous sections we have shown that there exist much varieties in 
metabolism and with this quantity of data available the chemist ought to 
use these parameters. Doping control without sufficient knowledge of meta­
bolic rates increases the chance of misinterpreting the measurements. At the 
renal excretion rate (jjig/min) 
1000-
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JO 
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time (.h) 
figure Г Renal excretion rate of amphetamine after different dosages Note that the 
maximum in the renal excretion rate in цд/гшп corresponds with the dose in mg 
(HCl salt) This coincidence may be used in doping control. 
186 
Olympiad in Munich we all read that some athletes had used drugs according 
to the standard of the Medical Committee The technical performance of the 
control unit was unarguably of high quality, but the additional parameters 
were completely ignored Misinterpretation and Expertologism were the re­
sults (The term expertologism, deskundologie, describes the apparent expert 
The original meaning of the word is something that is common knowledge) 
How to overcome these difficulties? We want to propose some improvements 
for the doping control 
A proposal for doping control 
Each athlete or subject, who has taken а С N S drug, can mark the moment 
at which the drug exerts an effect He can also notice, which minimum dose 
still has a noticeable effect This minimum effect, related dose and blood level 
can be estimated with many persons, so that after statistical computation, the 
minimum effective dose can be ascertained This dose may be called the 
adequate dose that in average individuals causes behavioural effects It has 
to be realized that it is diff icult to prove that a certain dose did affect the 
performance of the athlete in a positive way When the blood concentration of 
a particular drug cannot be measured, then the effect can be related to the 
renal excretion rate, provided that there exists a relationship between them 
(section I) 
dQ (renal) / dt = kr С k r renal clearance constant which is constant at 
constant urine pH 
In figure 1 the renal excretion rate of amphetamine is given after the ad­
ministration of different doses It may be concluded that the maximum in the 
renal excretion rate at f ixed pH (5) is related with the dose in mg HCl salt 
^ g / m i n = mg salt) (section I) In our experiments, an adequate dose of am­
phetamine was found to be 10 mg Its maximal excretion rate was found to 
be 10 цд/т іп It can therefore be concluded that when an excretion rate is 
found higher than 10 μg/mιn, there may be stimulation because an adequate 
dose has likely been ingested Obviously certain individuals may be more 
sensitive while also the moment of intake is not know It is therefore reasona­
ble to set a threshold for a positive-negative result at 2 μg/mιn That means 
that when the renal excretion rate of amphetamine of an athlete is beyond 
this value he should be declared positive 
The renal excretion rate is pH dependent so that the limit value should be 
reduced by a factor 10 at pH 6-7 For ephedrme this limit must be higher, 
15 ц д / т т due to the diminished lipid-solubility and enhanced renal excretion 
rate compared to amphetamine The limit of each compound should be establi­
shed on basis of a correlation with the minimum effective dose and effect 
With the use of these limits, athlete A with a renal excretion rate of 0 цд/т іп 
of amphetamine need not to worry about athlete В with a renal excretion rate 
of 0 1 μg/mιn amphetamine at a urine pH of 5, because at the time of the 
match, the concentration of amphetamine circulating in В is ten times less than 
the minimum effective dose This knowledge gives a feeling of rest and also 
diminishes the fear for doping control At the moment one does not use 
this concept of the limits, because few investigations about dose-effect re­
lations have been carried out 
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The renal excretion rate 
The renal excretion rate may be determined from an estimation of the quantity 
of drug in a fraction of urine if it is known during what time this fraction has 
been produced Information in this respect may be obtained by collection of 
two urine fractions in succession while recording time interval between the 
two samples If the first sample gives a positive test, the second sample also 
is subjected to a quantitative analysis of the amount of drug in this fraction 
The average excretion rate during that time interval then can be estimated 
Relationship between plasma concentration and urinary excretion rate 
Depending upon the halflife time of the doping agent, the amount in the body 
has decreased to one tenth of the initial (or roughly maximal) amount after 
3,5 times the halflife time and to 1 % of the initial amount after about 7 times 
the halflife time (see section I) Of amphetamines with a halflife time of 
production ml/mm 
cumulat ive renal 
excret ion rng 
10 
renal excret ion rate ug/mm 
10 
1 -
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Е І 0 т £ ephednne C-) HCl 
ephednne 
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figure 2 Renal excretion 
rate, urine pH, urine pro­
duction and cumulative 
renal excretion of ephednne 
and its metabolite norephe­
drine after the intake of 
about 10 mg ephednne in 
1 ml nasal drops Note that 
ephednne is excreted over 
a period of at least 60 hr, 
under normal urine condi­
tions 
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7-12 hours (pH5-6) after about 2 days (22 5-42 hours) 10 percent is left and 
after about 3-4 days (49-84 hours) only 1 % is left Obviously the effect of the 
minimum effective dose (10 mg) of dextro amphetamine lasts less than half a 
day (about 8 hours) From these quotations it may be concluded that for this 
purpose it is not useful to have extremely sensitive procedures for doping 
control since in that case a cyclist could be declared positive if he had used 
an amphetamine like agent a few weeks before, or had used ephednne for 
congestions of the nose (fig 2) Thus, an athlete with a certain amount of 
amphetamine in his urine, only can be declared positive, when the parameters 
mentioned are taken into account Examples will be given later 
Critical level of doping agents in the urine and critical level of renal excretion 
rate 
As explained before, it seems logical to leave the criterion for positive result 
of a doping test not to the level of sensitivity of the test procedure, but to 
establish for every potential doping agent a critical level with respect to the 
renal excretion rate, so that if the excretion rate is found below that level 
the test is found to be negative For amphetamine the critical level could 
be fixed at 2 μg/mιn It is however in the actual situation not easy to have 
information of the rate of urine production so that only the urine concen­
trations can be determined Given an average urine production rate in healthy 
people there is a simple correlation between the urinary excretion rate and 
the urine concentration In table 1 a tentative proposal for the critical levels of 
urinary excretion rate (which requires more than a simple urine sample) and 
urinary concentrations have been given This table may be used as a start 
for the doping control authorities for establishing limits 
Table 1 
Critical levels of amphetamine like compounds in doping control 
compound 
amphetamine 
N-methylamphetamine 
N-ethylamphetamine 
N-isopropylamphetamine 
N-dimethylamphetamine 
captagon 
ephednne 
amphepramon 
fencamfamine 
pipradrol 
A N 1 
phentermine 
excretion rate 
ц д / т і п 
2 
1 
2 
5 
2 
2 
15 
10 
5 
2 
2 
2 
urine concentration 
ц д / т і at pH 5 
1 - 3 
0 5 - 1 5 
1 - 3 
2 5 - 7 5 
1 - 3 
1 - 3 
10 -25 
5 -15 
2 5 - 7 5 
1 - 3 
1 - 3 
1 - 3 
halfhfe 
time (hr) 
7 
7 
3 
3 
4 
10 
7 
7 
7 
12 
6 
9 
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Examples of doping control carried out in Nijmegen 
Extensive control 
1) An athlete produced three urine samples at various time intervals. The pH 
was measured, the total amount in ml was recorded and the average excretion 
rate calculated. In table 2 these data are given. The compound identified was 
N-methylamphetamine. 
Table 2 
time of 
urine 
production 
hr 
0 
3 
11 
urine 
ml 
100 
540 
480 
average 
urine 
production 
ml/min 
1 00 
3.00 
1 00 
concentration μg|m\ 
amphetamine N-methylamphetamine 
0 7 190 
0 40 4 00 
0 80 6 0 
excretion rate ц д / т і п 
amphetamine N-methylamphetamine 
0.7 1 9 0 
1.20 120 
0 8 6 0 
From table 2 it can be concluded that the renal excretion rate of N-methyl-
amphetamine is higher than the fixed level of 1 цд/тіп. The conclusion must 
be: doping, N-methylamphetamine was taken as a pure compound and not in 
a miscellaneous, or formed as metabolite. The compound is taken during the 
race, 0,5 hr before the end. For a person in rest, the renal excretion rate 
reaches the maximum 2-3 hr after the administering, for a person doing havy 
work, with a high blood flow rate, the absorption is much faster. See figure 
3 a. 
2) Three urine samples obtained from a sporting event. The compound iden­
tified was amphetamine. The pH of the urine samples was 5.8 5,5 and 5.05 
(fig 3b). The low pH of the first samples indicates that the amphetamine 
was taken just before or during the match. The excretion rate shows a maxi­
mum of 5 цд/тіп in the second urine sample. This means that only 5 mg of 
amphetamine was taken. The conclusion must be: no doping. 
Normal control 
3) One urine sample obtained from a sporting event. The pH of the urine was 
4.95. The compound identified was ephedrine at a concentration of 1 29 цд/ті. 
The average urine production was about 1,5 ml/min. It must be concluded 
that the concentration and hence the renal excretion was too low for any 
effect. The conclusion must be: no doping. 
4) One urine sample obtained from a sporting event. The compound iden­
tified was ephedrine and its concentration was 2.04 μg/ml at a urine pH 5.30. 
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The renal excretion rate is below the limit of 15 μ9/Γηιη thus the conclusion 
must be: no doping. 
5) One urine sample obtained from a sporting event. The compound identified 
was amphetam ne at a renal excretion rate of 0.31 цд/тіп at pH 6.9 (figure 3c, 
athlete 101) The low pH of the urine may indicate that amphetamine is taken 
during the event. The renal excretion rate is too low to be considered as 
doping. 
6) One urine sample obtained from a sporting event. The compound identified 
was ephednne at a concentration of 29 цд/т і , at pH 5.17 which may corres­
pond with a renal excretion rate of about 30 цд/т іп. This excretion rate is 
higher than the limit of 15 μg/mιn, thus this amount of ephednne must be 
regarded as doping 
7) Urine samples were obtained from a sporting event. (Cycle cross) The sam­
ples did not contain forbidden doping substances, but the pH of the urine of 
some competitors was alkaline. After doing havy work, the pH of the urine 
ought to be between 5.0 and 6.0. In all samples analysed before, the pH was 
never beyond pH 6. In this case six of the nine competitors showed urine 
pH values between 6.30 and 7 0. There is a strong indication that sodium bi­
carbonate was used. 
LU .ne production ml/mm 
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figure 3: a) An examp'e of a positive results in the doping control when it is performed 
as proposed in this chapter. The dose, time of administration and the compound can 
be identified 
b) Just only 5 mg of amphetamine was taken before the event 
c) With only one urine sample, the compound can be identified, but important 
parameters as, renal excretion rate, halflife time and dosage must be ignored. 
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